Xxxxxxxx Xxxxxx 2000/32/XX
xx xxx 19. xxxxxx 2000,
xxxxxx se po xxxxxxx xxxxx přizpůsobuje xxxxxxxxxxx xxxxxxx xxxxxxxx Xxxx 67/548/EHS o xxxxxxxxxx právních x xxxxxxxxx předpisů xxxxxxxxxx xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx [1]
(Xxxx x xxxxxxxx pro XXX)
XXXXXX XXXXXXXXXX SPOLEČENSTVÍ,
s xxxxxxx xx Xxxxxxx x xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx,
x xxxxxxx xx xxxxxxxx Xxxx 67/548/XXX xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx x správních xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx [2], naposledy pozměněnou xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 1999/33/XX [3], x xxxxxxx xx xxxxxx 28 xxxxxxx směrnice,
vzhledem x xxxxx xxxxxxx:
(1) Příloha X xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxx xxxxx x xxxxxxxxxxx a označování xxxxx látky. Xxxxxxxx xxxxxxx x technické xxxxxxxx xxxxxxx, xx xx měl xxx xxxxxx nebezpečných látek x uvedené příloze xxxxxxxxxxx. Xxxxxxx jazykové xxxxx směrnice vyžadují xxxxxx určitých xxxxxx xxxxxxxxx x tabulky X x příloze X.
(2) Příloha XXX xxxxxxxx 67/548/XXX obsahuje xxxxxx xxx xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx x xxxxxxxxx. Xxxxxxx IV xxxxxxxx 67/548/XXX xxxxxxxx seznam xxx x xxxxxxxxxxxxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxxxx xxxxx a xxxxxxxxx. Xxxxxxx XX xxxxxxxx 67/548/XXX xxxxxxxx xxxxx ke xxxxxxxxxxx x k xxxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx směrnice vyžadují xxxxxx určitých oddílů xxxxxx XXX, XX x VI.
(3) X xxxxxxx X směrnice 67/548/XXX xx xxxxxxx xxxxxx xxx xxxxxxxxx xxxxxxxxx-xxxxxxxxxx vlastností, toxicity x xxxxxxxxxxx xxxxx x přípravků. Xx xxxxxxxx přizpůsobit xxxx xxxxxxx technickému xxxxxxx.
(4) Xxxxxxx XX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxxxx xxxxxxxx se uzávěrů xxxxxxxx proti xxxxxxxx xxxxx. Xxxx předpisy xx xxxx xxx xxxxxxxxxxxx x aktualizovány. Xx xxxxxxxx rozšířit xxxxxx, kde xx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx používají.
(5) Xxxxxxxx této xxxxxxxx xxxx x souladu xx xxxxxxxxxxx Výboru xxx xxxxxxxxxxxx technickému xxxxxxx xxxxxxx xxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xx xxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxx,
XXXXXXX XXXX XXXXXXXX:
Xxxxxx 1
Xxxxxxxx 67/548/XXX xx xxxx xxxxx:
1. Xxxxxxx X se xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxxxx x předmluvě xx xxxxxxxxx xxxxxxxxx X x příloze 1X této xxxxxxxx;
x) xxxxxxxxxxxx řádky x xxxxxxx X xx xxxxxxxxx xxxxx x xxxxxxx 1X této xxxxxxxx;
x) xxxxxxxxxxxx položky xx xxxxxxxxx položkami x příloze 1X xxxx xxxxxxxx;
x) xxxxxxxx xx xxxxxxx v xxxxxxx 1X této xxxxxxxx.
2. Xxxxxxxxxxxx xxxx x příloze III xx nahrazuje xxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x příloze 2 této směrnice.
3. Xxxxxxx XX xx xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxx v příloze XX xx nahrazují xxxxxxxxxxxx xxxxxx xxx xxxxxxxx zacházení x xxxxxxx 3X této xxxxxxxx;
x) odpovídající xxxxxx x xxxxxxx XX xx nahrazují xxxxxxxxxxxxx xxxxxxxxxxxx pokyny xxx xxxxxxxx zacházení v xxxxxxx 3B xxxx xxxxxxxx.
4. Xxxx X xxxxxxx V se xxxx xxxxx:
x) kapitola X.10 xx xxxxxxxxx xxxxxx v xxxxxxx 4X této xxxxxxxx;
x) xxxxxxxx X.11 xx xxxxxxxxx textem x xxxxxxx 4B této xxxxxxxx;
x) xxxxxxxx B.12 xx xxxxxxxxx textem x xxxxxxx 4C xxxx xxxxxxxx;
x) xxxxxxxx X.13 x X.14 xx xxxxxxxxx xxxxxx x příloze 4X xxxx xxxxxxxx;
x) xxxxxxxx X.17 xx nahrazuje xxxxxx x příloze 4X xxxx směrnice;
f) xxxxxxxx X.23 xx xxxxxxxxx xxxxxx x xxxxxxx 4F xxxx xxxxxxxx. Xxxxx xxxxxxxx X.23 xx xxxxxxxxxxx xx mění xxxxxxxxxxxxx xxxxxxxx;
x) xxxxxx xx xxxx v příloze 4X xxxx směrnice.
5. Xxxxxxx xx xxxxxx xxxxxxx xxxxxxxx xxxxx x části X xxxxxxx X.
6. Xxxxxxxxxxxx xxxxx x příloze XX xx xxxxxxxxx xxxxx x příloze 5 xxxx xxxxxxxx.
7. Xxxxxxx XX xx xxxx xxxxxxxx uvedeným x příloze 6 xxxx xxxxxxxx.
Xxxxxx 2
1. Xxxxxxx xxxxx xxxxxx x xxxxxxxx xxxxxx x xxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxx souladu x xxxxx xxxxxxxx xxxxxxxxxx do 1. xxxxxx 2001. Neprodleně x nich xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx státy xxxx xxxxxxxxx xxxxx xx xxxx směrnici xxxx xxxx xxxxxx xxxxx xxx učiněn při xxxxxx xxxxxxx xxxxxxxxx. Xxxxxx odkazu si xxxxxxx xxxxxxx státy.
2. Xxxxxxx xxxxx xxxxx Xxxxxx znění xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx, které xxxxxxx x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, a xxxxxxxxxx tabulku mezi xxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx.
Xxxxxx 3
Tato xxxxxxxx xxxxxxxx v xxxxxxxx xxxxxx xxxx po xxxxxxxxx x Xxxxxxx xxxxxxxx Evropských xxxxxxxxxxxx.
Xxxxxx 4
Xxxx xxxxxxxx xx xxxxxx členským xxxxxx.
X Bruselu dne 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Xxxxxxx xx xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Úř. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. xxxx. X 199, 30.7.1999, x. 57.
XXXXXXX 1X
XXXXXXXXX K XXXXXXX I
Vysvětlení xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx a označování xxxxx
(Xxxxxx xx xxxxxxx xxxxx)
PŘÍLOHA 1B
"TABULKA X
|
X |
Xxxxxx |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
18 |
Xx |
Xxxxx |
Xxxxx |
Xxxxx |
Αργό |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
|
64 |
Xx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Γαδολίνιο |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx" |
PŘÍLOHA 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x látkám |
Číslo XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx limity |
Poznámky x přípravkům |
|
006–011–00–7 |
karbaryl (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. kat. 3; X40 Xx; X22 X; R50 |
Xn; X X: 22–40–50 X: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (ISO) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 X; X34 X43 X; X50–53 |
X; N X: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
206–354–4 |
330–54–1 |
Xxxx. kat. 3; X40 Muta. xxx. 3; X40 Xx; R22–48/22 X; X50–53 |
Xx; N R: 22–40–48/22–50/53 X: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- xxxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
204–043–8 |
114–26–1 |
X; X25 N; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
xxxxxxxx (ISO) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 X; X24 X; R50–53 |
T+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
aminokarb (ISO) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; X24/25 X; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
xx-xxxxx (XXX) S-(2,3-dichlorallyl)-N,N-diisopropylthiokarbamát |
218–961–1 |
2303–16–4 |
Karc. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X R: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
xxxxxx (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-xxxxxxxxxx)xxxxxxxx |
202–930–4 |
101–27–9 |
Xx; R22 X43 N; R50–53 |
Xn; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
merkaptodimethur (ISO) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; R50–53 |
T; X R: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
proxan-natrium (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; X22 Xx; X38 N; X51–53 |
Xx; X R: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
karbofuran (ISO) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 X; X50–53 |
X+; X X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
xxxxxxxxx (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-sek-butyl-4,6-dinitrofenyl-isopropyl-karbonát |
213–546–1 |
973–21–7 |
T; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
dioxakarb (XXX) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; X25 X; X51–53 |
X; X X: 25–51/53 S: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-xxxxx-4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
243–433–2 |
19937–59–8 |
X; R50–53 |
N X: 5 0/ 5 3 S: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
xxxxxxxxxx (XXX) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx pyrimidin-4-yl-N,N-dimethylkarbamát |
245–430–1 |
23103–98–2 |
T; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
xxxxxxxxx (ISO) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-chlorallyl-N,N-dimethyldithiokarbamát |
E |
202–388–9 |
95–06–7 |
Karc. xxx. 2; R45 Xn; X22 X; X50–53 |
X; X X: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
xxx-xxxxx (XXX) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; R22–48/22 X43 X; X50–53 |
Xx; N X: 22–43–48/22–50/53 X: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (ISO) 3-(4-chlorfenyl)-1,1-dimethylmočovina |
205–766–1 |
150–68–5 |
Karc. xxx. 3; R40 Xx; X22 X; X50–53 |
Xx; N X: 22–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
xxxxxxx-XXX 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 36/38–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (ISO) xxxxxx-X-[(X-xxxxxxxxxxxxxxx)xxx]xxxxxxxxxxxxxx |
240–815–0 |
16752–77–5 |
X+; X28 X; R50–53 |
T+; X R: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
xxxxxxxxxx (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; X23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
xxxxxxxxx (XXX) xxxx: 3-(1-methylbutyl)fenyl-N-methylkarbamátu a 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; R24/25 N; X50–53 |
X; N X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
ethiofenkarb (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; R22 X; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-fenyl-1,1-dimethyluronium-trichloracetát |
— |
4482–55–7 |
Xi; R38 X; X50–53 |
Xx; N X: 38–50/53 X: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (ISO) 2-xxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–114–6 |
2631–40–5 |
Xx; X22 N; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xx; X21 X; X50–53 |
X+; X X: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 N; X51–53 |
Xx; X R: 22–51/53 S: (2-)24-61 |
|||
|
006–060–00–4 |
xxxxxxxxxxx (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; X22 X52–53 |
Xx R:22–52/53 X: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (XXX) 1,2-di[3-(methoxykarbonyl)thioureido]benzen |
245–740–7 |
23564–05–8 |
Muta. xxx. 3; R40 X; X50–53 |
Xx; X X: 40–50/53 S: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx N-cyklohexyl-N-methoxy-2,5-dimethyl-3-furamid |
262–302–0 |
60568–05–0 |
Karc. xxx. 3; X40 X; X50–53 |
Xx; X R: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) ethyl-N -[({[(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)xxx]xxxxxxxx}xxxxxxxxxxx)xxxxxxxx]-X-xxxxxxxxx-β-xxxxxxxx(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)-X-({[2-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxxxxxx}xxxxxxxx)-X-xxxxxxxxxxxxxx |
— |
82560–54–1 |
X; X23/25 X; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
X,X-xxxxxxxxxxxxxxxx 1,1-dimethylhydrazin |
E |
200–316–0 |
57–14–7 |
F; X11 Xxxx. xxx. 2; R45 X; X23/25 X; R34 X; X51–53 |
X; X; X X: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; X45 X; X23/24/25 N; X51–53 |
X; X R: 45–23/24/25–51/53 X: 53–45–61 |
X ≥ 25 %: X; R45–23/24/25 3 % &xx; X &xx; 25 %: X; X45–20/21/22 0,01 % &xx; C &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; X26/27/28 X; R35 |
T+; C X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: T+; C; X26/27/28–35 1 % ≤ C &xx; 7 %: T; X23/24/25–34 0,1 % ≤ X &xx; 1 %: Xn; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) X,X-xxxxxxxx-X -[(4(3 H)-oxo-1,2,3-benzotriazin-3-yl)methyl]-fosforodithioát |
201–676–1 |
86–50–0 |
T+; X26/28 X; R24 X43 X; R50–53 |
T+; X X: 24–26/28–43–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (ISO) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; X40 X; X23–48/25 Xx; X21/22 X; X50–53 |
X; X R: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
xxxxxxx-xxxxx (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; X24 X; X50–53 |
X+; X R: 24–28–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
triazofos (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 H- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xx; X21 X; X50–53 |
X; X R: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
chlorid xxxxxxx |
234–129–0 |
10545–99–0 |
X14 X; R34 N; X50 |
X; X X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ C &xx; 10 %: Xx; R36/37/38 |
||
|
016–014–00–5 |
chlorid xxxxxxxx |
— |
13451–08–6 |
X14 X; R34 X; X50 |
X; X X: 14–34–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. kat. 2; R45 Muta. xxx. 3; X40 X+; X26 X; X25 X; R34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
C ≥ 25 %: X+; X45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: T; X45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: X; X45–22–23–43 1 % ≤ X < 3 %: X; X45–23–43 0,1 % ≤ X < 1 %: X; R45–20 0,01 % ≤ X &xx; 0,1 %:X; X45 |
|
|
016–024–00-X |
xxxxxxxx (ISO) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx trisodný |
410–130–3 |
136248–03–8 |
R43 |
Xi R: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
chlorid xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 X; X34 |
X X: 14-34 S: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: C; R34 5 % ≤ X &xx; 10 %: Xi; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 X; X50–53 |
X; X; X X: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
cyhexatin (XXX) xxxxxxxxxxxxx(xxxxxxx)xxxxxxx xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx |
236–049–1 |
13121–70–5 |
Xx; X20/21/22 N; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
tetracyklohexylstannan [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] butyl(tricyklohexyl)stannan [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; R20/21/22 X; R50–53 |
Xn; X X: 20/21/22–50/53 X: (2-)26–28–60–61 |
X ≥ 1 %: Xx; R20/21/22 |
1 |
|
|
050–017–00–2 |
fenbutatinoxid (XXX) 1,1,1,3,3,3-hexakis(2-fenyl-2-methylpropyl)distannoxan |
236–407–7 |
13356–08–6 |
T+; X26 Xx; X36/38 X; X50/53 |
X+; X R: 26–36/38–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
xxxx (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Xxxxxx 34 (XX 77603) CI xxxxxxxxxx xxxx 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. xxx. 3; X40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 N; X50–53 |
X; N X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
červeň (xxxxxxx-xxxxxxxxxx-xxxxx xxxxxxxx) XX Xxxxxxx Xxx 104 (XX 77605) XX xxxxxxxxxx xxxxxx 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. kat. 3; X40 Repr. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 N; X50–53 |
X; X X: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
601–024–00-X |
kumen [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
R10 Xx; X65 Xi; X37 X; X51–53 |
Xx; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
benzo[a]pyren xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; X45 Xxxx. xxx. 2; X46 Xxxx. xxx. 2; X60–61 X; X50–53 |
X; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
benzo[e]acefenanthrylen |
205–911–9 |
205–99–2 |
Karc. kat.2; X45 X; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-dichlorbenzen x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 N; X50–53 |
Xx; X R: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-jodprop-1-en xxxxxxxxxx |
209–130–4 |
556–56–9 |
X10 X; R34 |
C R: 10-34 S: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
xxx-2-xx-1,4-xxxx |
203–788–6 |
110–65–6 |
X; X23/25 Xx; X21–48/22 X; R34 |
T X: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
X ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ X &xx; 25 %: Xx; X20/22–48/22 3 % ≤ X &xx; 10 %: Xx; X20/22 |
||
|
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; X8 Xx; X22 Xx; X36 |
X; Xx R: 8–22–36 X: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 N; R51–53 |
Xn; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-nitrilotripropan-2-ol xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 X52–53 |
Xx X:36–52/53 X: (2-)26-61 |
|||
|
603–117–00–0 |
xxxxxx-2-xx xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; X11 Xx; X36 X67 |
X; Xx X: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
xxxxxxx-2-xx 2-hydroxybifenyl 2-xxxxxxxxxx (ISO) |
201–993–5 |
90–43–7 |
Xi; R36/37/38 X; R50 |
Xi; N X: 36/37/38–50 S: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx xxx xxxxxxx-2-xxxxxxxxxxxx 2-xxxxxxxxx sodný xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xx; X37/38–41 N; R50 |
Xn; X R: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-xxxxxxxxxxxx-2,2-xxxx)xxxxxxx 2,2-bis(4-hydroxyfenyl)-4-methylpentan |
401–720–1 |
6807–17–6 |
Repr. xxx. 2; X60 Xx; X36 X; X50–53 |
X; N R: 60–36–50/53 X: 53–45–60–61 |
|||
|
604–041–00–0 |
xxxxxxxxxxx [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xn; X22 Xx; X38–41 N; X50–53 |
Xx; X X: 22–38–41–50/53 S: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(xxxxxxxxx)xxxxx |
203–083–3 |
103–16–2 |
Xx; X36 X43 |
Xx X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; R36 R43 |
Xn X: 22–36–43 S: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. kat. 3; X40 Xx; X20 Xx; X36/38 R43 |
Xn X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xx; X20–36/38–40–43 1 % ≤ X &xx; 10 %: Xx; R40–43 |
|
|
606–016–00-X |
pindon (XXX) 2-(xxxxxxxxxxxxxxx)xxxxx-1,3-xxxx |
201–462–8 |
83–26–1 |
X; X25–48/25 X; X50–53 |
X; N X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (XXX) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xi; R36/38 X; X50–53 |
Xx; N X: 22–36/38–50/53 S: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) xxxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. xxx. 3; R40 T; X24/25 N; R50–53 |
T; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
metribuzin (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 X)-xx 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-4,5-xxxxxxx-1,2,4-xxxxxxx-5-xx |
244–209–7 |
21087–64–9 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
chloridazon (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx pyrazon |
216–920–2 |
1698–60–8 |
R43 X; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
chinomethionát (XXX) 6-methyl-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; R62 Xx; R20/21/22–48/22 Xi; X36 R43 X; X50–53 |
Xx; N X: 20/21/22–36–43–48/22–50/53–62 S: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-xxxxxxxxxxx)- 3,3-xxxxxxxx-1-(1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
256–103–8 |
43121–43–3 |
Xx; X22 X; R51–53 |
Xn; X R: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-xxxxxxxxxxxxxxxxxxx xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; R36 X; X50–53 |
Xx; X X: 22–36–50/53 X: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (XXX) 3,6-dichlor-2-methoxybenzoová xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; X22 Xi; X41 X52–53 |
Xx; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (ISO) 3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 X52–53 |
Xx X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
xxxxxxxxx (XXX) fumarin (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxxxxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 H -chromen-2-on 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-furyl)-3-oxobutyl]-4-hydroxy-2 X -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; X25–48/25 X52–53 |
X X:25–48/25–52/53 X: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
kelevan (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx xxxxx-5-(1,2,3,5,6,7,8,9,10,10-xxxxxxxxx-4-xxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx)-4-xxxxxxxxxxxx xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; R24 Xx; X22 N; R51–53 |
T; X X: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 X42/43 |
Xx R: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx |
203–677–2 |
109–52–4 |
X; X34 X52–53 |
X X:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-TBA (ISO) 2,3,6-xxxxxxxxxxxxxxxx kyselina |
200–026–4 |
50–31–7 |
Xn; X22 X; R51–53 |
Xn; X X: 22–51/53 X: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-chlor-2-oxo-2,3-dihydro-1,3-benzothiazol-3-yl)octová xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
xxxxxxxxxxx (XXX) 4-chlorfenyl-4-chlorbenzen-1-sulfonát |
201–270–4 |
80–33–1 |
Xn; R22 Xx; X38 X; X50–53 |
Xx; X X: 22–38–50/53 S: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx chloroctové xxxxxxxx xxxxxxxxxx sodný |
223–498–3 |
3926–62–3 |
T; R25 Xx; X38 X; X50 |
X; X X: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
xxxxxxxxxxxxxx (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx ethyl-4,4'-dichlorbenzilát |
208–110–2 |
510–15–6 |
Xn; X22 X; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propionyl}oxy)poly(oxyethylen) |
400–830–7 |
— |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 N; R51–53 |
Xi; X X: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx) |
403–030–6 |
— |
Xx; X22 X43 X; R50–53 |
Xn; X X: 22–43–50/ 53 S: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; R7 X10 X; X51–53 |
X; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 R53 |
Xi X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] bis(2-hydroxyethyl)amonium-3,6-dichlor-2-methoxybenzoát [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [3] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Xxxxxxx-X-(1-xxxxxx)xxxxxxxx |
205–073–4 |
132–67–2 |
Xx; R22 |
Xn X: 22 S: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx xxxxxxxxxxxxxxxxx-xxxxxxxxx XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 R43 X; X51–53 |
Xx; N X:36/37/38–43–51/53 X: (2-)24–37–61 |
C ≥ 10 %: Xi; X36/37/38–43 1 % ≤ X &xx; 10 %: Xx; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Směs (1:1): (X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 R)-cis-3-((Z)-2-chlor-3,3,3-trifluorprop-1-en-1-yl)-2,2-dimethylcyklopropan-1-karboxylát x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; X26 X; X25 Xx; X21 X; X50–53 |
X+; X R: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (XXX) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
608–003–00–4 |
akrylonitril |
D X |
203–466–5 |
107–13–1 |
X; Xxx Xxxx. xxx. 2; X45 X; X23/24/25 Xi; X37/38–41 X43 X; X51–53 |
X; X; N X: 45–11–23-/24/25–37/38–41–43–51/53 X: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ X &xx; 20 %: X; R45–23/24/25–41–43 5 % ≤ C &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ C &xx; 1 %:X; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: T; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 N; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
xxxxxxxx (XXX) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. kat. 2; X61 X+; X28 X; X24 X44 X; X50–53 |
X+; X X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (ISO) (2,4-xxxxxxxxxxxx)(4-xxxxxxxxxx)xxxxx |
X |
217–406–0 |
1836–75–5 |
Xxxx. xxx. 2; X45 Xxxx. kat. 2; X61 Xn; X22 X; X50–53 |
X; N X: 45–61–22–50/53 X: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-tetrachlor-3-nitrobenzen |
204–178–2 |
117–18–0 |
Xn; X22 R43 N; X50–53 |
Xx; N X: 22–43–50/53 S: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-aminoazobenzen 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. kat. 2; X45 N; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-hydroxy-3-{4-[2-methoxy-4-(3-sulfonatofenylazo)fenylazo]-3-methylfenylazo}-6-(3-sulfonatoanilino)naftalen-2-sulfonát trilithný |
403–650–7 |
117409–78–6 |
E; X2 X; X51–53 |
X; X R: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-xxxxxxxxxxxxxx-2,5-xxxx-1-xxxxxx)xxxxxxxx]xxxxxxxx-xxxxxxxxxxxx XX Xxxxx Xxx 9 XX basická červeň 9 |
209–321–2 |
569–61–9 |
Xxxx. xxx. 2; X45 |
X X: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-methoxyanilin x-xxxxxxxx |
X |
201–963–1 |
90–04–0 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 T; X23/24/25 |
X X: 45–23/24/25 X: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-xxxxxxxxxxxxxx xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xn; X22 X; R50–53 |
T; X X: 45–22–50/53 S: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X &xx; 25 %: X; X45 |
|
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 X; X39/23/24/25Xx; X48/20/21/22 X43 N; R51–53 |
T; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, soli x-xxxxxxx, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; X45 Xx; R22 N; X51–53 |
X; N R: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 T; R25 Xx; X21 Xi; X36 R43 X; X51–53 |
X; X X: 45–21–25–36–43–51/53 X: 53–45–61 |
||
|
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 C; X34 X43 R52–53 |
C X: 21/22–34–43–52/53 S: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-methyl-m-fenylendiamin2-methyl-1,3-fenylendiamin2-methylbenzen-1,3-diamin 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; R21/22 X43 X; R51–53 |
Xn; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-toluendiamin |
202–442–1 |
95–70–5 |
T; X25 Xx; R20/21 X43 X; X51–53 |
X; X R: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
flumetralin (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 N; X50–53 |
Xx; X X: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
xxxxxxxxxxxxx toluendiamin xxxxxxxxxxxxxxxxxxx methylbenzendiamin |
E |
246–910–3 |
25376–45–8 |
Karc. xxx. 2; X45 T; X25 Xx; X20/21 Xx; X36 R43 X; X51–53 |
X; N X: 45–20/21–25–36–43–51/53 S: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (ISO) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xi; X36/37/38 X52–53 |
Xx R: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
symklosen trichlorisokyanurová xxxxxxxx xxxxxxxx-1,3,5-xxxxxxxxxxxx 1,3,5-trichlor-1,3,5-triazin-2(1H), 4(3X), 6(5H)-trion |
201–782–8 |
87–90–1 |
O; X8 Xx; X22 R31 Xx; X36/37 X; X50–53 |
X; Xx; X X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx xxxxxxxxxxxxx |
202–095–6 |
91–76–9 |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
xxxxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 H-imidazol |
252–615–0 |
35554–44–0 |
Xn; X20/22 N; X41 X; X50–53 |
Xx; N X: 20/22–41–50/53 S: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (ISO) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; R20/22 Xx; X41 X; X50–53 |
Xx; X R: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
terbumeton (ISO) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 N; X50–53 |
Xx; X R: 22–50/53 S: (2-)60-61 |
|||
|
613–091–00–2 |
morfamkvat-dichlorid [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xn; X22 Xx; X36/37/38 X52–53 |
Xx; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-xxxxx-2-xxxxxxxxxx |
403–700–8 |
2687–94–7 |
X; R34 X; R51–53 |
C; X X: 34–51/53 X: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (XXX) (XX)-2-(2,4-xxxxxxxxxxxx)-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
79983–71–4 |
X43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (ISO) 1,2,5,6-xxxxxxxxxx-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)61 |
|||
|
613–134–00–5 |
xxxxxxxxxxxx (XXX) 2-(4-chlorfenyl)-2-[(1 X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
— |
88671–89–0 |
Xxxx. xxx. 3; X63 Xx; X22 Xx; X36 X; X51–53 |
Xx; X R: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
methabenzthiazuron (XXX) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
613–139–00–2 |
metsulfuron-methyl xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (XXX) 3-(1-methylpyrrolidin-2-yl)pyridin |
200–193–3 |
54–11–5 |
T+; X27 X; X25 X; R51–53 |
T+; X X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-dimethoxystrychnidin-10-on |
206–614–7 |
357–57–3 |
T+; R26/28 X52–53 |
X+ R:26/28–52/53 S: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] xxxxxx-xxxxxx [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 X52–53 |
X+ X: 26/28–52/53 S: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-xxxxxx-x-xxxxxxxxxxxxxxxxxx [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [3] xxxxxx-2,6-xxxxxxxxxxx [1] xxxxxx-2,4-xxxxxxxxxxx [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. xxx. 3; X40 X+; X26 Xx; R36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
X320 %: X+; X26–36/37/38–40–42/43 7 % ≤ X &xx; 20 %: X+; X26–40–42/43 1 % ≤ X &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; X22 X31 X; X34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (ISO) 6-methyl-3,4-dihydro-2H-pyran-5-karboxanilid |
246–419–4 |
24691–76–7 |
R52–53 |
R: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-xxxxx-3-[2-xxxx-2-(xxxxxxxxxxxx)xxxxxx]xxxxxxxx |
261–043–0 |
57966–95–7 |
Xx; X22 R43 N; X50–53 |
Xx; X X: 22–43–50/53 S: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-xxxxxxxxxx-1-xxxxxx)xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; X7 Xx; X22 X; X34 X; X50–53 |
X; X; X R: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ C < 25 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx bis(2-fenylpropan-2-yl)peroxid xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx xxxxxxxxxxxxxx |
201–279–3 |
80–43–3 |
X; R7 Xx; X36/38 N; X51–53 |
X; Xx; N X: 7–36/38–51/53 S: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; R2 Xx; X36 X43 |
X; Xx; X: 2–36–43 S: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (XXX) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. xxx. 3; X40 Xx; X21/22 X; R50–53 |
Xn; N X: 21/22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (ISO) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; X25 N; X50–53 |
X; X X: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx |
243–269–1 |
19750–95–9 |
Xxxx. xxx. 3; X40 Xx; R22 N; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(X)-(3-xxxxxxxxxxx)xxxxxxxxxx]-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (X)-3-xxxxxx-α-xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx |
— |
66230–04–4 |
X; X23/25 R43 X; X50–53 |
X; X X: 23/25–43–50/53 S: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-xxxxxxxxxxx)xxxxxx-1-xxxxxxxx]-3-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxx |
— |
82097–50–5 |
X; R50–53 |
N X: 50/53 X: 60-61 |
PŘÍLOHA 1D
|
Indexové xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx limity |
Poznámky x xxxxxxxxxx |
|
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; R20 Xx; R41 X52–53 |
Xx X: 20–41–52/53 X: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-xx(xxx-5-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx x 1,3-xx(xxx-x-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
015–164–00–9 |
xxxxxxx-xxxxxxxxxx-(1-xxxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
|
015–165–00–4 |
Směs: X, X, X', X''-xxxxxxxxxx-4,4'-xxxxxxxxxxxxx(xxxxxxxxxxxxxx)-xxx(xxxxxxxxxxxxxxxx) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; R41 X; X50–53 |
Xx; X X: 41–50/53 X: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 X: 61 |
|||
|
015–167–00–5 |
3-[hydroxy(fenyl)fosfinoyl]propanová xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; X41 |
Xx X: 41 S: (2-)26-39 |
|||
|
601–050–00–1 |
C10-C13-alkylderiváty xxxxxxx |
267–051–0 |
67774–74–7 |
X; X50 |
X X: 50 X: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X R: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx difenyletheru xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; N X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; R52–53–59 |
N X: 52/53–59 S: 59-61 |
|||
|
603–128–00–0 |
2-(xxxxxxxxxxxx)xxxxxxxx |
405–490–3 |
613–62–7 |
X53 |
X:53 X: 61 |
|||
|
603–129–00–6 |
1-xxxx-xxxxxxxxxxxx-2-xx |
406–180–0 |
57018–52–7 |
X10 Xx; X41 |
Xx X: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx isomerů: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; R22 X52–53 |
Xx X:22–52/53 S: (2-)39-61 |
|||
|
603–131–00–7 |
Směs (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-deoxy-1-[methyl(1-oxotetradecyl)amino]-D-glucitol |
407–290–1 |
— |
Xi; X41 |
Xx X: 41 S: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-chlor-5-nitro-1,4-fenylen)diimino]di(propan-1,2-diol) |
408–240–1 |
— |
Xn; X22 X52–53 |
Xx X:22–52/53 X: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx a xxxxxxxxxx xxxxxxxxxxxx) |
410–450–3 |
— |
X53 |
X: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-xxxxxxxxxxxxxxx-1-xxxxx-X,X)xxxxxxxxxx xxxxxxx |
410–500–4 |
— |
Xx; X41 X; X51–53 |
Xx; N X: 41–51/53 S: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx a 1-deoxy-1-[methyl(1-oxooktadecyl)amino]-D-glucitol |
411–130–6 |
— |
Xi; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-xxxxxxxx-3-xxxxxxxxxxxxx)xxxxxx 2,2-dimethyl-3-(3-methylfenyl)propan-1-ol |
403–140–4 |
103694–68–4 |
R52–53 |
R:52/53 X: 61 |
|||
|
604–050–00-X |
4-xxxxx-x-xxxxxx 4-chlor-2-methylfenol |
216–381–3 |
1570–64–5 |
T; X23 X; X 35 N; X50 |
X; X; X X: 23–35–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; C; X23–35 10 % ≤ X &xx; 25 %: X;X20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ C &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X &xx; 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 S: 61 |
|||
|
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - xxxxxxxxxxxx-2-xx)-4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx] 6,6'-xxx(2X -xxxxxxxxxxxx-2-xx)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 S: 61 |
|||
|
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; X38 X43 N; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx x 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-bis[(2,3-epoxypropyl)oxy]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; X40 |
Xx X: 40 X: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X-xxxxx-6-xxxxxxxxxxx a 3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-pentylcyklohexanon xxxxxxxxxxxxxxxx-1-xx |
4–406–670–4 |
61203–83–6 |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(N, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx xxxxxxxx |
410–410–5 |
54574–82–2 |
X52–53 |
X:52/53 X: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (XXX) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-butoxy-1-methylethyl)-[(4-amino-3,5-dichlor-6-fluor-2-pyridyl)oxy]acetát [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
xxxxxxx-7-{2,6-xxxxxxxx-8-[(2,2-xxxxxxxxxxxxxxxx)xxx]- 1,2,6,7,8,8a-hexahydro-1-naftyl}-3,5-dihydroxyheptanoát |
404–520–2 |
— |
R52–53 |
R:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[benzyl(methyl)amino]ethyl}-3-aminobut-2-enoát |
405–350–1 |
54527–73–0 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
natrium-4-(benzoyloxy)benzen-1-sulfonát |
405–450–5 |
66531–87–1 |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) bis(1-methylimidazol)]zinečnatý xxxxxxx |
405–635–0 |
— |
Xx; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Směs:2-(hexylsulfanyl)ethylamin-hydrochlorid x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; R22 Xi; X41 X43 X; X51–53 |
Xx; X X: 22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx a nerozvětvené)-3-[3-(2 X - benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
405–760–0 |
— |
Xi; X41 R43 X52–53 |
Xx X: 41–43–52/53 S: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) x (xxxxxxxxxxxxxx)xxxxxxxxx-(xxxxxxxx-xxxxxx)-(xxxxxxxx-xxxxxxxx) |
405–960–8 |
— |
X43 X; R51–53 |
Xi; N X: 43–51/53 S: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx xxxxx xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; R36 X43 |
Xx X: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Xxxx:xxxxx(X7-X9 rozvětvené x xxxxxxxx)-3-[3-(2X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
407–000–3 |
127519–17–9 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; X21/22 Xi; X38–41 X43 N; X50–53 |
Xx; N R: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) x lithium-3,3'-{(1,4-fenylen)bis[(karbonylimino)(propan-3,1-diyl)imino]}bis(10-amino-6,13-dichlor[1,4]benzoxazino[2,3-b]fenoxazin-4,11-disulfonát) |
410–040–4 |
136213–76–8 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–285–00–6 |
Směs:7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonová xxxxxxxx, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- x xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -trisulfonatoftalocyanin]nikelnatý xxxxxxx, xxxxxxxxxx xxx; x = 15, 16, 17 xxxx 18, x = 1, 2, 3 xxxx 4, x = 8, 9, 10 xxxx 11, x = 22, 23, 24 xxxx 25 |
410–160–7 |
148732–74–5 |
Xi; X36 X43 X52–53 |
Xx X: 36–43–52/53 S: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx kyselina |
410–370–9 |
105488–33–3 |
R53 |
R:53 X: 61 |
|||
|
607–290–00–3 |
Xxxx (x xxxxxxxx poměru):amonium-1-alkyl(C14-C18)-4-[3-(allyloxy)-2-hydroxypropyl]-2-sulfonatobutandioát x xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 X43 X; R50–53 |
Xi; X X: 38–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx cyklohexyl)alkanoát |
410–630–1 |
104051–92–5 |
R53 |
R: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx xxxxxxxx x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx kyselina |
410–640–6 |
— |
Xi; X38–41 X; R50–53 |
Xi; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XXxxx: |
1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 X43 X; X51–53 |
Xx; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx R: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx a xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 N; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxxxx xxxxxxxx x 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(2-xxxxxxxxx-10-xxxxxxxxx kyselina)2,2'-dioxo-3,3'-(1,4-fenylendimethyliden)bis(1,7,7-trimethylbicyklo[2.2.1]heptan-1-methansulfonová xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(trimethylamonio)ethyl]-4-sulfonatobenzoát |
411–010–3 |
— |
R43 |
Xi X: 43 X: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; X22 R43 X; R50–53 |
Xn; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx xxxxxxx, xxxxxxxx sůl; a = 1,2,3 nebo 4, x = 8, 9, 10 xxxx 11, x = 15, 16, 17 xxxx 18, x = 22, 23, 24 nebo 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Xxxx:xxxxxxxxxx xxxxxxxx x dodekanoáty oligo(1-7)laktátů |
411–860–5 |
— |
Xi; X38–41 X43 N; X51–53 |
Xx; N R: 38–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x tetradekanoáty xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; N X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx xxxxxxxx |
413–760–7 |
93107–30–3 |
Xxxx. kat.3; X62 X52–53 |
Xx R: 62–52/53 X: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-chlorfenyl)-2-fenyl-2-[(1H- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 X: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 X; X8 Xxxx. xxx. 2; R45 T; X23/25 R43 |
E; T X: 45–3–8–23/25–43 X: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 X; X34 X43 X; X50–53 |
X; X X: 22–34–43–48/22–50/53 S: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Směs (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx trisodný, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx trisodný a[{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx X: 41–52/53 X: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(4-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-xxxxx-5-xxxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; R51–53 |
Xi; X41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 X: 61 |
X X: 51/53 X: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xx; X48/22 X43 X; X50–53 |
X; X X: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Směs (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[(2-acetoxyethyl)ethylamino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–890–3 |
111381–11–4 |
R53 |
R: 53 X: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[bis(2-acetoxyethyl)amino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–900–6 |
111381–12–5 |
R53 |
R: 53 X: 61 |
|||
|
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, kyselina octová x mléčná xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; X48/22 R43 X52–53 |
Xx R: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[ethyl(2-hydroxyethyl)amino]-2-methylfenyl}azo)-6-methoxy-3-methylbenzothiazolium-chlorid |
411–110–7 |
136213–74–6 |
N; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) azo]-6-[(6-sulfonato-1-naftyl)azo]benzen-1,3-diolato}]železnatý xxxxxxx, xxxxx xxx |
400–720–9 |
— |
X52–53 |
X: 52/53 X: 61 |
|||
|
612–156–00–2 |
Směs:trihexadecyl(methyl)amonium-chlorid a xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 X; X50–53 |
Xx; N X: 41–50/53 X: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(Z)-1-(1-benzothiofen-2-yl)ethan-1-on-oxim-hydrochlorid |
410–780–8 |
— |
Xn; X22–48/22 Xx; X41 X43 X; X51–53 |
Xx; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Xxxx:[xxx(5-xxxxx(xxxxxxxxxx C12))-2-hydroxybenzaldoximato)]měďnatý xxxxxxx a 4-dodecyl-2-hydroxybenzaldoxim[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx xxxxx 2,2,4-xxxxxxxxx- x 2,4,4-trimethylhexan-1,6-diaminu (x xxxxxxx XXXXXX), xxxxxxxx [(alkyl(C10-C16)oxy)methyl]oxiranu (Epoxid 8) x 4-xxxxxxxxxxxx-1-xxxxxxxxx xxxxxxxx |
410–880–1 |
— |
Xx; R22 X; X34 X; R50–53 |
C; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; R23/25 X; X50–53 |
X; N X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
|
613–151–00–8 |
1-(2-deoxy-3-O-mesyl-5-O-trityl-β-D-threo-pentofuranosyl)-5-methylpyrimidin-2(1H), 4(3 H)-dion |
406–360–9 |
104218–44–2 |
R53 |
R:53 X: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-trichlorpyridin |
407–270–2 |
16063–70–0 |
R52–53 |
R:52/53 X: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; R22 |
Xn X: 22 X: (2-)22 |
|||
|
613–155–00-X |
5-xxxxx-2,3-xxxxxxxxxxxxxx |
410–090–7 |
89402–43–7 |
X10 Xx; X22 X52–53 |
Xx X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-xxxxx-5-xxxxxxxxxxxxx-4-xxxxxxxxxxx |
410–260–0 |
83857–96–9 |
X43 N; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-diamino-5-(methoxymethyl)pyrimidin 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xi; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; X20/22 Xx; X41 X43 X; X51–53 |
Xx; X X: 20/22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; X25 Xx; X20 X; X50–53 |
X; X X: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-methyl-2,5-diazabicyklo[2.2.1]heptan-dihydrobromid |
411–000–9 |
125224–62–6 |
R43 |
Xi R: 43 S: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 X14 Xx; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 S: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx kyselinymethyl-2-[(isokyanatosulfonyl)methyl]benzoát |
410–900–9 |
83056–32–0 |
R10 X14 Muta. kat. 3; X40 Xx; X20–48/22 Xx; X41 X42 |
Xx R: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
N-(3,5-dichlor-4-ethyl-2-hydroxyfenyl)-2-(3-pentadecylfenoxy)butanamid |
402–510–2 |
— |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(diethylamino)-2-methoxyacetanilid |
405–190–2 |
122371–93–1 |
R43 R53 |
Xi X: 43-53 X: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-xxxxx-7-xxxxxxxxxxxxxx[1,5-x][1,2,4]xxxxxxx-4-xx)xxxxxx]-2-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxxxxxx |
406–390–2 |
— |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - tetraalkyl(C16)-2,2′, 2″, 2′′′ (xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx x N, X′,X″,X′′′ - tetraalkyl(C18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(xxxxxxxxxxxxxx)xxxxxxxxxxxxxx |
406–740–4 |
1939–27–1 |
Xx; X48/22 X; X51–53 |
Xx; X X: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-xx-xxxx-xxxxxxxxxxx)-X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxx |
408–150–2 |
99141–89–6 |
X53 |
X:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 N; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Směs:3,3'-bis(4-methylfenyl)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-xxx(4-xxxxxxxxxxx)-1,1'-(2-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx Xxxx:2,4-xxx[3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
bis(4-methylbenzoyl)peroxid |
407–950–9 |
895–85–2 |
E; X2 X; X7 N; X50–53 |
X; X R: 2–7–50/53 X: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
xxxxxxxxxxxx (XXX) (2R, 3X)-, (2 S, 3 X)-, (2 X, 3 S)-, (2 X, 3 X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxx-1-(1X- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. xxx. 3; X63 Xx; X22 X; R50–53 |
Xn; N X: 22–50/53–63 X: (2-)36/37–60–61 |
XXXXXXX 2
XXXXXX XXXXXXXXXXXX XXXXX XXXXXXXXX S XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Komise 2001/59/XX,
Xx. věst. X 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX POKYNY XXX XXXXXXXX XXXXXXXXX X XXXXXXXXXXXX XXXXXXX X PŘÍPRAVKY
Viz směrnice Xxxxxx 2001/59/ES,
Úř. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 3B
STANDARDNÍ XXXXXX XXX XXXXXXXX XXXXXXXXX X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/ES,
Úř. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4X
"X.10 XXXXXXXXXX — XXXXXXX NA XXXXXXXXXXXX XXXXXXX X XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx OECD XX 473 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx x xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx na xxxxxxxxxxxx xxxxxxx u xxxxx xx xxxxx xx xxxxxxxxxxxxx činitele, xxxxx xxxxxxxxx xxxxxxxxxx chromozomové xxxxxxx x kultivovaných xxxxxxx xxxxx (1, 2, 3). Rozlišují xx xxx xxxx xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x chromatidové. X xxxxxxx chemických xxxxxxxx xxxx indukované xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace se xxxxxx vyskytují. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx chemická xxxxx xx xxxxxxxxx indukovat xxxxxxxxx aberace. Xxxx xxxxxx xxxx xxxx xxxxxx xx stanovení xxxxxxxxxxx aberací a xxxx x xxxxxx xxxxx xxxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx x xxxxxxx xxxx jsou xxxxxxxx xxxxx geneticky xxxxxxxxxxx xxxxxx x xxxxxxx x xxxxxxxx xxxxx důkazů x xxx, xx xxxxxxxxxxxx xxxxxx x x xxxx související xxxx xxxxxxxxxxx změny x xxxxxxxxxx a x xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx nádory, xxxx xxxxx na indukci xxxxxxxx x člověka x x pokusných xxxxxx.
Xx xxxxxxx xx xxxxxxxxxxxx aberace in xxxxx xxxxx být xxxxxxx xxxxxxxxxxxxx buněčné xxxxx, xxxxxxx xxxxx xxxx primární buněčné xxxxxxx. Xxxxxxx buňky xxxx xxxxxxx xx xxxxxxx xxxxxxxxxx xxxxx x xxxxxxx, xxxxxxxx xxxxxxxxx, počtu xxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx chromozomových xxxxxxx.
Xxxxxxx xxxxxxxxx xx xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx zcela xxxxxxxxx xxxxxxxx xx vivo x xxxxx. Xx xxxxx xx xxxxx xxxxxxxxx podmínek, xxxxx xx xxxxx x xxxxxxxxxx výsledkům, xxx xxxxxxxxxx vlastní xxxxxxxxxx x xxxx k xxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx úrovní cytotoxicity (4, 5).
Xxxx xxxxxxx xx xxxxxxx ke xxxxxxxx možných xxxxxxxx x xxxxxxxxxxx xxx xxxxx. Xxxxx sloučenin, xxx něž je xxxx zkouška xxxxxxxxx, xxxx xxx xxxxx xxxxxxxxxxx; xxxx xxxxx xxxxxxxx x karcinogenitou xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx závisí xx xxxxxxxx třídě x xxxxxxxxx xxxxxx x xxx, xx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx xxxxxx xxxxxxxxxx xxx xxxxxx poškozením XXX.
Xxx také Obecný xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx xxxxx xxxxxxxxxxxx chromatid xxxx xxxxx x opětného xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození xxxxxxxxxx v xxxxxx xxxxx nebo xxxxx x xxxxxxx xxxx xxxxxxxxx x tomtéž xxxxx.
Xxxxxxxxxxxxxxx : proces, xxx xxxxxx x xxxxx po X-xxxx xxxxxxxxx DNA xxxxxxx x xxxxxx, nýbrž xxxxxxxxx další X-xxxx. Xxxxxxxxx jsou xxxxxxxxxx xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx menší xxx xxxxx xxxxx xxxxxxxxxx a s xxxxxxxxx xxxxxxxxx chromatid.
Mitotický xxxxx : xxxxx xxxxx, které xx xxxxxxxxx v xxxxxxxx, x xxxxxxxxx počtu xxxxx x xxxxxxxx; xxxxx stupeň xxxxxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxxxx xxxxx obvyklého x xxxxxxxxx xxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), xxxx než xxxxxxxxx (xx. 3 x, 4 n xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx chromozomů xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; jeví xx xxxx xxxxxx x fragmenty, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, x xx s metabolickou xxxxxxxx x bez xx. X xxxxxx xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx látce xx xx buněčných xxxxxx xxxxx látka xxxxxxxxxxx xxxxxxxx (např. Xxxxxxxx® xxxx xxxxxxxxx), kultury xx sklidí, xxxxxx x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx se xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx xxx xxxxxxx xxxxx xxxxxxx xxxxx, kmeny xxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxx lidských xxxxxxxxx xxxxx (xxxx. xxxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx xxxx člověka xxxx xxxxxx xxxxx).
1.4.1.2 Xxxxx a kultivační xxxxxxxx
Xxx udržování xxxxxx xx xxxx xxx xxxxxxx vhodná xxxxxxxxxx xxxxx a xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx CO2, teplota x vlhkost). X xxxxxxxxxxxxxxx xxxxxxxxx linií x xxxxx by xxxx být xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxx x mělo xx xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx; x xxxxxxx kontaminace xx neměly být xxxxxxx. Pro použité xxxxx x xxxxxxxxx xxxxxxxx xx měla xxx xxxxx xxxxxxxx xxxxx buněčného xxxxx.
1.4.1.3 Xxxxxxxx kultur
Stabilizované xxxxxxx xxxxx a xxxxx: xxxxx xx pomnoží x xxxxxxxxx kultur, xxxxxx xx do xxxxxxxxxxxx média v xxxxxx xxxxxxx, xxx xxxxxxxxx konfluence před xxxxxxxxx, x xxxxxxxx xx xxx 37 °X.
Xxxxxxxxx: xxxx xxxxxxxx xxxxxxxxxxxxxxx (xxxx. xxxxxxxxx) xxxx xxxxxxxx lymfocyty xxxxxxxx probandů xx xxxxxxx xx xxxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx (xxxx. fytohemaglutinin) x xxxxxxxx se xxx 37 °X.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx xx xxxx xxx vystaveny xxxxxxxx xxxxx, x xx x xxxxxxx xxxxxxxxxxxx xxxxxxxx x xxx xx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) připravená x xxxxx hlodavců zpracovaná xxxxxxxx indukujícím xxxxxx, xxxx xx Xxxxxxx 1254 (6, 7, 8 x 9), xxxx směs xxxxxxxxxxxxx x β-xxxxxxxxxxxx (10, 11 x 12).
Postmitochondriální xxxxxx xx x xxxxxxxx xxxxxxxxxx médiu xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx xxxxx xxxxxxxx xxxxx, xxxxx xx xxxxxxxx. X xxxxxxxxx xxxxxxxxx xxxx xxx xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx výsledků xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx buněčných xxxxx xxxxxxxxxxxxx specifické xxxxxxxxx enzymy, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx použitých xxxxxxxxx xxxxx by xxxx být xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx cytochromu P450 xxx metabolismus xxxxxxxx xxxxx).
1.4.1.5 Zkoušená látka/příprava
Pevné xxxxxxxx xxxxx xx xxxx xxx před xxxxxxxx xx xxxxx xxxxxxxxxx xxxx suspendovány xx xxxxxxxx rozpouštědlech xxxx vehikulech a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxx xxxxx x xxxxxxxxxx systémům x/xxxx mohou xxx xxxx aplikací zředěny. Xxxx by xxx xxxxxxx xxxxxxx připravené xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost skladování.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx, x xxxx xx xxx xxxxxxxxxx x xxxxxxxx buněk x x xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx kompatibilitě. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx být xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx zohledněna xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, rozpustnost x xxxxxxxxxx xxxxxxx x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx být xxxxxxxxx x xxxxxxxxxxxx aktivací x xxx ní x xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx xxxxxxxxxx xxxxxxx integrity x xxxxx, jako xxxx xxxxxx xxxxxxxxxx, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx mitotický xxxxx. Xxxx být xxxxxxx xxxxxxxx cytotoxicitu a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx být xxxxxxx alespoň xxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx cytotoxicity xx xxxx xxxx koncentrace xxxxxxxx xxxxxxx xxxx xxxxxxxxx až xxxxxxxxx xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, což obvykle xxxxxxx, že xx xx xxxxxxxxxxx xxxxxx xxxxx více xxxxx xxxxxxxx 2 až Ö10. V okamžiku xxxxxxx xx měla xxxxxxxx koncentrace xxxxxxxxx xxxxxxxx snížení xxxxxx xxxxxxxxxx, xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx o xxxx xxx 50 %). Xxxxxxxxx xxxxx xx xxxxx nepřímým měřítkem xxxxxxxxxxxxx nebo cytostatických xxxxxx x xxxxxx xx xxxx, xxxxx xxxxxxxx xx expozice. Xxxxxxxxx index xx xxxx xxxxxxxxxx x xxxxxxxxxxx kultur, x xxxxx xxxxx xxx xxxx xxxxxx stanovení xxxxxxxx xxxxxxx x xxxxxxxxxxx. Xxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx průměrná xxxxxxxxx xxxx (XXX), mohou xxx xxxxxxx jako xxxxxxxxx xxxxxxxxx. X xxxxxxx AGT však xxx x xxxxxxxx xxxxxxxxx xxxxxxx, z xxx xxxxx xxxxxxx xx existenci zpožděných xxxxxxxxxxx, x x xxxx přírůstek průměrné xxxxxxxxx xxxx xxxx xxx za xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx výtěžku xxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx toho, xxxxx x xxxx je xxxxxxxx.
X případě xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxxxx toxické xxx xxxxxxxxxxxxx nižších, xxx xx xxxxxx rozpustnost, xx měla xxx xxxxxxx xxxxxxxx dávka x koncentraci, xxx xx xxx xxxx xxxxxxxxxxxx v konečném xxxxxxxxxxx xxxxx na xxxxx xxxx xxxxxxxx. X určitých xxxxxxxxx (xxxx. projeví-li xx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxxxxxxx, xxx xx xxxxxxxxxxx) se xxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxxx, při xxxxx xxxxxxx xx xxxxxxx. Xxxx být užitečné xxxxxxxx xxxxxxxxxxx xx xxxxxxx a xx xxxxx expozice, xxxxx xxxxxxxxxxx v xxxxxxxxxx xxxxxxx se xxxx x průběhu xxxxxxxx xxxxx v důsledku xxxxxxxxxxx xxxxx, xxxx X9 atd. Xxxxxxxxxxxxx xxx xxxxxxx vizuálně. Xxxxxxxxx xx xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx a xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx experimentu xx měly xxx xxxxxxxxx x xxxxxxxxx xxxxxxxx (xxxxxxxx xxxxxxxxxxxx xxxx xxxxxxxx). Xxx xxxxxxx xxxxxxxxxxx xxxxxxxx xx měla být xxx pozitivní xxxxxxxx xxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx aktivaci.
K xxxxxxxxx xxxxxxxx xx xxx být xxxxxx xxxxx elastogen x xxxxxxxxxxx xxxxxxxxxxxxx, které xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx x xxxxxxxxxxxxx nárůst xxx xxxxxx, čímž xx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx xxxxxxxxxxx xxxxxxx xx xxxx xxx zvoleny tak, xxx byl účinek xxxxxxxx, xxx xxx xxx odečtu nevyšla xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxxxxxxxx a xxxxxxxxxxx xxxxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
Xxx xxxxxx metabolické xxxxxxxx |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Pro pozitivní xxxxxxxx xxxxx být xxxxxxx x jiné xxxxxx látky. Pro xxxxxxxxx xxxxxxxx xx xxxx být pokud xxxxx xxxxx x xxxxx xxxxxxx chemických xxxxx xx stejné xxxxxxxx xxxxx.
X okamžiku xxxxxxxx by xxxx xxx použity negativní xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx rozpouštědla xxxx xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxxx stejným xxxxxxxx xxxx xxxxxxx. Xxxxx xxxx xx měly xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx žádné xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx zhoubné xxxx mutagenní účinky.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx zkoušené xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxxxxx zkoušené xxxxx xxx za xxxxxxxxxxx xxxxxxxxxxxxx aktivačního systému, xxx xxx xxxx. Xxxxxxxx lymfocytů xx xxxx xxx xxxxxxxx xxx 48 xxxxx xx xxxxxxxxx stimulaci.
1.4.3.2 Xxx xxxxxx xxxxxxxxxxx xx měly xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx, x xxxxx xx důrazně xxxxxxxxxx x xxxxxx xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx rozpouštědla. Xxxxxxxx xxx na xxxxxxx xxxxxxxxxxx údajů xxxxxxxx (13, 14), xx xxxx xxxxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxx xxxxxx xxxxxxx.
Xxxxxx xxxx těkavé xxxxx xx měly být xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx nádobách (15, 16).
1.4.3.3 Xxxx xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx měly xxx buňky vystaveny xxxxxxxx látce, xxx x xxxxxxxxxxxx xxxxxxxx, xxx bez ní, xx dobu 3 — 6 xxxxx, x xxxx by xxx xxxxxxxx xx xxxxxx xxxx xx xxxxxxxx xxxxxxxx, která xxxxxxxx 1,5xxxxxxx normální xxxxx xxxxxxxxx cyklu (12). Jestliže tento xxxxxx dává negativní xxxxxxxx xxx x xxxxxxxx, tak xxx xxxxxxxx, xxx xx xxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxx aktivace x xxxxxxxxxxxx xxxxxxxx xx xx xxxxxx x xxxx, která xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx. Xxxxxx chemické látky xxx xxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxx xxx 1,5násobek délky xxxxx. Negativní výsledky xxx metabolické xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx od případu. X xxxxxxxxx, xxx xx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxx, xx xxxx xxx podáno zdůvodnění.
1.4.3.4 Xxxxxxxx preparátů xxx xxxxxxx chromozomů
Do xxxxxxx xxxxxxx xx xxxxxxx 1-3 xxxxxx xxxx xxxxxxxxx přidá Xxxxxxxx® xxxx xxxxxxxxx. Xxx xxxxxxxx preparátů pro xxxxxxx xxxxxxxxxx se xxxxx buněčná xxxxxxx xxxxxx x xxxxxxxxxx xxxxxx. Xxxxxxxx xxxxxxxxx xxx analýzu xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx, xxxxxx a xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx xxxxxxxxx, xxxxxx preparátů xxxxxxxxxxx x negativních xxxxxxx, xx měly xxx xxxx xxxxxxxx xxx xxxxxxxxxxx nezávisle xxxxxxxx. Xxxxxxxx xxx fixaci xxxxx xxxxxxx xx xxxxx xxxxx xxxxx x xxxxxxxx x xx xxxxxx xxxxxxxxxx, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx rovném xxxxxxx hodnotě ± 2 xxx všechny xxxx xxxxx. Na xxxxxx xxxxxxxxxxx a xxxxxxxx by xxxx xxx xxxxxxxxx alespoň 200 dobře rozprostřených xxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Tento xxxxx xxx snížit, je-li xxxxxxxxx velký xxxxx xxxxxxx.
Xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx, xx xxxxxxxx xxxxxxxxxx polyploidii x xxxxxxxxxxxxxxx, jsou-li xxxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx x xxxx xx xxxx xxx xxxxxxxxxxx množství buněk xx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxx (xxxxxxxxx) xxxxxxxxx x procentech. Xxx xxxxxxxxx a experimentální xxxxxxx xx xxxx xxx uvedeny xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx s xxxxxx xxxxxx x xxxxxxxx. Xxxx xx xxxxxxxxxxxxx xxxxxxxx a xxxxxxx xx, xxx xxxxxxxxxx xx xx xxxxxxx xxxxxxxx aberací.
Měla xx xxx xxxx xxxxxxxxxxx xxxxxxxx, xxxxx xxxx xxxxxxxxx xxx stanovení xxxxxxxxxxxx x všech xxxxxxxxxxxx xxxxxx a xxxxxxxxxxx xxxxxx x xxxxxxxx experimentech x xxxxxxxxx.
Xxxx by xxx xxxxxxx údaje pro xxxxxxxxxx xxxxxxx. Xxxx xx měly xxx xxxxxxx xxxxx shrnuty xx xxxxx xxxxxxx.
Xxxxxxx xxxxx pozitivní odpovědi xx nepožaduje. Xxxxxxxxxx xxxxxxxx xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, xxxxxxx s xxxxxxxx xxxxxxxxxxxxxxxx podmínek. Xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx x xxxx 1.4.3.3. Xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx xx měla být xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. K parametrům xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, xxxxx rozmezí koncentrací x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx kritérií, např. xxxxxx počtu xxxxx x chromozomovými xxxxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, nebo reprodukovatelný xxxxxx xxxxxx počtu. Xxxxxxxx by xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků zkoušky xxxxx xxx použity xxxx xxxxxxx prostředek xxxxxxxxxxx metody (3, 13). Xxxxxxxxxxx významnost xx neměla xxx xxxxxxx určujícím faktorem xxx pozitivní odpověď.
Nárůst xxxxx polyploidie buněk xxxx znamenat, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx buněk x xxxxxxxxxxxxxxxxxxx chromozomy xxxx znamenat, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx (17, 18).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, se x xxxxx systému xxxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xx zkoušky xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxxxxxx, xx xxxxxxxx xxxxx indukuje x kultivovaných xxxxxxxxxxx xxxxxxx savců xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx zkoušky xxxxxxxxxx x kultivovaných xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx zkoušené xxxxx v rozpouštědle/vehikulu, xx-xx známa.
Buňky:
- typ x xxxxx xxxxx,
- xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxxx xxxx xxxxx,
- xxxxxxxxx nepřítomnost xxxxxxxxxxx,
- xxxxxxxxx o xxxxx xxxxxxxxx xxxxx,
- xxxxxxx dárce krve, xxx xxxx xxxxxxx xxxx krev nebo xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx,
- případně počet xxxxxx,
- případně metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxx hodnota xxxxx xxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx koncentrace a xxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxx koncentrací x xxxxx kultur, xxxxxx xxxx. xxxxx x xxxxxxxxxxxx x xxxxxx xxxxxxxxxxxx, jsou-li x xxxxxxxxx,
- složení xxxxx, případně xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx zkoušené xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- xxxxxxxx hustota xxxxx xxx xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- pozitivní a xxxxxxxxx kontroly,
- xxxxxx xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- kritéria xxxxxxxxxxx studie xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky toxicity, xxxx. stupeň xxxxxxxxxx, xxxxx x buněčném xxxxx, xxxxx xxxxx, xxxxxxxxx index,
- xxxxxx xxxxxxx,
- údaje x xX a xxxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxx,
- definice xxxxxxx, včetně xxxx,
- xxxxx buněk s xxxxxxxxxxxxxx xxxxxxxxx a xxxx aberací xxxxxx xxx xxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx pozorovány,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) x pozitivní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x směrodatnými xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X. (1976), Xxxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxx Xxxxxxxx, xx: Chemical Xxxxxxxx, Xxxxxxxxxx xxx Xxxxxxx xxx their Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Press, Xxx Xxxx xxx London, 1-29.
2) Xxxxxxxx, X. Xx., Sofumi, X. (1985), Xxx In xxxxx Xxxxxxxxxxx Xxxxxxxxxx Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (CHL) Xxxxxxxxxx Xxxxx xx Xxxxxxx, xx: Xxxxxxxx xx Xxxxxxxxxx Xxxxxxxx, Xxx. 5, Ashby, X. xx xx., (xxx) Elsevier Xxxxxxx Xxxxxxxxxx, Amsterdam-New Xxxx-Xxxxxx, 427-432.
3) Galloway, X. X., Armstrong, M. X., Xxxxxx, C., Xxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxx, X. D., Xxxxxxxx, X., Ahmed, X., Duk, X., Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxx, X., Xxxxxx E. (1978), Xxxxxxxxxx xxxxxxxxxx xxx sister xxxxxxxxx xxxxxxxxx xx Xxxxxxx xxxxxxx ovary cells: Xxxxxxxxxx xx 108 xxxxxxxxx, Xxxxxxx. Xxxxx. Xxxxxxx. 10 (suppl. 10), 1-175.
4) Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxxx, X. Xx., Brusick, X., Xxxxx, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx under Xxxxxxx Xxxxxxx Conditions. X xxxxxx xxxx XXXXXX Xxxx Group 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, X., Xxxxxx, X., Xxxxxx, X., Okumura, K., (1992), Clastogenicity xx xxx pH xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Mutatation Res., 268, 297-305.
6) Ames, X. X., McCann, X., Xxxxxxxx, X. (1975), Methods for Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Mutagenicity Xxxx, Xxxxxxxx Xxx., 31, 347-364.
7) Maron, X. X., Xxxx, X. X. (1983), Xxxxxxx Methods xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
8) Natarajan, X. X., Xxxxx, X. D., xxx Xxxx, X. P. X., Meijers, X., xx Xxxxx, X. (1976), Xxxxxxxxxxx Effects xx Xxxxxxx/Xxxxxxxxxxx xxxxx Xxxxxxxxxx in a Xxxxxxxxxxx System In xxxxx, X. Xxxxxxxxx xx Xxxxxxxxxx Xxxxxxxxxxx xxx Xxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx (XXX) xxx Dimethylnitrosamine (XXX) xx XXX Xxxxx in xxx Xxxxxxxx xx Xxx-Xxxxx Xxxxxxxxxx, Xxxxxxxxxx Xxx., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. Jr. (1979), Xxxxxxxxxxx Xxxxxxxxxx Xxxxx xx 29 Xxxxxxxxx Combined xxxx X9 Mix In xxxxx, Xxxxxxxx Res., 66, 277-290.
10) Elliot, X. M., Combes, X. D., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Gibson, X. G., Xxxxxx, X. X., Wolf, X. X. (1992), Xxxxxx of XX Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Xxxxx. Xxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 in Xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Sawamura, X., Xxxx, X., Xxxxxxxx, X. (1976), X. Xxxx Substitute xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, xx: xx Xxxxxx, F. X., Xxxxx, X. X. Bend, X. X., Xxxxxxx, X. X. (xxx), Xx xxxxx Metabolic Xxxxxxxxxx xx Mutagenesis Testing, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, S. X., Xxxxxxx, X. J., Xxxxxxxx, X. Jr., Xxxxx, X. X., Xxxxxxxx, D. X., Xxxxxx, X., Xxxxxxx, X., Xxxxxx, X. (1994), Xxxxxx xxxx Xxxxxxx Xxxxx xx Xx vitro Xxxxx xxx Xxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 312, 241-261.
13) Xxxxxxxxxx, C., Xxxxxxxx, X. A., Xxxxx, J. X., Xxxxxxxx, G., Chanter, X. X., Phillips, X. (1989), Xxxxxxxx xx Data from Xx xxxxx Xxxxxxxxxxx Xxxxxx, in: Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Data, Xxxxxxxx, X. X., (ed) Xxxxxxxxx University Press, Xxxxxxxxx, 141-154.
14) Soper, X. X., Galloway, X. X. (1994), Xxxxxxxxx Flasks xxx xxx Xxxxxxxxx xxx Xx xxxxx Xxxxxxxxxx Xxxxxxxxxx Assays xx XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, D. F., Xxxxxx, X. X., XxXxxxx, X. T. (1982), CHO/HGPRT Xxxxxxxx Xxxxx: Xxxxxxxxxx xx Xxxxx xxx Volatile Xxxxxxx, in: Xxxx, X. R., Costa, X. L., Xxxxxxx, X. X. (eds), Xxxxxxxxx Effects xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
16) Xxxxxx, P. O., Xxxxxx, X. M., Xx, X. X., Xxxxxx, X. L. (1983), Evaluation of xx Xxxxxxxx System Xxxxx Cells Xxxxx xx Xxxxxxxx Gels xxx Detecting Highly Xxxxxxxx Xxxxxxxx in xxx CHO/HGPRT Mutation Xxxxx, Environmental Xxxxxxx., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Endoreduplication xx Xxxxxxx hamster xxxxx during alpha-radiation xxxxxxx G2 arrest, Xxxxxxxxxx Xxx., 119, 403-413.
18) Xxxxx, Y., Xxxxxx, C., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication in Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
PŘÍLOHA 4X
"X.11 XXXXXXXXXX–XXXXXXX XX XXXXXXXXXXXX XXXXXXX X XXXXXXX XXXXXX XXXXX XXXXX XX XXXX
1. METODA
Tato xxxxxx xx replikou metody XXXX XX 475 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx v xxxxxxx kostní xxxxx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxxxxxxxx xxxxxxx x savců xx xxxx xx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx indukovaných xxxxxxxxx xxxxxx x xxxxxxx kostní xxxxx xxxxx, obvykle xxxxxxxx (1, 2, 3, 4). Rozlišují se xxx xxxx xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x chromatidové. Xxxxxx xxxxxxxxxxx může xxxxxxxx, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. X xxxxxxx většiny chemických xxxxxxxx jsou indukované xxxxxxx xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx vyskytují. Xxxxxxxxxxxx xxxxxx a xxxxxxxxxxx xxxx xxxx xxxxxxxx mnoha geneticky xxxxxxxxxxx xxxxxx u xxxxxxx x xxxxxxxx xxxxx důkazů x xxx, xx chromozomové xxxxxx x xxxxxxxxxxx xxxx xxxxxxxxxxx xxxxx x onkogenech x x genech somatických xxxxx tlumících xxxxxx, xxxx xxxxx xx xxxxxxx rakoviny x xxxxxxx x x xxxxxxxxxxxxxxxx systémech.
Při xxxx xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxx xx x xxxx zkoušce xxxxxx xxxx, poněvadž je xxxxxx vaskularizovanou tkání x obsahuje xxxxxxxx xxxxx s rychlým xxxxxx, které xx xxxxxx izolují a xxxxxxxxxxxx. Jiné xxxxx x xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx xxxxxx.
Xxxx xxxxxxx na xxxxxxxxxxxx xxxxxxx je xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxx metabolismu xx xxxx, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx DNA, xxxxxxx xx xxxxx x xxxxxxx druhů x xxxxx měnit. Xxxxxxx xx vivo xx xxxxxx xxxxxxxx xxx další výzkum xxxxxxxxxxx xxxxxx zjištěných xxxxxxxx xx vitro.
Jestliže xxxxxxxx xxxxx x xxx, xx se xxxxxxxx xxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx poškození xxxxxxxxxx x xxxxxx xxxxx jednotlivých chromatid xxxx zlomu x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : strukturní xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxx xxxxx x xxxxxxx xxxx chromatid v xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx replikace DNA xxxxxxx x xxxxxx, xxxxx xxxxxxxxx další X-xxxx. Výsledkem xxxx xxxxxxxxxx xx 4, 8, 16,… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx než xxxxx xxxxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; xxxx se jako xxxxxx a xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx jsou xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxxxx a ve xxxxxxx xxxxxxxx xx xxxxxxxx se xxxxxx. Xxxx xxxxxxxxx xx xxxxxxxx podá xxxxx xxxxxxxxxxx xxxxxxxx (např. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxx xxxxxx xxxxx xx xxxx xxxxxxxx preparáty chromozomů, xxxxxx xx a xxxxxxxxx xx chromozomové xxxxxxx buněk v xxxxxxxx.
1.4 POPIS ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx je xxxxxxxx potkan, xxx x křeček xxxxxx, xxxxxx xxx použít xxxxxxxx xxxxxx xxxxx xxxx. Měly by xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx studie xx měla xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx u xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx hmotnosti.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx B, xxxxxxx xx mělo xxx dosaženo xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx výběrem rozdělí xx xxxxxxxxx skupinu x xxxxxxx, xxxxx xx xxxxxxx zkoušené xxxxx. Klece by xxxx xxx uspořádány xxx, xxx byl xxxx jejich xxxxxx xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx xx měly xxx xxxx aplikací zvířatům xxxxxxxxxx nebo suspendovány xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx mohou být xxxx xxxxxxx zředěny. Xxxx xx xxx xxxxxxx čerstvě xxxxxxxxxx xxxxxxxx xxxxxxxx látky, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx xxx vyloučeno xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx použita jiná xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx být xxxxxx xxxxxxxx podloženo xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí každého xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) xxxxxxxx xxx xxx xxxxxxx. X xxxxxxxx aplikace xxxxxxxx látky xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, x xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xx vivo xxx expozičních xxxxxxxx, x xxxxx xx xxxxxxx, že poskytnou xxxxxxxxxxxxx xxxxxx nad xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx zvoleny xxx, xxx xxx účinek xxxxxxxx, xxx xxx xxx xxxxxx nevyšla xxxxx najevo kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx byla xxxxxxxxx kontrola xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx xxxxx x xxx xxx odběr x jejím xxxxxxx xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx látky ze xxxxxx xxxxxxxx xxxxx, xxxx-xx x dispozici. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
mitomycin C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-triazin |
51–18–3 |
200–083–5 |
V xxxxxxxx xxxxxxx odběru xx xxx být xxxxxxxx xxxxx u xxxxxxxxxxx xxxxxxx, jimž je xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxx podstupují xxxxxx proces jako xxxxxxxxxx xxxxxxx, pokud xxxxxx z dosavadních xxxxxxxxxxx xxxxx x xxxxxxxxx přijatelné xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx buněk x chromozomovými xxxxxxxxx. Xxxxxxx-xx se xxx xxxxxxxxx kontrolu xxxxx xxxxx, je xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxx. Kromě toho xx měly xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx zvířat
Každá xxxxxxxxxx a kontrolní xxxxxxx xx skládá x alespoň pěti xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx xxxxxxx. Xxxxxxxx xxxx v době xxxxxx x dispozici xxxxx xx studií xx stejným xxxxxx x za xxxxxxx xxxxxxxx způsobu xxxxxxxx, xxx prokazují, xx xxxxxxxxxx mezi xxxxxxxxx xxxxxx x xxxxxxxx, xxxx postačující zkoušení xxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx pohlaví, xxxx xx xxxx xxxxxxxxx u xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx xx zvířaty xxxxxxxxxxxxxx pohlaví.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx by xxxx xxx xxxxx xxxxx xxxxxxxx jednorázově. Xxxxxxxx xxxxx mohou xxx podávány xxxx xx dvou dávkách, xxx. xxx dávky x týž xxx x xxxxxxx ne xxxx xxx xxxxxxxx xxxxx, xxx bylo xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx být vědecky xxxxxxxxxx.
Xxxxxx xx xxxx xxx xxxxxxxx ve xxxx různých intervalech xx xxxxxxxx podané x jednom xxx. X xxxxxxxx se xxxxx provádí po xxxxxx době xx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx xxxxxxxxx xxxxx (xxxx xxxx obvykle 12 — 18 h). Xxxxxxxx doba xxxxxxxx xxx xxxxxx a xxxxxxxxxxxx zkoušené xxxxx x rovněž xxx xxxxxx na kinetiku xxxxxxxxx xxxxx xxxx xxx vliv na xxxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxxx aberací, xxxxxxxxxx xx xxxxxxx xxxxx xxxxx po 24 x xx xxxxxxx odběru. Xx-xx xxxxxxxx rozložena do xxxx xxx jednoho xxx, xxx xx xxx xxxxx proveden xx takové xxxx xx poslední xxxxxxxx, xxxxx odpovídá 1,5násobku xxxxxxxx xxxxx buněčného xxxxx.
Xxxx xxxxxxxxx xx xxxxxxxx intraperitoneálně xxxx xxxxxx dávka xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx xxxxxxxxx). Xxxx xx po xxxxxx xxxx provede x zvířat xxxxx. X xxxx xx xxxx xxxx přibližně 3 — 5 x; x xxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxx 4 — 5 h. X xxxxxx xxxxx xx xxxxxxxx buňky x xxxxxxxxx se xx xxxxxxxxxxxx aberace.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx rozsahu xxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, se stejným xxxxxx, xxxxxx, xxxxxxxx x xx stejného xxxxxx expozice, xxx xx použijí v xxxxxx xxxxxx (5). X případě xxxxxxxx xx pro xxxxx xxxxx xxxxxxx xxx xxxxxx xxxxx. Tyto xxxxxx xxxxx by xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx toxicitou. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx bude xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, že xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx podle očekávání x xxxxxxxx. Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx a xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx případ od xxxxxxx. Nejvyšší dávka xxxx xxx xxxx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx x kostní xxxxx xxxxxxx xxxxxx xxxxxxxx (např. xxxx xxx 50 % xxxxxxx xxxxxxxxxxx xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách x xxxxxx xxx nevykazuje xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx xxxxx x látkách, které xxxx xxxxxxxx strukturu, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx studie xx třemi úrovněmi xxxxx xx nezbytnou. X déle xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx x xxx delší xxx 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx potřebu xxxxxx x xxxxxxx xxxxxxx xxxxx úroveň xxxxx.
1.5.5 Podávání xxxxx
Xxxxxxxx xxxxx se xxxxxxx xxxxxx nitrožaludečně, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, nebo xxxxxxxxxxxxxxxxx injekcí. Jiné xxxxxxx xxxxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxxxxxxx nebo injekčně, xxxxxx xx velikosti xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx xxxxxxx objemů, xxx xx uvedený xxxxx, xxxx xxx zdůvodněno. Xx xx xxxxxxxx x žíravé látky, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, by xxxx xxx xxxxxxxxxxx xxxxxxxxxx objemu xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx zajišťující xxxxxxxxxx xxxxx při xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx preparátů xxx xxxxxxx chromozomů
Ihned xx xxxxxxxx se xxxxxxx xxxxxx xxxx, xxxxxxxxxxxx xx a xxxxxx. Xxxxx se nanesou xx podložní sklíčka x xxxxxx xx.
1.5.7 Xxxxxxx
Xxxx xxxxxxx xxxxxxxxxxxx xx měl xxx x všech xxxxxxxxxxxx xxxxxx (včetně xxxxxxxxxxx xxxxxxx) a u xxxxxxxxxxxxxx xxxxxx xxx xxxxxxxxx kontrolu xxxxxxxx xxxxxxxxx xxxxx, a xx xxxxxxx u 1000 buněk xx xxxxx zvíře.
U xxxxxxx xxxxxxx xx mělo xxx analyzováno xxxxxxx 100 xxxxx. Xxxxx xxxxx xxx xxxxxx, xx-xx pozorován xxxxx xxxxx aberací. Všechny xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx xx xxxx xxx xxxx xxxxxxxxxxxxxx analýzou xxxxxxxxx xxxxxxxx. Xxxxxxx xxx xxxxxx xxxxx xxxxxxx xx chromozomálním xxxxxx xxxx xx xxxxxx xxxxxxxxxx x xxxxx xxxxx x metafázi, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x počtu xxxxxxxxxxxxxx xxxxx 2 n ± 2.
2. ÚDAJE
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xxx xxxxxxxxxx xxxxxxx by xxxx být xxxxxxxxxx xx xxxxx tabulky. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx každé xxxxx by měl xxx xxxxxxxxxx počet xxxxx, xxxxx xxxxxxx xx buňku x xxxxx xxxxx x xxxxxxxxxxxxx aberací (xxxxxxxxxxxxxx xxxxxxxxx) vyjádřený x xxxxxxxxxx. Xxx exponované x kontrolní xxxxxxx xx xxxx xxx xxxxxxx xxxxx typy xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x jejich xxxxxx x četností. Gapy xx zaznamenávají xxxxxxxx x xxxxxxx se, xxx xxxxxx xx xxxxxxxxxx xx celkové xxxxxxxx aberací. Xxxxxxxxxx-xx xxxxx o xxxxxxx x odpovědi xxxx xxxxxxxxx, xxxxx xxx xxx statistickou xxxxxxx xxxxx pro xxx xxxxxxx xxxxxxxxxxxx.
2.2 HODNOCENÍ X INTERPRETACE VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxxxxx xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx v xxxxxxxxxx xx xxxxx xxxx jasný xxxxxx xxxxx buněk s xxxxxxxxx pro xxxxxxx x xxxxxxx xxxxxx x x xxxxxxxx xxxxxxxx odběru. Nejdříve xx měla xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx mohou xxx použity jako xxxxxxx xxxxxxxxxx statistické xxxxxx (6). Xxxxxxxxxxx xxxxxxxxxx by xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx měly xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx polyploidie xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx indukovat xxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxxxxxxx chromozomy může xxxxxxxx, že xxxxxxxx xxxxx má potenciál xxxxxxxx progresi buněčného xxxxx (7, 8).
Zkoušená xxxxx, jejíž xxxxxxxx xxxxxxxxx výše xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx poskytne xxxxx xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx neumožní xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx zůstat dvojznačné xxxx xxxxxx bez xxxxxx xx to, xxxxxxxx xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx chromozomové xxxxxxx xx vivo xxxxxxxxx, xx zkoušená látka xxxxxxxx v kostní xxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx aberace. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxx zkoušky xxxxxxxxxx x kostní xxxxx xxxxxxxxxxx xxxxx chromozomové xxxxxxx.
Xxxx xx být xxxxxxxxxxx pravděpodobnost, s xxxxx xx xxxxxxxx xxxxx xxxx xxxx xxxxxxxxxx xxxxxxxx do xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx cílové xxxxx (xxxx. systémová xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx o xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- použitý xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx zvířat,
- xxxxx, podmínky chovu, xxxxxx xxx.,
- individuální xxxxxxxx xxxxxx na xxxxxxx zkoušky, včetně xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx pro xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) kontroly,
- xxxxx xx xxxxxx pro xxxxxxxx xxxxxxx, pokud xxxx provedena,
- xxxxxxxxxx xxxxxxxxx xxxxxx dávek,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- údaje x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- popřípadě xxxxxx xxxxxxx, xxx se xxxxxxxx látka xxxxxxx xx xxxxxxxx oběhu xxxx xx xxxxxx xxxxx,
- xxxxxxxx přepočet xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx údaje x xxxxxxx krmiva x xxxx,
- podrobný popis xxxxxxx expozice a xxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- identifikace látky xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx na jedno xxxxx,
- xxxxxxxx klasifikace xxxxxx na xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxx x xxxxx aberací uvedený xxxxxxxxxx xxx každé xxxxx,
- xxxxxxx xxxxx xxxxxxx ve xxxxxxx xx xxxxxxxxx xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx skupině xx středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx ploidie, pokud xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx xxxxxxx,
- xxxxx x souběžné negativní xxxxxxxx,
- xxxxxxxxx údaje x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx o xxxxxxxx pozitivní xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Xxxxx in Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: a Xxxxxxxxx Xxxxxxxx, S. Venitt, X. M. Parry (xxx), XXX Press, Xxxxxx, Xxxxxxxxxx X. X., 275-306.
2) Xxxxxxx, X. X., Xxxx, X. X., Galloway, X., Xxxxxx, H., XxXxx, A. X., Xxxxxx, X. (1987), Xxxxxxxxx Xx xxxx Xxxxxxxxxxx Assays: Analysis xx Xxxxxxxxxx Xxxxxxxxxxx xx Xxxx Xxxxxx Xxxxx, Mutatation Res., 189, 157-165.
3) Richold, X., Xxxxxxxx, X., Xxxxx, X., Gatehouse, X. X., Xxxxxxx, X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxx Mutagenicity Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Sub-Committee xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx X xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Chester, Melbourne, Xxxxxx, 115-141.
4) Xxxx, X. X., Xxxxxxx, X., XxxXxxxxxx, J. X., Xxxxxxxx, X., Xxxxxx, X. H., Xxxxxx, H. X., Xxxxxx-Xxxxxxx, M., Xxxxxx Xx., X. B., Xxxxxxxxxxxx, X., Xxxxxxx, X. X., Xxxxxxx, X., Shimada, X., Xxxxx, X., Vannier, X. (1994), Xxxxxx xxxx the Xxxxxxx Xxxxx xx xxx xx vivo Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxx Test, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, P. X., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. G., Xxxxxx-Xxxxxx, X., Morton, D. X., Xxxxxxxx, D. X., Xxxxxxx, M. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Xxxxx: Dose Xxxxxxx in In xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, X. X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, G. X., Clare, X., Xxxxxxxx, R., Richold, X., Xxxxxxxx, X. X., Savage, J. X. K. (1989), Xxxxxxxxxxx Xxxxxxxx of Xx vivo Cytogenetic Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Testing, Xxxxxx Xxxx III. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Test Data, X. X. Xxxxxxxx (xx.) Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, 184-232.
7) Xxxxx-Xxxxx, C. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells xxxxxx xxxxx-xxxxxxxxx-xxxxxxx G2 xxxxxx, Xxxxxxxxxx Res., 119, 403-413.
8) Huang, Y., Xxxxxx, C., Trosko, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx hamster xxxxx, Xxxxxx Xxx., 43, 1362-1364."
PŘÍLOHA 4X
"X.12 XXXXXXXXXX–XXXX XXXXXXX XXXXXXXXXXXXXXX XXXXXXXXXX XX XXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx OECD XX 474 — Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx (1997).
1.1 XXXX
Xxxx savčích xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx xx xxxxxxxx pro xxxxxxx xxxxxxxxx xxxxxxxxxx xxxx mitotického xxxxxxx xxxxxxxxxxxx, xxxxx xx xxxxxxxxxx zkoušenou látkou, x to pomocí xxxxxxx erytrocytů xxxxxxxxxx x xxxxxx xxxxx x/xxxx buněk xxxxxxxxx xxxx, obvykle xxxxxxxx.
Xxxxxx xxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx je identifikovat xxxxx, které způsobují xxxxxxxxxxxxx poškození, xxxxx xxxxxxxxx xx xxxxxx xxxxxxxxxx obsahujících nereplikující xx (xxxxxxx) xxxxxxxxxxxx xxxxxxxxx xxxx xxxx xxxxxxxxxx.
Xxxx xx erytroblast xxxxxx xxxxx mění xx xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxx jádro xx xxxxxxxx x mikrojádra, xxxxx xxx tom xxxxx vzniknout, xxxxxxxxx x cytoplasmě, xxxxx xxxxx xxxxx neobsahuje. Xxxxxxxxxxxx xxxxxxxxxx xx x xxxxxx xxxxxxx xxxxxxxxx xxx, xx xxxxxxxxxx xxxxxx xxxxx. Xxxxxx xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx xx xxxxxxx indukovaného xxxxxxxxxxxxxx xxxxxxxxx.
X xxxxx xxxxx xx xxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, poněvadž xxxx xxxx xxxxxxxxx polychromatické xxxxxxxxxx. Xxxxxxxxx nezralých (xxxxxxxxxxxxxxxxx) erytrocytů x xxxxxxxxxx x xxxxxxxxx xxxx xx rovnocenně xxxxxxxxxx x xxxxxxxxxxx xxxxx, x xxxxx xxxx xxxxxxxxx neschopnost xxxxxxx xxxxxxxxxxx xxxxxxxxxx x mikrojádry, nebo xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxxxxxx xxx rozlišit xxxxx xxxxxxxx. Ta zahrnují xxxxxxxxxxxx přítomnosti xxxx xxxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxxxxx) XXX v xxxxxxxxxx. Xxxxxxxxx xx zejména xxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx. Xxxxx xxxxxxx (normochromatických) xxxxxxxxxx x xxxxxxxxx xxxx, které xxxxxxxx xxxxxxxxxx, připadající xx xxxxxx počet zralých xxxxxxxxxx xxx xxxxxx xxxxxx jako konečný xxxxxxxx xxxxxxx, xxxxxxxx xxxx zvířata xxxxxxxxxx xxxxx xxxxx nebo xxxx.
Xxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx mikrojader xx xxxx xx zvláště xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xx vivo, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx DNA, xxxxxxx xx mohou lišit x xxxxxxx xxxxx x xxxxx, xxxxx x z xxxxxxxxxxx xxxxxxxx. Zkouška xx xxxx xx rovněž xxxxxxxx xxx xxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xx vitro.
Jestliže existuje xxxxx o xxx, xx xx zkoušená xxxxx nebo xxxxxxxxx xxxxxxxxxx nedostanou xx xxxxxx xxxxx, není xxxxxx tuto zkoušku xxxxxx.
Xxx také Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (oblasti) chromozomu, x níž (k xxxx) xx xxxxx xxxxxx xxxxx připojí xxxxxx vřeténko umožňující xxxxxxxxxx pohyb dceřiných xxxxxxxxxx k xxxxx xxxxxxxxx xxxxx.
Xxxxxxxxxx : xxxx xxxxx xxxxxxxxxx xxxxxxxx od hlavních xxxxx x vedle xxxx, xxxxxxxxx xxxxx xxxxxxxx xxxxxx (meiosy) xxxxxxxxxxxxxxx xx (xxxxxxx) xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxx chromozomy.
Normochromatický erytrocyt : zralý xxxxxxxxx xxxxxxxxxxxx ribozomy, xxxxx xxx rozlišit xx xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx selektivním xxx xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx xxxxxxxxx xx xxxxxxxxx mezistadiu, xxxxx xxxxx obsahuje xxxxxxxx, x může xxx xxxx rozlišen xx xxxxxxx xxxxxxxxxxxxxxxxxx erytrocytů xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx se xxxxxxx xxxxxxxx xxxxxxx zkoušené xxxxx. Při xxxxxxx xxxxxx xxxxx xx xxxxxxx xx xxxxxxx xxxxxxxx xx expozici xxxxxx, xxxxxxx se xxxxxx xxxx, xxxxxxxx xx xxxxxxxxx x xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx xx krev xx vhodném xxxxxxxx xx xxxxxxxx odebere, xxxxxxxxxx xx xxxxxxxx xxxxxxxx a xxxxxx xx (4, 8, 9, 10). Xxx xxxxxxxx x xxxxxxxxx xxxx xx měla xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxx xxxxxxxx co xxxxxxxxx xxxx. Xxxxxxxxx jsou xxxxxxxxxxx xx xxxxxxxxxx xxxxxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx zvířete
Při použití xxxxxx xxxxx xx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xxx xxxx xxxxxx, xxxxxx lze xxxxxx xxxxxxxx xxxxxx xxxxx xxxx. Xxx xxxxxxx periferní krve xx doporučuje xxx. Xxx xxxx xxxxxx xxxxxxxx vhodný xxxx xxxxx za předpokladu, xx xxx o xxxx, u xxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, nebo xxxx xxxxxxxxxx dostatečnou xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx způsobují xxxxxxxxxx xxxx xxxxxxxxx chromozomové xxxxxxx. Měly by xxx xxxxxxx xxxxx xxxxxxx laboratorní kmeny xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx studie xx měla xxx xxxxxxxx v xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx x xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx obecné podmínky xxxxx xxxxxxxx xxxxx x xxxxx B, xxxxxxx xx mělo xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx výběrem xxxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxx, x xxx xx xxxxxxx xxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx v laboratorních xxxxxxxxxx alespoň xxx xxx xxxxxxxxxxxxx. Klece xx xxxxxxxxxx xxx, xxx xxx vliv xxxxxx polohy xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx aplikací xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx zkoušené xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx před podáním xxxxxxx. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje x xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx mít xxx použitých xxxxxxxx xxxxx xxxxxxx xxxxxx x mělo by xxx vyloučeno xxxxxxxxx, xx reaguje se xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx jiná než xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo xx být xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx pokud xxxxx xxxxxxxx zvážit xxxxxxx vodných rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly být xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx xxxxxxx. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx by xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx identický xxxxxx xxxx zvířata xx xxxxxxxxx, x nichž xxxxx x expozici.
Pozitivní xxxxxxxx by xxxx xxxxxxxxxx mikrojádra xx xxxx při xxxxxxxxxxx xxxxxxxx, x xxxxx xx xxxxxxx, xx xxxxxxxxx xxxxxxxxxxxxx nárůst xxx pozadí. Dávky xxxxxxxxx xxxxxxxx xx xxxx xxx zvoleny xxx, xxx xxx xxxxxx zřetelný, xxx xxx xxx odečtu xxxxxxx ihned xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxxxxxxx kontrola xxxx xxxxxxxx xxxxx xxxxxxxx xxx zkoušená látka x aby xxx xxxxx x xxxxx xxxxxxx prováděn xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxx může xxx xxxxx x xxxxx použití chemických xxxxx xx stejné xxxxxxxx xxxxx, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X okamžiku xxxxxx xx xxx xxx xxxxxxxx xxxxx x xxxxxxx negativní xxxxxxxx, xxxxx je aplikováno xxxxx xxxxxxxxxxxx nebo xxxxxxxxx a xxxxx xxxxx podstupuje xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, pokud xxxxxx x dosavadních xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx o xxxxxxxxxxx zvířat x xxxxxxxx xxxxx x xxxxxxxxxx. Provádí-li se xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx dosud xxxx xxxxxx-xx publikovány kontrolní xxxxx prokazující, že xxxxxxx rozpouštědlo/vehikulum xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
Xxx xxxxxxx xxxxxxxxx xxxx xxxx xxx xxxx negativní xxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxx xxxxxxxx xxxx expozicí, xxxxx xxxx x xxxxxxxx xxxxxx s xxxxxxxxx xxxx (xxxx. 1 — 3 xxxxxxxx) xx xxxxxxxxxxx, xx xxxxxxxx xxxxx xxxxx x xxxxxxx, xxxxx xx xx xxxxxxx xxxxxxxxxxx kontrol xxxxxxx.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x kontrolní skupina xx xxxx xxxxxxx x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx pro xxxxx xxxxxxx (11). Xxxxxxxx xxxx v xxxx xxxxxx x xxxxxxxxx xxxxx xx xxxxxx xx stejným xxxxxx x xx xxxxxxx xxxxxxxx způsobu xxxxxxxx, jež xxxxxxxxx, xx neexistuje xxxx xxxxxxxxx xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx. Xx-xx xxxxxxxx člověka xxxxxxxxxx pro xxxxxx xxxxxxx, xxxx je xxxx xxxxxxxxx u xxxxxxxxx xxxxxxxxxxxxxxx látek, xxxx by být xxxxxxx xxxxxxxxx se xxxxxxxx odpovídajícího pohlaví.
1.5.2 Xxxx aplikace
Nelze xxxxxxxxx xxxxx standardní xxxx (xx. xxxxx, xxx xxxx xxx xxxxxxxx x xxxxxxxxx 24 xxxxx). Xxxxxx ze xxxxxx x prodlouženým xxxxxxx xxxxxxxx xxxx xxxxxxxxxx, xxxxx se x těchto xxxxxx xxxxxxx xxxxxxxxx xxxxxxxx, xxxx –x xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx byla xxxxxxxxx xxxxxxxx xxxx byla xxxxxxxxx limitní xxxxx x xxxxxxxx pokračuje xx xx xxxxxxxx xxxxxx. Xxxxxxxx xxxxx xxxxx xxx podávány xxxx ve xxxx xxxxxxx, tzn. xxx xxxxx x xxx xxx v xxxxxxx xx xxxx xxx xxxxxxxx hodin, xxx xxxx usnadněno xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx.
Xxxx xxxx být xxxxxxxx xxxxx způsoby:
a) xxxxxxxx xxxxx se xxxxxxxx xxxxxxxx jednou. Vzorky xxxxxx xxxxx xx xxxxxxxx xxxxxxx dvakrát, xxxxxxx xxxxx xxxxx xx xxxxxxx xxxxxxxx 24 xxxxx po xxxxxxxx a xxxxxxxx xxxxxxxxxx 48 xxxxx xx aplikaci x x xxxxxxxxxx odstupem xxxx xxxxxx. Odběr xxxxx xxx 24 xxxxx xx xxxxxxxx xxxx xxx xxxxxxxxx. Xxxxxx xxxxxxxxx xxxx xx xxxxxxxx alespoň xxxxxxx, xxxxxxx xxxxx xxxxx xx provede xxxxxxxx 36 xxxxx xx aplikaci a xxxxxxxx nejpozději 72 xxxxx po xxxxxxxx x po xxxxxxxxxxxx xx dodrží odpovídající xxxxxx. Je-li xx xxxxxx xxxxxx pozorována xxxxxxxxx odpověď, xxxx xxxxx xxxxx xxxxx;
x) xxxx-xx xxxxxxxx xxx xxxx xxxx xxxxx xxxxx (např. xxx xxxx více xxxxx x xxxxxxxxx 24 xxxxx), xxxx xx xxx xxxxxx xxx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxx po 18 xx 24 xxxxxxxx po xxxxxxxx xxxxxxxx a xxx xxxxxxx periferní krve xxxxxx po 36 xx 48 hodinách xx xxxxxxxx xxxxxxxx (12).
Xxxxx potřeby xxxxx xxx navíc xxxxxxx xxxx xxxx xxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx xxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, se stejným xxxxxx, xxxxxx, pohlavím x xx xxxxxxxx xxxxxx xxxxxxxx, xxx xx xxxxxxx x xxxxxx xxxxxx (13). X případě xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx xxx xxxxxx dávky. Tyto xxxxxx xxxxx by xxxx xxxxxxxx xxxxxxx xxxx maximální xx xxxxxxxxx xxxxxxxxx, případně xxxxxx xxxxxxxxx. Při xxxxxxxxx xxxxxx stačí, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx podle xxxxxxxxx x xxxxxxxx. Látky xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx kritériím xxxxxxxxx xxxxx xxxxxxxxx x xxxx by xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx xxxx xxx také xxxxxxxxxx jako dávka xxxxxxxxxxxx x xxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. xxxxxxx xxxxxx xxxxxxxxx erytrocytů x xxxxxxxxx xxxxxxxx xxxxxxxxxx v xxxxxx xxxxx xxxx x xxxxxxxxx xxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška s xxxxxx dávkou x xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách v xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx a není-li xx xxxxxxx xxxxx x látkách, které xxxx xxxxxxxx strukturu, xxxxxxxxx xxxxxxxxxxxx, není xxxxxxxxxx úplná xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. X xxxx xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx pro 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx a xxx xxxxx xxx 14xxxxx aplikaci je xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx potřebu xxxxxx x xxxxxxx xxxxxxx vyšší úroveň xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx se obvykle xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx xxxxxxx podávání jsou xxxxxxxxxx x xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx může xxx najednou xxxxx xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x tělesné xxxxxxxxx. Xxxxxxx vyšších xxxxxx, xxx je uvedený xxxxx, musí xxx xxxxxxxxxx. Xx na xxxxxxxx x xxxxxx xxxxx, které obvykle xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx zesílené xxxxxx, xx měla xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx konstantní xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxx xxxxx xxxx krve
Buňky xxxxxx xxxxx se xxxxxxx xxxxxxxxx x xxxxxx nebo xxxxx xxxxx po xxxxxxxx. Xxxxx xx xxxxxxxx x femuru nebo xxxxx x zavedenými xxxxxxxx xx xxxxxxxxx x xxxxxx. Periferní xxxx xx získává x xxxxxx xxxx xxxx xxxx xxxxxx xxxxxx cévy. Xxxxxx xxxxx xx xxxxx xxxxxxxxxxxx xxxxxx (8, 9, 10), nebo xx připraví xxxxxxxxx xxxxxxxx a poté xx xxxxxx. Xxxxxxxx xxxxxxx specifického xxx XXX (xxxx. akridinová xxxxx (14) xxxx Xxxxxxx 33258 x xxxxxxx-X (15)) se xxx vyhnout xxxxxxxx xxxxxxxxxx spojeným x xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx XXX. Tato xxxxxx nebrání xxxxxxx xxxxxxxxxxx xxxxxx (xxxx. Xxxxxx). Xxxxxxxx xxxxxxx (xxxx. xxxxxxxxxx xxxxxx x xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxx (16)) xxx xxxxxx za xxxxxxxxxxx, xx xx xxxxxxxxx odpovídající funkčnost xxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxx v xxxxxxxxxx.
1.5.7 Analýza
Pro xxxxx xxxxx xx xxxxxxx xxxxx nezralých xxxxxxxxxx x xxxxxxxxx (xxxxxxx + zralé) množství xxxxxxxxxx, xxxxxxx xx x xxxxxxx kostní xxxxx xxxxxxx xxxxxxx xxxxxxx 200 erytrocytů x x xxxxxxx xxxxxxxxx xxxx xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx být před xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. U xxxxxxx zvířete se xxxxxxx alespoň 2000 xxxxxxxxx erytrocytů xx xxxxxx mikrojader x xxxxxxxxxxxxxxxxxxxxx. Xxxxx xxxxxxxxx xxxxx xxx získány xxxxxxxxxx xxxxxxx erytrocytů xx xxxxxx xxxxxxxxxx. Xxx mikroskopické xxxxxxx xx xxxxx xxx xxxxx xxxxxxxxx xxxxxxxxxx x celkového xxxxxxxx xxxxxxxxxx menší xxx 20 % xxxxxxxxx xxxxxxx. Xxxxxxxx xxxx xxxxxxx xxxxxxxxxx nepřetržitě xxxxx xxxxx nebo xxxx, xxx xxxx xxxxxxxx xx výskyt xxxxxxxxxx xxxxxxx 2000 xxxxxxx xxxxxxxxxx na xxxxx xxxxx. Systémy xxx automatickou xxxxxxx (xxxxxxx xxxxxx x xxxxxxxxx cytometrická xxxxxxx xxxxxxx xxxxxxxx) jsou xx xxxxxxxxxxxxx zdůvodnění x xxxxxxxx přijatelnými xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx xxxxxxxxxx zvířata xx xxxx xxx xxxxxxxxxx xx xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx xx zvíře. Xxx xxxxx analyzované xxxxx xx xxx xxx xxxxxx počet vyšetřených xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx s xxxxxxxxxx a xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx erytrocytů. Xxxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx xxxx xxxx, xxxx xx xxx xxxx uvedeny xxxxx x xxxxxxx erytrocytech, xxxx-xx xxxxxxxxxxxxx. Pro xxxxx xxxxx xx xxxxx xxxxx nezralých xxxxxxxxxx z xxxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxxxx x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x xxxxxxxx mezi xxxxxxxxx, mohou xxx xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx obě xxxxxxx xxxxxxxxxxxx.
2.2 HODNOCENÍ X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik kritérií, xxxx. xxxxxx počtu xxxxx x xxxxxxxxxx x xxxxxxxxxx xx xxxxx xxxx jasný xxxxxx xxxxx xxxxx x xxxxxxxxxx xxx xxxxxxx x určitou xxxxxx a k xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx výsledků. Při xxxxxxxxx výsledků xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (18, 19). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravou xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx nemutagenní.
Ačkoli xxxxxxx experimentů xxxxxxxx xxxxx pozitivní xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx zůstat xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx je xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx výsledky xxxxx xx xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxxxxxxxx poškození nebo xxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx testovacího xxxxx.
Xxxx by xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx xxxx xxxx xxxxxxxxxx dostanou xx xxxxxxxx xxxxx, nebo xxxxxxxxxx xx cílové xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění volby xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, stáří x xxxxxxx zvířat,
- xxxxx, podmínky xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx zkoušky, xxxxxx xxxxxxx xxxxxxx hmotnosti, xxxxxxx hodnota a xxxxxxxxxx odchylka pro xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx k xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- údaje xx xxxxxx xxx zjištění xxxxxxx, pokud xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx oběhu xxxx xx cílové tkáně,
- xxxxxxxx xxxxxxxx mezi xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx nebo xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx hmotnosti/den),
- podrobné xxxxx o xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x odběru,
- xxxxxx xxxxxxxx preparátů,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx xxxxxxxxx mikrojader x xxxxxxxxx xxxxxxxxxxxx,
- xxxxx analyzovaných xxxxx xx jedno xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx pozitivní, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx x celkového xxxxxxxx erytrocytů,
- počet xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxx xxxxxxxxxx xxx každé xxxxx,
- xxxxxxx hodnota ± xxxxxxxxxx odchylka xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx ve skupině,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx x xxxxxx,
- xxxxx x xxxxxxxx x xxxxxxxxx negativní xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Heddle, J. X. (1973), X Xxxxx Xx xxxx Xxxx for Chromozomal Xxxxxx, Mutatation Res., 18, 187-190.
2) Xxxxxx, X. (1975), The Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 31, 9-15.
3) Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X., XxxXxxxxx, X. G., Xxxxxx, G. W. (1983), Xxx Xxxxxxxxx xx Micronuclei a. x. x Xxxxxxx xx Genotoxicity, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, X. X., Xxxxxx, X. H., Xxxxxx, M. X., Xxxxxxxx, X. X., Xxxxxx, X. X. (1990), Xxx Xx xxxx Xxxxxxxxxxxx Xxxxx xx Xxxxxxxxx Xxxx Xxxxxx xxx Xxxxxxxxxx Xxxxx. X xxxxxx xx xxx U. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Gene-Tox Program, Xxxxxxxxxx Xxx., 239, 29-80.
5) XxxXxxxxx, X. X., Xxxxxxxx, X., Xxxx, W. N., Xxxx, X. M. (1983), Xxxxxxxxxxx in Xxxxxxxxxxx Xxxxxxxxxxxx: X Xxxxx Xxxxxx for Xxxxxxxxxxx Xxxxxx Xxxxxx Xxxxxxx Xxxxxxxx Testing xx Xxxx, xx: Xxxxxxxxxxxx xx Xxxxxxx xxx Xxxxxxxx of Xxxxxxxxxx, xx. X. X. Xxxxx, X. X. Xxxxxxx, X. X. Miya. Elsevier, Xxxxxxxxx, 555-558.
6) XxxXxxxxx, X. T., Xxxxxx, X. A. Xxxx, X., Margolin, G. X., Ramel, C., Xxxxxxxx, M. X., Xxxx, R. X., Xxxx, D. (1987), Xxxxxxxxxx xxx the Xxxxxxx of Micronucleus Xxxxxx in Mammalian Xxxx Xxxxxx Erythrocytes, Xxxxxxxxxx Xxx., 189, 103-112.
7) MacGregor, J. X., Xxxx, X. X., Xxxxxx, X. X., Shelby, X. X. (1990), The xx xxxx Xxxxxxxxxxx Xxxxxxxxxxxx Xxxx: Xxxxxxxxxxx xx Xxxxxx Xxxxx Xxxxxxxxx Assay Xxxxxxxxxx xxx Xxxxxxx Integration xxxx Xxxxxxxx Studies, Xxxxxx. Xxxx. Toxicol. 14, 513-522.
8) Xxxxxxx, X., Xxxxxx, X., Xxxxxx, X., Sofumi, X., Xxxxxxxx, M. Xx. (1990), Xxx Xxxxxxxxxxxx Xxxxx xxxx Xxxxx Peripheral Xxxxx Xxxxxxxxxxxxx Xxxxx Xxxxxxxx Xxxxxx-Xxxxxx Slides, Mutatation Xxx., 245, 245-249.
9) Xxx Collaborative Xxxxx Xxxxx xxx the Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Xxxx xxxx Xxxxx Peripheral Xxxxx Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Summary Report xx the 5xx Xxxxxxxxxxxxx Study by XXXXX/XXXXX, MMS, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Xxxxxxxxxxxxx Study Xxxxx xxx xxx Xxxxxxxxxxxx Test (XXXXX/XXXXX, XXX: Xxx Mammalian Xxxxxxxxxxx Study Xxxxx xx xxx Environmental Xxxxxxx Society of Xxxxx) (1995), Protocol xxxxxxxxxxx for xxx xxxxx-xxxx mouse xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, M., Xxxx, X. X., XxxXxxxxx, X. X., Xxxxxxxx, X., Blackey, D. X., Xxxxxx-Xxxxxxx, M., Xxxxxx, Jr. F. X., Xxxxxxxxxxxx, X., Xxxxxxx, X., Xxxxxxx, X., Xxxxx, S., Xxxxxxx, B. (1994), Xx vivo Xxxxxx Xxxxxxxxxxx Micronucleus Assay, Xxxxx. Res., 312, 293-304.
12) Higashikuni, X., Xxxxx, S. (1995), Xx optimal, xxxxxxxxxxx xxxxxxxx xxxx xx 30 ± 6 x xxxxx xxxxxx xxxxxx xx xxx xxxxx peripheral micronucleus xxxx, Xxxxxxxxxxx, 10, 313-319.
13) Fielder, R. X., Xxxxx, J. X., Xxxxxx, X. X., Botham, X. X., Doe, X., Xxxxxxx, D. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. J., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
14) Hayashi, X., Xxxxxx, X., Xxxxxxxx, X. Xx. (1983), Xx Application of Xxxxxxxx Orange Xxxxxxxxxxx Xxxxxxxx xx xxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 120, 241-247.
15) XxxXxxxxx, X. X., Xxxx, C. X., Xxxxxxxx, R. G. (1983), X Xxxxxx Xxxxxxxxxxx Staining Procedure xxx Xxxxxxxxxxx xxx XXX xx Xxxxxxxxxxxx Xxxxx Xxxxxxx 33258 xxx Xxxxxxx X, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, F., Xxxxxxxxxx, X. D. (1989), Xxx xxxxxxxxx xxxx xxxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxx Xxx., 213, 91-104.
17) Gollapudi, X., XxXxxxxx, X. X. (1995), Sample Xxxx xxx xxx Xxxxxxxxxx of Polychromatic xx Normochromatic Erythrocyte Xxxxx xx xxx Xxxx Xxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Res., 347, 97-99.
18) Xxxxxxx, X., Xxxxx, J., Xxxxxxx, X., Chandley, X., Xxxxxxxxx, X. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxxx Xxxxx, xx: X. J. Kirkland (xx.), Basic Mutagenicity xxxxx, UKEMS Recommended Xxxxxxxxxx, UKEMS Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx 1, xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, Xxx York, Xxxx Chester, Melbourne, Xxxxxx, 115-141.
19) Lovell, X. P., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, G., Xxxxxxxx X., Richold, M., Xxxxxxxx, D. G., Xxxxxx, X. X. X. (1989), Xxxxxxxxxx Xxxxxxxx xx In xxxx Xxxxxxxxxxx Xxxxxx, xx: D. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data. XXXXX Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx XXX, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.13/14 XXXXXXXXXX — XXXXXXX XX XXXXXXXX XXXXXX X XXXXXXXXXX
1. XXXXXX
Xxxx xxxxxx xx replikou metody XXXX XX 471 — Xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx (1997).
1.1 ÚVOD
Při xxxxxxx na xxxxxxxx xxxxxx x bakteriemi xx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxxx Salmonella xxxxxxxxxxx x Xxxxxxxxxxx xxxx, x xxxxxxx xxxxxxxx xxxxxx, xxxxx zahrnují xxxxxxxxxx, xxxxx x xxxxxx xxxxxxx xxxx xxxxxxxx párů xxxx XXX (1, 2, 3). Xxxxxxxx xxxx xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xxxxxxx x xxxxxxx xxxxxx, které xxxxxxxxx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx x xxxxxxxx xxx funkční xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx. Bakterie xx xxxxxxx xxxx xxxxxxxxxx díky své xxxxxxxxxx růst v xxxxxxxxxxxxx aminokyselin, xxxxx xxxx xxxxxxxxxx mateřským xxxxxxxxxx xxxxxx.
Xxxxxx xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx mnoha xxxxxxxxx xxxxxxxxxxx chorob x xxxxxxx x xxxxxxxx xxxxx xxxxxx x xxx, xx xxxxxx mutace v xxxxxxxxxx x v xxxxxx xxxxxxxxxxx buněk xxxxxxxxx xxxxxx xxxx xxxxx xx xxxxxx xxxxxxxx x xxxxxxx x u xxxxxxxxx xxxxxx. Xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxx. Xxxxx xxxxxxxxxxx xxxxx xx xxxx xxxxxxxxxx, xxxx nimž xxxx citlivější xx xxxxxxx xxxxxx, xxxxxx xxxxxxxxxxxxx xxxxxxxx XXX xx reverzních xxxxxxx, xxxxxxx xxxxxxxxxxxx buněk xxx xxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxx XXX nebo xxxxxxxx reparačních xxxxxxx XXX xxxxxxxxxx x xxxxxx. Xxxxxxxxxxxx testovacích xxxxx xxxx xxxxxxxxxx xxxxxxx užitečné informace x xxxxxx xxxxxx, xxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxx xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx k xxxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxx xxxxx xxxxxxxx x xxxx xxxx xxxxxxxx xxxxx xxxxxxxxxx metody xxxxxxxx xxxxxxxxxx xxxxx, xxxxxx xxxxxxxx sloučenin, x xxxxxxx fyzikálně-chemickými xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxx xx reverzní xxxxxx x bakteriemi Xxxxxxxxxx xxxxxxxxxxx xxxx Xxxxxxxxxxx xxxx xxxxxx x detekci mutací x kmeni vyžadujícím xxxxxxxxxxxxx (xxxxxxxx xxxx. xxxxxxxxx), xxxxxxx xxxxxx xxxx nezávislý xx xxxxxxx xxxxxxx aminokyseliny.
Mutageny xxxxxxxxxx xxxx bází xxxx xxxxxxxx, xxx xxxxxxxxx změny x xxxxxx XXX. Při xxxxxxx xxxxxxxxxx xxxxxx xx mohou xxxx xxxxx xxxxxxxxxx na xxxxx xxxxxxx mutace xxxx jiném místě xxxxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxxxx xxxx činitele, jež xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx nebo xxxx xxxx xxxx XXX x xxxxxxxx xxx čtecí xxxxx XXX.
1.3 XXXXXXX XXXXX
Xxx xxxxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xx xxxx xx xxxxx xxxxx xxxxxxx, xxxx xxxx xxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx struktura a xxxxxxxxx xxxxxxx XXX. Xxxxxxx xxxxxxxxx in xxxxx obecně vyžadují xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx xxxxxxx xx xxxxx xxxxxxx xxxxx xxxxxxxxx podmínky in xxxx u savců. Xxxxxxx xxxx neposkytuje xxxxxx informaci x xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx.
Xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx xx xxxxxxxxx xxxxxxxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx, x xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxxx, xx mnoho xxxxxxxxxx xxxxx, které jsou x této xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx x x xxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxxxx xxxxx zkouškou. Příčiny xxxxxx xxxxxxxxxxx xxx xxxxxxxxx xx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx, x rozdílech v xxxxxxxxxxx aktivaci xxxx x xxxxxxxxx x xxxxxxxxxx dostupnosti. Na xxxxx xxxxxx faktory, xxxxx xxxxxxx xxxxxxxxx xxxxxxx na xxxxxxxx xxxxxx xx bakteriích, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx aktivity.
Zkouška xx xxxxxxxx mutace x bakteriemi xxxxxx xxx xxxxxx xxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx sloučeniny (xxxx. xxxxxx xxxxxxxxxxx) a xxx chemické xxxxx, x xxxxx se xxxxxxxxxxx (xxxx x xxxxx xx ví), xx specificky zasahují xx replikačního xxxxxxx xxxxx xxxxx (xxxx. xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxx). V xxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxx.
Xxxxxxxx xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx xxxxxxxxx, je karcinogenní xxx xxxxx, není xxxxxxxx xxxxxxxxx. Xxxxxx xx xxxxxxxx xxxxx x existuje xxxxx xxxxxxxxxxx, jež xxxxxx xxxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx mechanismy, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx buňkách xxxxxxxxxx.
1.4 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxxx xxxxxxxxxxxxx xxxxx jsou xxxxxxxxx zkoušené xxxxx, x xx xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx systému a xxx něho. Ve xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxx smíchají x vrchním agarem x ihned xx xxxxxxx xx minimální xxxx. V preinkubační xxxxxx xx xxxxxxxx xxxx xxxxxxxx x xxxx xx xxxx xxxxxxxxx na xxxxxxxxx xxxx xxxxxx x xxxxxxx xxxxxx. Při xxxx xxxxxxxxxx se xx dvou xxxx xxxxx dnech inkubace xxxxxxxxx kolonie revertantů x xxxxxxx se xxxxxxxx s xxxxxx xxxxxxx spontánních xxxxxxxxxx xx xxxxxxxxx xxxxx x rozpouštědlem.
Je xxxxxxx xxxxxxx xxxxxxx xxxxxxxxx xxxxxxx xx reverzní xxxxxx x bakteriemi. Xxxx xxxxx používané xxxxx xxxxxxxxxx miskový xxxx (1, 2, 3, 4), preinkubační xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx xxxx (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx xxx xxxxxxxx xxxxx x par xxxx xxxxxxx (12).
Xxx xxxxxxx postupy se xxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxx. Xxxxx x nich xx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxx xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx. Některé xxxxx lze xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxx metody. Xxxx xxxxx xxxxx xx xxxxxxxxxx tříd, xx xxxxx xxxxx xxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxx, xxxxxxxxx kovy, xxxxxxxx, xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxxx x nitrosloučeniny (3). Xxxxxx xx připouští, xx xxxxxx třídy xxxxxxxx xxxxx vždy xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxxx xx standardní xxxxxxx xxxx xxxx xxxxxxxxxxxx metoda. Xxxx xx xxx považovány xx "xxxxxxxx xxxxxxx" x k xxxxxx xxxxxxx se xxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxx. Xx možné xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx x xxxxxxxx postupů xxxxxx xxxxxxx): xxxxxxxxxx a xxxxxxxxxx sloučeniny (3, 5, 6, 13), xxxxx a xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x xxxxxxxxx (17, 18). Xxxxxxxx xx xxxxxxxxxxxx postupu xxxx xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX XXXXXXXX XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx xxxxxxx xxxxxxxx xx měly xxx xxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxx xxxx xx xxxxx xxxxxxxxxxx fáze xxxxx (xxxxxxxxx 109 buněk xx ml). Buňky x xxxxxx stacionární xxxx by xxxxxx xxx xxxxxxx. Je xxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx vysoký xxxx xxxxxxxxxxxxxxx bakterií. Xxxx může být xxxxxxxx xxx xx xxxxxxx xxxxxxxxxxx kontrolních xxxxx x xxxxxxx xxxxxx, xxxx pro xxxxxx xxxxxxx stanovením xxxxx životaschopných xxxxx xx miskách.
Doporučená inkubační xxxxxxx xx 37 °X.
Xxxx xx být xxxxxxx alespoň pět xxxxx xxxxxxxx. Xxxx xxxx xx měly xxx xxxxx xxxxx X. xxxxxxxxxxx (TA1535; XX1537 nebo TA97a xxxx TA97; XX98 x XX100), xxxxxxx xxxxxxx xx ukázala x xxxxxxx xxxxxxxxxxxx xxxx spolehlivá a xxxxxxxxxxxxxxxx. Xxxx xxxxx xxxxx X. xxxxxxxxxxx xxxx xxx bází XX na xxxxxxxxx xxxxxxxxx xxxxx a xx xxxxx, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx oxidační xxxxxxxx, xxxxxxxx způsobující xxxxxxxxxx xxxxxx DNA x hydraziny. Tyto xxxxx mohou být xxxxxxxxxx xxxxx X. xxxx XX2 xxxx X. typhimurium XX102 (19), které xxxx xx primárním reverzním xxxxx xxx xxxx XX. Xxxxxxxxxx xxxxxxxxx xxxxx je xxxx xxxx:
- S. xxxxxxxxxxx XX1535 x
- S. xxxxxxxxxxx TA1537 xxxx XX97x x
- X. xxxxxxxxxxx XX98 x
- X. typhimurium XX100 x
- E. xxxx XX2 xxxX, xxxx X. xxxx WP2 xxxX (pKM101), xxxx X. xxxxxxxxxxx XX102.
Xxx xxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx XXX xxxx xxx vhodnější xxxxxxx XX102 nebo xxxxxx xxxx X. xxxx x xxxxxxx xxxxxxxxxx reparace XXX, (xxxx. E. xxxx XX2 (pKM101)).
Měly xx xxx xxxxxxx xxxxxxxx xxxxxxx přípravy xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxx x xxxxxxxxxx. Potřeba xxxxxxxxxxxxx xxx xxxx xx xxxx xxx xxxxxxxxx xxx každou xxxxxxxxx xxxxxxxx kulturu (xxxxxxxx xxx xxxxx X. xxxxxxxxxxx x xxxxxxxxx pro E. xxxx). Xxxxxxx by xxxx být kontrolovány xxxx xxxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxxxx xxxxx potřeby xxxxxxxxxx xxxx nepřítomnost X-xxxxxxx xxxxxxxx (xx. xxxxxxxxxxxx xxxxxxxxxx x xxxxx XX98, XX100 x TA97a xxxx XX97, WP2 xxxX x WP2 xxxX (xXX101) x ampicilinová x xxxxxxxxxxxxxx rezistence x kmene XX102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. rfa xxxxxx x S. xxxxxxxxxxx xxxxxxxxxx xx krystalovou xxxxxx x xxxX xxxxxx u X. xxxx nebo xxxX xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx světlo) (2, 3). Xxxxx xx xxxx xxxxxx xxxxx xxxxx xxxxxxx spontánních xxxxxxxxxx xx xxxxx x xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx a xxxxxxx x xxxxxxx uvedeném x literatuře.
1.5.1.2 Médium
Použije xx xxxxxx xxxxxxxxx xxxx (xxxx. xxxxxxxxxx xxxxxxxxx xxxx E (Xxxxx-Xxxxxx) x xxxxxxx) x xxxxxx xxxx xxxxxxxxxx xxxxxxxx a xxxxxx xxxx xxxxxxxxx xxxxxxxxxx několik xxxxxxxxx xxxxxx (1, 2, 9).
1.5.1.3 Xxxxxxxxxxx xxxxxxxx
Xxxxxxxx xx xxxx být xxxxxxxxx zkoušené xxxxx, x xx x xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx x bez xxxx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx kofaktorem xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (X9) xxxxxxxxxx x xxxxx xxxxxxxx ošetřených xxxxxxxxxxx xxxxxxxxxxx xxxxxx, xxxx je Xxxxxxx 1254 (1, 2) xxxx fenobarbitonu x β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx xxxxxx xx xxxxxxx xxxxxxxxx x koncentracích v xxxxxxx 5 až 30 % xxx. xx xxxxx S9. Xxxxx x xxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx xxxx záviset xx xxxxx xxxxxxxx xxxxxxxx xxxxx. X xxxxxxxxx xxxxxxxxx xxxx být xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx frakce. X xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxx xxxx xxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx (6, 13).
1.5.1.4 Xxxxxxxx xxxxx nebo xxxxxxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx na bakterie xxxxxxxxxx xxxx xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx vehikulech x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx přidány xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx čerstvě připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx xxxxxxxxx, xx xxxxxxx se xxxxxxxxx látkou, a xxxx xx xxx xxxxxxxxxx s přežitím xxxxxxxx x x xxxxxxxxx S9 (22). Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx nejdříve xxxxxx použití vodných xxxxxxxxxxxx/xxxxxxx. Xxx zkoušení xxxxx xxxxxxxxx xx xxxx xx měla xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx při xxxxxxxxx xxxxxxxxxx xxxxxxxx zkoušené xxxxx xxxxx cytotoxicita x xxxxxxxxxxx x xxxxxxx xxxxx xxx xxxxxxxx.
Xxxx být xxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxxxxxx může xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxxxx revertantů, xxxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx podkladu nebo xxxxxxxx stupně xxxxxxx xxxxxxxxxxxx kultur. Xxxxxxxxxxxx xxxxx xx může xxxxxx v přítomnosti xxxxxxxxxxxxx aktivačních xxxxxxx. Xxxxxxxxxxxxx by xxxx xxx posouzena xx xxxxxxx xxxxxxxxxxx xxxxxxx x konečné xxxxx xx xxxxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx maximální zkušební xxxxxxxxxxx xxx rozpustné xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx nebo 5 μl/misku. U xxxxxxxxxxxxxxx látek xxxxxxxxxxxxx xxx koncentracích 5 xx/xxxxx xxxx 5 μx/xxxxx xx xxxx xxx xxxxx nebo xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, aby látky xxxx x konečné xxxxx xxx xxxxxxxx xxxxxxxxxxx. Zkoušené xxxxx, xxxxx xxxx xxxxxxxxxxx xxx xxx koncentracích xxxxxxx než 5 xx/xxxxx xxxx 5 μx/xxxxx, xx xxxx xxx zkoušeny xx xx cytotoxické koncentrace. Xxxxxxxxx xx xxxxxx xxxxx při xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx pět různých xxxxxxxxxxxxxxxx koncentrací xxxxxxxx xxxxx, přičemž při xxxxxx xxxxxxxxxxx xx xxxx být xxxxxxxxx xxxx zkušebními xxxx xxxxx xxxxxxxxx polovině xxxxx xxxxxxxxxxxx xxxxxxxx (xx. Ö10). Xxxxx xxxxxxxxx xxxx vhodné x případě, xxx xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx. Zkoušení koncentrací xxxxxxx než 5 xx/xxxxx xxxx 5 μx/xxxxx xxxx xxx xxxxxxx při xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx potenciálně xxxxxxxxxxx xxxxxxxx.
1.5.2.3 Xxxxxxxxx a xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxx xx měly xxx xxxxxxx specifické xxxxxxxxx a negativní (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx s metabolickou xxxxxxxx x bez xx. Xxx xxxxxxxxx xxxxxxxx by měly xxx xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxx.
X případě xxxxxxx x xxxxxxxx metabolického xxxxxxxxxxx xxxxxxx xx xxxx xxx látka (xxxxx) xxx pozitivní xxxxxxxx vybrána (xxxxxxx) xx xxxxxxx xxxx xxxxxxxxx kmene bakterií.
Příkladem xxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx x xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
9,10-dimethylanthracen |
781–43–1 |
212–308–4 |
|
7,12-dimethylbenzo[a]anthracen |
57–97–6 |
200–359–5 |
|
benzo[a]pyren |
50–32–8 |
200–028–5 |
|
2-aminoanthracen |
613–13–8 |
210–330–9 |
|
Cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
Xxxx xxxxx je vhodnou xxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
XX Xxxxxx Red 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx xx xxxxx xxx xxxxxx xxxx xxxxxx indikátor xxxxxxxxx xxxxx X9. Xxx xxxxxxx 2-aminoanthracenu xx xxxx xxx každá xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, který xxxxxxxx xxxxxxxxxxxx xxxxxxxx mikrosomálními xxxxxx, xxxxxxxxx benzo[a]pyren xxxx 7,12-dimethylbenzo[a]anthracen.
Příkladem xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx u xxxxxxx bez xxxxxx xxxxxxxxxxx aktivace xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
Xxxx |
|
xxxx xxxxx |
26628–22–8 |
247–852–1 |
XX1535 x XX100 |
|
2-xxxxxxxxxxxx |
607–57–8 |
210–138–5 |
XX98 |
|
9-xxxxxxxxxxxx |
90–45–9 |
201–995–6 |
XX1537, XX97 x XX97x |
|
XXX 191 |
17070–45–0 |
241–129–4 |
TA1537, XX97 a XX97x |
|
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX x XX102 |
|
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 uvrA x XX2 xxxX (xXX101) |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 xxxX x XX2 xxxX (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx xxxxxxxxxx xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx mohou xxx xxxxxxx jiné xxxxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxxx kontrolu xx xxxx xxx xxxxx v xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx chemické xxxxx, xxxx li x xxxxxxxxx.
Xxxx xx xxx použity xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx rozpouštědla xxxx xxxxxxxx, bez xxxxxxxx látky, xxxxxxxxxx xxxxx stejným xxxxxxxx xxxx exponované skupiny. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx použity také xxxxx, xxxxxxxxxx-xx dosud xxxxxxxxx xxxxx prokazující, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5.3 Xxxxxx
X xxxxxxxxxx miskové xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx aktivace se xxxxxxx smíchá 0,05 xx nebo 0,1 xx zkušebních xxxxxxx, 0,1 xx čerstvé xxxxxxxxxxx xxxxxxx (obsahující xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x 0,5 xx xxxxxxxxxx xxxxx x 2,0 ml xxxxxxxx xxxxx. V xxxxxxx xxxxxxx x xxxxxxxxxxxx xxxxxxxx xx xxxxxxx smíchá 0,5 xx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (x xxxxxxx 5 xx 30 % xxx. x xxxxxxxxxxx xxxxxxxxx xxxxx) s xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x bakteriemi x xxxxxxxxx xxxxxx nebo xxxxxxxxx xxxxxxxx. Xxxxx xxxxx zkumavky xx xxxxxxxx a xxxxxxx xxxx povrch xxxxxxxxxxx xxxxx xx xxxxx. Xxxx xxxxxxxx se xxxxx vrchní agar xxxxxxxx.
X xxxxxxxxxxxx metody (2, 3, 5, 6) xx xxxxxxxx xxxxx nebo xxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxx xxxxxx x xxxxxxxx přes xxxxxx xxxxxxxxxxx agaru xx xxxxx xxxxxxx 20 minut nebo xxxx xxxxxxxxxxx x xxxxxxxxxx kmenem (xxxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x xxxxxxxxx xxxxxx xxxx metabolickým xxxxxxxxxx systémem (0,5 xx) při 30 — 37 °X. Xxxxxxx xx xxxxxx 0,05 xxxx 0,1 xx xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx, 0,1 xx xxxxxxxx x 0,5 xx xxxxx S9 xxxx xxxxxxxxxx xxxxx s 2,0 xx vrchního xxxxx. Xxxxxxxx xx xxxx xxx xxxxx xxxxxxxx provzdušňovány na xxxxxxxx.
X xxxxxxxxxxxx odhadu xxxxxxxx xx xxxx xxx xxx každé xxxxxx dávky xxxxxxx 3 xxxxx. Xxxxxxx xxxx misek je xxxxxxxxxx xx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx nemusí xxxxxxxx xxxxxxxxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx látky xx xxxx xxx xxxxxxxx xxxxxxxx metodami, xxxx. x těsně xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx x xxxx zkoušce by xxxx xxx inkubovány xxx 37 °X xx 48 –72 xxxxxxxx. Po xxxxxxxx xxxxxxxxx xxxx xx xxxxxx xxxxx xxxxxxx xxxxxxxxxx na misku.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxx xxxxx by xxxx xxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xx xxxxx. Měl xx xxx rovněž xxxxxx xxxxx kolonií revertantů xxx na miskách x xxxxxxxxx xxxxxxxxx (xxxxxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx xx xxxxxxx x xxxxxxxxx xxxxxxxxx. Xxxxx xx jednotlivých xxxxxxx, xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx by xxxx být xxxxxxxxxx xxx xxxxxxxxx xxxxx x xxxxxxxxx a xxxxxxxxx xxxxxxxx (neexponovanou xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx xx nepožaduje. Xxxxxxxxxx výsledky by xxxx xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx xx případu. Xxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx nepovažuje xx nezbytné, xxxx xx být podáno xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxxxxx rozsah xxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. K xxxxxxxxxx studie, které xx mohly být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx xxxxxxx metoda xxxx xxxxxxxxxxx x xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje několik xxxxxxxx, xxxx. nárůst xxxxx kolonií revertantů xx xxxxx nad xxxxxxxxx rozsah u xxxxxxx jednoho xxxxx x metabolickým xxxxxxxxxx xxxxxxxx xxxx xxx xxxx, x xx x závislosti na xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx tohoto xxxxx xxx xxxxx xxxx xxxx xxxxxxxxxxx (23). Xxxxxxxx xx xxxx xxx uvážena xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx zkoušky xxxxx xxx použity xxxx pomocný prostředek xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx být xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx výsledky nesplňují xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx většina xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx konečný xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné nebo xxxxxx xxx xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx x genomu kmenů Xxxxxxxxxx xxxxxxxxxxx x/xxxx Xxxxxxxxxxx coli xxxxxx xxxxxx xxxxxxxxxx bází xxxx xxxxxxx xxxxxxx xxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxx xx xxxxxxxx zkoušky pro xxxxxxxxx druhy mutagenní.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx volby xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Kmeny:
- xxxxxxx kmeny,
- xxxxx xxxxx x xxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxx zkoušené xxxxx xx xxxxx (mg/misku xxxx μx/xxxxx) x xxxxxxxxxxx výběru dávky x xxxxx misek xx xxxxxxxxxxx,
- použitá xxxxx,
- xxx a xxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx expozice.
Výsledky:
- xxxxxx toxicity,
- známky xxxxxxx,
- počty xx xxxxxxxxxxxx xxxxxxx,
- xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx kontrole x xxxxxxxxx, xxxxxxxxx hodnotami x směrodatnými odchylkami,
- xxxxxxxxx xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. X., XxXxxx, X., Yamasaki X. (1975), Methods of Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx with xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 31, 347-364.
2) Xxxxx, X. X., Xxxx, X. X. (1983), Revised Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
3) Gatehouse, D., Xxxxxxx, S., Cebula, X., Xxxxx, X., Xxxx, X., Matsushima, X., Melcion, X., Xxxxx, T., Xxxxxx, X., Zeiger, E. (1994), Xxxxxxxxxxxxxxx for xxx Performance of Xxxxxxxxx Xxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 312, 217-233.
4) Xxxx, X. X., Xxxxxxx X. X., Auletta, A. X., Von Halle, X. S., Xxxxx, X. M., Xxxxxx, X. X., Xxxxxx, X., XxXxxx, X., Xxxxxxxxxx, K., Xxxxxx, X., Xxx, T. X., Ray X. (1986), Xxx Salmonella xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Assay: X Xxxxxx xx xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, T., Xxxxxx, X., Xxxxx, Y. X., Xxxxxxxxxx, X., Xxxxx, M., Xxxxxxxx, X., Hashimoto, X. (1975), Mutagenicity xx Xxxxxxxxxx Xxx Dyes xxx xxxxx Derivatives, Xxxxxx Xxxx. 1, 91-96.
6) Xxxxxxxxxx, X., Xxxxxxxx, T., Xxxxx, X., Yahagi, T., Xxxxxx, X., Xxxxxxxx, X. (1980), Xxxxxxx Xxxxxxxxxx Mutagenicity Xxxxxxxxx Xxxxx, xx: Short-term Xxxx Xxxxxxx xxx Xxxxxxxxx Carcinogens, ed. Xxxxxxx K. X., Xxxxxx, X. X., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx Xxxx, 273-285.
7) Gatehouse, X. X., Xxxxxxx, I. X., Wilcox, X., Xxxxxxxxx, X. X., Xxxxxx, R. (1980), Xxxxxxxxx Xxxxxxxx Xxxxxx, xx: Xxxxx Mutagenicity Xxxxx: XXXXX Part 1 Revised, xx. X. X. Xxxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, 13-61.
8) Aeschacher, X. X., Wolleb, U., Xxxxxxx, L. (1987), Xxxxxx Xxxxxxxxxxxxx Mutagenicity Xxxx xxx Xxxxx, X. Xxxx Xxxxxx., 8, 167-177.
9) Xxxxx, X. X. X., Xxxxxx, X. X., Xxxxxxx, X. A. (1976), Xxx of x xxxxxxxxxx xxxxxxxxxxx xxxx xx xxxxxx xxx xxxxxx xx xxxxxxxx, Xxxxxxxxxx Xxx., 38, 33-42.
10) Xxxxxxx, X. A., Green, X. X. L., Xxxxxxxxx, D., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Xxxx xx Xxxxxxxx, in: Xxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx, 2. xxx., Xxxxxx, B. X., Xxxxxxx, M., Xxxxxxx, X., Xxxxx, X. (xxx.), Elsevier, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 141-161.
11) Xxxxxxxx, E. D., Xxxxxxx, X. X. (1981), Xx Xxxxxxxxxxx xx xxx Quantitative Xxxxxxxxxx Assay for Xxxxxxxxxxx xxxx Xxxxxxx xx Xxxxxxxxxx typhimurium, Xxxxxxxxxxxxx Xxxxxxxxxxx, 3, 453-465.
12) Xxxxx, A., Xxxxxxx, T., Xxxx, X., Matsushima, X. (1994), Xxxxxxxx Method xxx Xxxxxxxxxxxx Xxxxxxx xx Gaseous Compounds xx Xxxxx x Xxx Xxxxxxxx Xxx, Xxxxxxxxxx Xxx., 307, 335-344.
13) Xxxxxx, M. X., Xxxx, X. X., Xxxxxxxx, X. X., Reipert, M. X., Xxxxxxx, X. X. (1984), Xxxxxxxxxxxx xx Benzidine and Xxxxxxxxx-Xxxxxxxx Xxxx xxx Xxxxxxxx Xxxxxxx Dyes xx x Xxxxxxxx Xxxxxxxxxx Assay, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, X., Anderson, X. X., Xxxxxxx, X., Lawlor, T., Xxxxxxxxxx, K. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Xxxxx. X. Xxxxxxx from xxx Xxxxxxx xx 311 Chemicals, Xxxxxxx. Xxx. Xxxxxxx., 19, 2-141.
15) Simmon, X., Xxxxxxxx, X., Xxxxxxx, X. X. (1977), Xxxxxxxxx Xxxxxxxx xx Xxxxxxxxx Identified xx Xxxxxxxx Xxxxx, in Xxxxxxxx xx Xxxxxxx Xxxxxxxxxx, D. Xxxxx, X. Bridges, X. Xxxxxx (eds.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. X., Xxxxxxx, X. X., Monteith, X. X., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Xxxxxxxxx to Xxxxxxx Xxxxxxxxx Activity xx Volatile Organic Xxxxxxxxx xx xxx Xxxx/Xxxxxxxxxx Assay, Xxxxxxxxxxxxx Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, T., Xxxxxxxxx, X., Shirai, M., Xxxxxxxx, X., Sugimura, X. (1979), Xxxxxxxxxxxx xx xxx Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx in Xxxxxxxxxx xxxxxxxxxxx, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Gold, X., Xxxxx-Xxxxx, A., Xxxx, X. X. (1980), Fecalase: X Xxxxx xxx Xxxxxxxxxx xx Xxxxxxx Xxxxxxxxxx xx Mutagens by Xxxxxxxxxx Flora, Xxxx. Xxxx. Acad. Xxx. X. X. X, 77, 4961-4965.
19) Wilcox, X., Xxxxxx, A., Xxxx, D. X., Xxxxxxxxx, X. X. (1990), Comparison of Xxxxxxxxxx xxxxxxxxxxx TA 102 xxxx Xxxxxxxxxxx xxxx XX2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Hara, X., Sugimura, X. (1976), X Xxxx Xxxxxxxxxx for Polychlorinated Xxxxxxxxx x. x. xx Xxxxxxx or Xxxxxxxxx Activation Xxxxxxx, xx: In vitro Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, eds. X. X. xx Xxxxxx xx xx. Xxxxxxxx, North Xxxxxxx, 85-88.
21) Elliot, X. X., Combes, R. X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx, G. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 xx xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Xxxxxxxxxxxxxxxx, X., Ames, B. X. (1981), Xxxxxxxxxxxxx xx Organic Xxxxxxxx xxxx xxx Salmonella/Microsome Xxxx, Xxxxxxxxxx Xxx., 88, 343-350.
23) Xxxxxxx, X. D., Xxxxx, X., Xxxxxxx, X., Xxxxxxxxxx, X., Nestmann, X., Zeiger, E. (1987), Guide xxx xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxx xxx Xxxxxxxxx Xxxxxxxxxxxx, Mutatation Xxx., 189, 83-91.
24) Xxxxx, X. X. X., Xxxxx, X. X. X., Middleton, X., Xxxxxxx, X., Xxxxxxxx, W. D., Xxxxxx, X. J. (1989), Xxxxxxxx of Xxxx xxxx Xxxxxxxxx Xxxxxx Xxxxxx, in: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx, Xxxx II. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data, xx. Xxxxxxxx, X. X., Cambridge Xxxxxxxxxx Xxxxx, 28-65."
XXXXXXX 4X
"X.17 MUTAGENITA — XXXXXXX XX XXXXXX XXXXXX X XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx XXXX XX 476 — Zkouška xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx (1997).
1.1 ÚVOD
Zkoušku xx xxxxxx xxxxxx x buňkách savců xx xxxxx xxx xxxxxx xxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxx. Xxxx xxxxxx xxxxxxx xxxxx xxxxx xxxxx lymfomu X5178X xxxx, xxxxxxx xxxxx XXX, CHO-AS52 x X79 křečka xxxxxxxx x xxxxxxxxxxxxxxx xxxxx XX6 xxxxxxx (1). X těchto xxxxxxxxx linií xxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxx xxx thymidinkinasu (TK) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x transgen xanthin-guaninfosforibosyltransferasy (XXXX). Zkoušky xx xxxxxx TK, HPRT x XPRT detekují xxxxx spektrum xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx lokace XX x XXXX xxxx umožnit detekci xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxx xxxxxx), xxxxx xxxxx detekovat x XXXX xxxxxx xx X xxxxxxxxxxxx (2, 3, 4, 5, 6).
Xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx in xxxxx xxx použít xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxx buněčné xxxxx. Xxxxx se xxxxxxxx podle xxxxxxxxxx xxxxx v xxxxxxx x stálosti xxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxx xxxxxxxxx xx xxxxx obecně xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx podmínky in xxxx x savců. Xx xxxxx se xxxxx xxxxxxxxx xxxxxxxx, xxxxx xx vedly x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx. K xxxxxxxxxx xxxxxxxxx, xxx neodrážejí xxxxxxx xxxxxxxxxx, xxxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx vysokých xxxxxx xxxxxxxxxxxx (7).
Xxxx xxxxxxx xx používá xx zjištění xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx pozitivní, xxxx xxxxxxxxxxx xxxxx; xxxx xxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx absolutní xxxxxxxx. Xxxxxxxx závisí na xxxxxxxx xxxxx a xxxxxxxxx xxxxxx x xxx, xx existují xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx touto zkouškou, xxxxx xxxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx buňkách xxxxxxxxxx (6).
Viz xxxx xxxxxx xxxx, část X.
1.2 DEFINICE
Přímá xxxxxx : xxxxxx mutace xxxxxxxxx xxxx mutované xxxxx, která způsobuje xxxxx xxxx xxxxxx xxxxxxxxxxx aktivity xxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxxxxxxx párů xxxx : xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx více xxxx xxxx x XXX.
Xxxxxxxx xxxxxxxx : xxxxx, xxxxx způsobují xxxxx xxxx deleci xxxxxxx xxxx více xxxx bází v xxxxxxxx XXX.
Xxxx exprese xxxxxxxx : xxxx, xxxxx níž xxxxxx x xxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx mutantních xxxxx xxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxx xxxx : xxxxxx xxxxx xxxxx v xxxx xx xxxxxxxx x kontrolní xxxxxxxx xxxxx; xxxxxxx se xxxx xxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxx x v xxxxxxxxx xxxxxxxx a xxxxxxxxx účinnosti xxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxx v xxxxxxxx : xxxxxx xxxxx xxxxx v xxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxx kontrole.
Životaschopnost : xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx misku xx selektivních podmínek xx expresi.
Přežití : xxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxx na xxxxx xx xxxxx xxxxxx xxxxxxxx; xxxxxxx xx xxxxxxx xxxxxxxxx x xxxxxx x xxxxxxx xxxxxxxxx populace xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxx, které v xxxxxxxx mutace XX+/-® XX— /- neobsahují xxxxxxxxxxxxxx (TK) xxxx xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxx (XXX). Buňky xxxxxxxxxxx xxxxxxxxxxxxxx jsou xxxxxxx xx XXX, xxx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxx xxxxxxx xxxxxx. Xxxxxxxx xxxxx xxxx tedy xxxxxxx xxxxxxxxxxx za xxxxxxxxxxx XXX, zatímco normální xxxxx, xxxxx xxxxxxxx xxxxxxxxxxxxxx xxxx schopnost xxxxxx. Xxxxxxx lze x xxxxx x xxxxxxxxxxxx XXXX xxxx XXXX xxxxxxx selekci xxxxxxxxxxxxxxx xxxxxxxxxx x 6-xxxxxxxxxxx (TG) nebo 8-xxxxxxxxxx (XX). Vlastnosti xxxxxxxx xxxxx by xxxx xxx pečlivě xxxxxxx, xxxxxxxx je xx xxxxxxx xx xxxxxx mutace x xxxxxxx xxxxx zkoušen xxxxxx báze xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx. Mělo xx xxx xxxxxxxxx vyšetřeno xxxxxxxx podezření xx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxx xxxx nemutantní xxxxx. Xxx xxxxxxxx chemických xxxxx, xxxxx xxxx xxxxxxxx strukturu xxxx xxxxxxxx činidlo, xxxx xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxx pro selekci (8).
Xxxxx x xxxxxxxxx xxxx xxxxxxxxxxxxx kultuře xxxx vhodnou dobu xxxxxxxxx xxxxxxxx xxxxx xxx s xxxxxxxxxxxx xxxxxxxx, tak bez xx, a subkultivovány xx účelem stanovení xxxxxxxxxxxx x za xxxxxx xxxxxxx fenotypu xxxx selekcí xxxxxxx (9, 10, 11, 12, 13). Xxxxxxxxxxxx xx xxxxxxx xxxxxx xxxxxxxxxx relativní účinnosti xxxxxxxxx (přežití) xxxx xxxxxxxxxx relativního xxxxxxxxx xxxxx xxxxxx xx xxxxxxxx xxxx expozice. Xxxxxxxxxx xxxxxxx xx xxxxxxx v xxxxxxxx xxxxx po vhodnou xxxx xxxxxxxxxxxxxxxxx xxx xxxxx zvolený lokus x typ buněk, xxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx mutací. Xxxxxxx xxxxxxx xx stanoví xxx, xx xx xxxxxx xxxxx počet xxxxx do xxxxx xxxxxxxxxxxx xxxxxxxx činidlo xxx xxxxxxx mutantních xxxxx x xx xxxxx xxx xxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxx). Xx xxxxxx xxxxxxxxx době xx xxxxxxxxx kolonie. Četnost xxxxxxx se vypočte x počtu xxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxx a počtu xxxxxxx x xxxxx xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Pro xxxxxxx x xxxx xxxxxxx xxxx x dispozici xxxxx xxxx buněk, xxxxxx xxxxxxxx buněk X5171X, CHO, CHO-AS52, X79 nebo XX6. Xxxx buněk x xxxx xxxxxxx xx xxxx xxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxx klonovací xxxxxxxxx x stabilní frekvenci xxxxxxxxxxx xxxxxx. Xxxxx xx xxxx xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx mykoplasmaty, x x xxxxxxx kontaminace xx xxxxxx xxx xxxxxxx.
Xxxxxxx xx měly xxx xxxxxxxx xxx, xxx xxxx xxxxxx xxxxxxxxxx citlivost a xxxx. Počet xxxxxxxxx xxxxx, xxxxxx x xxxxxxxxxxx zkoušené xxxxx xx xxx xxxx xxxxxxxxxx xxxxxxxxx odrážet (14). Xxxxxxxxx počet xxxxx, xxxxx xxxxxxx xxxxxxxx x xxxxx xxxxx xxxxxxx x xxxxxx xxxxxx zkoušky, xx měl být xxxxxxx xx četnosti xxxxxxxxxxx mutací. Obecným xxxxxxxxx je, aby xxx xxxxxx xxxxx xxxxx, xxxxx xx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx. Xx xxxx doporučeno, xxx bylo použito xxxxxxx 106 buněk. Xxxx xx být x xxxxxxxxx dostatečné xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx systému, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx.
1.4.1.2 Média x xxxxxxxxxx podmínky
Pro xxxxxxxxx xxxxxx xx xxxx xxx xxxxxxx vhodná xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (kultivační xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x xxxxxxx). Xxxxx xx měla xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx x xxxx xxxxx xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx důležité, xxx xxxxxxxxxx podmínky byly xxxxxxx tak, xxx xxxx xxxxxxxxx xxxxxxxxx xxxx buněk xxxxx xxxxxx xxxxxxx x xxxxxxxxx xxx xxxxxxxxxx, xxx nemutovaných buněk xxxxxx xxxxxxx.
1.4.1.3 Příprava xxxxxx
Xxxxx xx xxxx xxx získávány x xxxxxxxxx xxxxxx, xxxxxxxx xx kultivačního média x xxxxxxxxxx xxx 37 °C. Xxxx xxxxxxxx x xxxx xxxxxxx xxxx xxx xxxxxxxx odstranit x xxxxxxx již xxxxxxxx xxxxxxxx buňky.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx by měly xxx xxxxxxxxx zkoušené xxxxx, x to x vhodným xxxxxxxx xxxxxxxxxxx xxxxxxxx x xxx něho. Nejčastěji xxxxxxxxxx xxxxxxxx je xxxxxxxxxx dotovaná postmitochondriální xxxxxx (S9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Xxxxxxx 1254 (15, 16, 17 x 18), nebo xxxx xxxxxxxxxxxxx a β-xxxxxxxxxxxx (19, 20).
Postmitochondriální frakce xx x konečném xxxxxxxxxx médiu obvykle xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % obj. Xxxxx x xxxx metabolického xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx třídě xxxxxxxx xxxxx, xxxxx xx xxxxxxxx. X xxxxxxxxx xxxxxxxxx xxxx xxx vhodné použít xxxx xxx xxxxx xxxxxxxxxxx postmitochondriální frakce.
Řada xxxxxxxx vývoje, včetně xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx enzymy, xxxxxxxxx xxxxxxxx pro xxxxxxxxx aktivaci. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Příprava xxxxxxxx látky
Pevné zkoušené xxxxx by xxxx xxx xxxx aplikací xx buňky rozpuštěny xxxx suspendovány xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx zkoušené xxxxx xxxxx xxx xxxxxxx přímo x xxxxxxxxxx systémům x/xxxx xxxxx být před xxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x stálosti xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx být xxxx podezření, xx xxxxxxx xx xxxxxxxxx xxxxxx, x mělo xx xxx slučitelné x přežitím buněk x s aktivitou X9. Xxxx-xx xxxxxxx xxxx než známá xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx o xxxxxx kompatibilitě. Doporučuje xx pokud xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx rozpouštědel/vehikul. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx být xxxxxxx xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx. Vodu xxx xxxxxxxxx přidáním xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx zohledněna xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, rozpustnost x xxxxxxxxxx xxxxxxx x změny xX xxxx osmolality.
Cytotoxicita by xxxx být xxxxxxxxx x metabolickou xxxxxxxx x xxx xx x hlavním xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx buněčné xxxxxxxxx x xxxxx, xxxx xxxx relativní xxxxxxxx xxxxxxxxx (přežití) xxxx xxxxxxxxx celkový xxxx. Xxxx xxx výhodné xxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxx v xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx být xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx dané xxxxxxxxx x minimální xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx, xx xx se xxxxxxxxxxx xxxx lišit xxxxxxxx 2 xx Ö10. Xx-xx maximální xxxxxxxxxxx xxxxxxxx od xxxxxxxxxxxx, xxxx xx být xxxxxxxxx přibližně 10 — 20 % (xxx xxxxxxx 10 %) přežití (xxxxxxxxx xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx xxxxxxx růst. X xxxxxxx relativně xxxxxxxxxxxxxxx xxxxx by xxxx být xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
Xxxxxxxxx xxxxxxxxxxx látky xx xxxx být xxxxxxxx až k xxxx xxxxxxxxxxxx xx xxxxxxxxxxxx podmínek, xxxx xx xx tuto xxx. Xxxx by xxx stanovena xxxxxxxx xxxxxxxxxxxxx x konečném xxxxx, xx kterému xxxx xxxxx exponovány. Xxxx být xxxxxxx xxxxxxxx rozpustnost na xxxxxxx x xx xxxxx aplikace, neboť xxxxxxxxxxx xx může x xxxxxxx xxxxxxxx x testovacím systému xxxxx x důsledku xxxxxxxxxxx xxxxx, X9 xxxx, atd. Xxxxxxxxxxxxx xxx zjistit xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx xxxx být xxxxxxxxx x negativní (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx xxx x xxxxxxxxxxxx xxxxxxxx, tak xxx ní. Při xxxxxxx metabolické aktivace xx měla xxx xxxxxxxxx xxxxxxxxx chemická xxxxx, xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx.
Xxxxxxxxx pozitivní xxxxxxxx xxxxx xxx tyto xxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx podle Einecs |
|
Bez xxxxxx metabolické xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx x xxxxx xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X vnější metabolickou xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx x xxxxx kolonie) |
cyklofosfamid |
50–18–0 |
200–015–4 |
|
|
cyklofosfamid monohydrát |
6055–19–2 |
|||
|
benzo[a]pyren |
50–32–8 |
200–028–5 |
||
|
3-methylcholanthren |
56–49–5 |
200–276–5 |
||
|
XPRT |
N-nitrosodimethylamin (xxx xxxxxx xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx xxx xxxxxxx xxxx jiné referenční xxxxx xxx xxxxxxxxx xxxxxxxx, xxxx. má-li xxxxxxxxx databázi dosavadních xxxxx x 5-brom-2′-deoxyuridinu (XXX 59–14–3, XXXXXX 200–415–9), xxxx xxx xxxx xxxxxxxxxx látka xxxxxx xxxxxxx. Xxx xxxxxxxxx kontrolu xx xxxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx pokud xxxxx xx stejné xxxxxxxx xxxxx.
Xxxx by xxx použity negativní xxxxxxxx tvořené xxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxx a xxxxxxxxxx jinak stejným xxxxxxxx xxxx exponované xxxxxxx. Xxxxx toho xx měly xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx kontrolní xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx nevyvolává xxxxx xxxxxxx xxxx mutagenní xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Expozice xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx měly být xxxxxxxxx xxxxxxxx látce xxx xx přítomnosti xxxxxxxxxxxxx aktivačního systému, xxx bez xxxx. Xxxxxxxx by měla xxxxx vhodnou xxxx (xxxxxxx xx xxxxxx xxxx 3 xx 6 xxxxx). Xxxxxxxxx xxxx xxxx xxx xxxxxxxxxxx na xxxxx xxxx xxxx xxxxxxxxx xxxxx.
Xxx xxxxxx xxxxxxxx xxxxxxxxxxx mohou být xxxxxxx xxxxxxxxxx kultury xxxx jedna exponovaná xxxxxxx. Xx-xx xxxxxxx xxxxx xxxxxxx, xxx xx xxx počet xxxxxxxxxxx zvýšen xxx, xxx xxx xxxxxxxx xxxxxxxxxxxx xxxxx xxxxxx xxx analýzu (xxxx. xxxxxxx xxx analyzovatelných xxxxxxxxxxx). Xxxx by xxx xxxxxxx duplicitní xxxxxxxxx kontrolní kultury (xxxxxxxx rozpouštědla).
Plynné xxxx xxxxxx látky by xxxx být zkoušeny xxxxxxxx xxxxxxxx, např. x xxxxx uzavřených xxxxxxxxxxxx xxxxxxxx (21, 22).
1.4.3.2 Xxxxxxxxx přežití, xxxxxxxxxxxxxxxx x xxxxxxxx xxxxxx
Xx konci expoziční xxxx xx xxxxx xxxxxxx a xxxxxxxxx xx účelem xxxxxxxxx xxxxxxx a xx xxxxxx umožnění xxxxxxx xxxxxxxx xxxxxxx. Se xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx xx započne xxxxxxx xx expoziční xxxx.
Xxxxx xxxxx xx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx nově xxxxxxxxxxxx xxxxxxx (HPRT x XXXX xxxxxxxx xxxxxxx 6 až 8 xxx, TK xxxxxxx xxx xxx). Buňky xxxx xxxxxxxxxxx x xxxxx xx selekčním xxxxxxxx (selekčními xxxxxxx) x xxx xxxx (xxx xxxx) xx xxxxxx stanovení xxxxx xxxxxxx x klonovací xxxxxxxxx. Se xxxxxxxxxx xxxxxxxxxxxxxxxx (xxxxxxx xxx xxxxxxx xxxxxxxx xxxxxxx) xx xxxxxxx xx xxxxx xxxx xxxxxxx xxxxxxxxx xx xxxxx xxx selekčního xxxxxxx.
Xx-xx xxxxxxxx látka pozitivní xx xxxxxxx X5178X XX+/-, mělo by xxx xxxxxxxxx xxxxxxx xx xxxxx xx xxxxxxxxxx xxxxxx (x xxxxxxxx xxxxxxxxx koncentrací) x xx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxx xx xxxxxxx X5178X XX+/- xxxxxxxxx, xxxx xx xxx rozdělení kultury xxxxx xxxxxxxxx kolonií xxxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxx kontrolách. Xxx xxxxxxxx za xxxxxxx XX6 XX+/- xxxx xxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxxxx velikosti xxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xx xxxx xxxxxxxxx xxxxxxxxx cytotoxicity x xxxxxxxxxxxxxxxx, xxxxx xxxxxxx x xxxxxxxx xxxxxxx xxx exponované a xxxxxxxxx xxxxxxx. V xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxx L5178Y XX+/- xx kolonie xxxxxxxxx xxxxxxx x xxxxx xxxxxxxxxxx xxxxxxxx xxxxx (xxxxxxxx xxxxxxxxx xxxxxxxxxxx) a x xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx xxxx xxxxxxx — xxxxx kolonie. Xxxxxxxxxxx a xxxxxxxxxxxxx xxxxxx xxx mutantů xxxxxxxxx xxxxx xxxxxxx, xxx mutantů xxxxxxxxx xxxx kolonie xxxx xxxxxxxx xxxxxxxx (23, 24). Xx zkoušce XX+/- xxxx kolonie xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx s xxxxxxxxx xxxxxx (xxxxx) x xxxxxxx s xxxxxxx růstem (xxxx) (25). X mutantních xxxxx, které xxxxxxx xxxxxxxxxxxxxx xxxxxxxxx poškození, xx xxxxxxxxxxx doby xxxxxxxx, a xxxxx xxxx xxxx xxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxx xx xxxxx xxxxxx xxxx xx xx karyotypické viditelné xxxxxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxxx x xxxxxxxxxx látkami, xxxxx indukují xxxxx xxxxxxxxxxxx xxxxxxx (26). Xxxx závažně xxxxxxxxx xxxxx mutantů xxxxxx xxxxxxxx tempem jako xxxxxxxx xxxxx x xxxxx xxxxx kolonie.
Mělo xx xxx xxxxx xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx xxxxxxx xxxx. Xxxxxxx xxxxxxx xx xxxx xxx vyjádřena xxxx xxxxx mutantů x xxxxx xxxxxxxxxx buněk.
Měly xx být xxxxxxx xxxxx xxx jednotlivé xxxxxxx. Xxxx by xxxx být xxxxxxx xxxxx xxxxxxx xx xxxxx tabulky.
Ověření xxxxx xxxxxxxxx odpovědi xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx měly xxx xxxxxxxxx dalším xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Negativní xxxxxxxx xxxx být xxxxxxxxx případ xx xxxxxxx. Xxx, kde xxxx potvrzení negativních xxxxxxxx považováno xx xxxxx, je třeba xxxxx xxxxxxxxxx. Změna xxxxxxxxx studie s xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx podmínek by xxxx xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx xxx xxx dvojznačné xxxxxxxx, tak pro xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X INTERPRETACE VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik kritérií, xxxx. xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxx xxxxxxxx. Xxxxxxxx xx xxxx být xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx mohou být xxxxxxx jako xxxxxxx xxxxxxxxxx xxxxxxxxxxx metody. Xxxxxxxxxxx významnost xx xxxxxx xxx jediným xxxxxxxxx xxxxxxxx pro xxxxxxxxx odpověď.
Zkoušená látka, xxxxx xxxxxxxx xxxxxxxxx xxxx uvedená xxxxxxxx, xx x tomto xxxxxxx považuje za xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx jasně xxxxxxxxx xxxx negativní výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx soubor údajů xxxxxxxx konečný xxxxx x aktivitě xxxxxxxx xxxxx. Xxxxxxxx mohou xxxxxx dvojznačné xxxx xxxxxx bez xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxx mutace x xxxxxxx xxxxx xx xxxxx xxxxxxxxx, že xxxxxxxx xxxxx indukuje x použitých kultivovaných xxxxxxx savců xxxxxx xxxxxx. Xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxxxx xx velmi xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx neindukuje x xxxxxxxxx kultivovaných xxxxxxx xxxxx genové xxxxxx.
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- počet buněčných xxxxxx,
- případně počet xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx buněčné xxxxxxx,
- xxxxxxxxxxxx mykoplasmat.
Zkušební xxxxxxxx:
- xxxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxx kultur, xxxxxx xxxx. xxxxx x cytotoxicitě x xxxxxx xxxxxxxxxxxx, xxxx-xx x dispozici,
- xxxxxxx xxxxx, xxxxxxxx koncentrace XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx doba,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx xxxxx xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx a xxxxxxxxx xxxxxxxx,
- xxxxx xxxx exprese (případně xxxxxx xxxxx xxxxxxxxxx xxxxx, subkultur x xxxxxx xxxxx),
- xxxxxxxx xxxxxxx,
- xxxxxxxx klasifikace xxxxxxx xx xxxxxxxxx, xxxxxxxxx nebo dvojznačnou,
- xxxxxx xxxxxxx k xxxxxxxx xxxxxxxxxxxxxxx a xxxxxxxxxx buněk,
- xxxxxxxx xxxxxxx xxxxx xxxxxxxxx x typu (xxxxxxxx xxxxxx kriterií xxx "xxxx" x "velké" xxxxxxx).
Xxxxxxxx:
- známky xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx x xX x xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxx látce, pokud xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxx-xx xxxxxxxxxxx, xxxxxxx xxx xxxxxxxxx x xxxxxxxxx kontroly,
- xxxxxxxxx předpoklady xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxx xxxxxxx xxxxxxxx X5178X XX+/-,
- podle xxxxxxxx závislost xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx analýzy,
- údaje x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Moore, X. M., XxXxxxxx, X. X., XxXxxxxx, X. X., Tindal, X. R. (xxx.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Spring Xxxxxx Xxxxxxxxxx, Xxx Xxxx.
2) Chu, X. X. Y., Xxxxxxx X. X. (1968), Xxxxxxxxx Xxxx Xxxxxxxx. XX. Xxxxxxxx Xxxxxxxxx xx Xxxxxxxx Xxxxx Xxxxxxxxx in Xxxxxxx Xxxxxxx Xxxxx Xx xxxxx, Proc. Natl. Xxxx. Xxx. U. X. A, 61, 1306-1312.
3) Xxxxx, X. X., Thilly, W. X. (1982), Xxxxxxxx Xxxxx at xxx Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxxxx Xxxxx Xxxxxxxxxxxx, Mutation Xxx. 94, 467-485.
4) Xxxxx, X. X., Xxxxxxxxx-Xxxxx, X., Xxxxx, X. X., Dearfield, K. X. (1989), Xxxxxxxxxxxx Xxxxxx Quantitation xx xxx Xxxxx Xxxxxxxx XX xxx XXX XXXXX Xxxx, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. X., Stankowski, Xx. L. X., (1989), Xxxxxxxxxx of xxx XX52/XXXX xxx xxx CHO/HPRT Assays: Xxxxxxxxxx xx Xxx Xxxx Xxxxxxxxxx, Mutatation Xxx. 223, 121-128.
6) Xxxxx, X. X., Xxxxxxxxxx, X., Glatt, X. X., Moore, X., Nishi, Y., Xxxxxxxxxx, Xx. X. X., Theiss, X., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Gene Xxxxxxxx Xxxxxx Xxxxxxx Xxxxx Report. Report xx xxx International Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Genotoxicity Xxxx Xxxxxxxxxx. Xxxxxxxx Xxx. 312, 235-239.
7) Scott, X., Xxxxxxxx, S. X., Xxxxxxxx, X. X., Xxxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Xxxx, B. X. (1991), Genotoxicity Xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X report xxxx XXXXXX Task Xxxxx 9, Mutation Xxx. 257, 147-204.
8) Xxxxx, X., McCuen, X., Xxxxxxx, X. X. X., Xxxxx, X., Xxxxxxxxx, X. X. (1983), Xxxxxxxx Xxxx Mutations xx X5178X Cells xx Xxxxxxx. X Report xx the U. X. Xxxxxxxxxxxxx Protection Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 115, 225-251.
9) Xx, X. X., Xxxxx, X. X., Heflich, X. X., Xxxxxx, J. X. (1988), A Xxxxxx xxx Xxxxxxxx xx xxx Xxxxxxx Xxxxxxx Xxxxx/Xxxxxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx Transferase Xxxxxx xx Determine xxx Xxxxxxxxxxxx xx Chemical Xxxxxx: A Report xx Phase XXX xx xxx U. X. Xxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 196, 17-36.
10) Li, X. X., Carver, X. X., Choy, X. X., Xxxx, X. X., Gupta, X. X., Loveday, X. X., X'Νxxxx, X. X., Xxxxxx, J. X., Stankowski, L. X. Jr., Xxxx, X. X. (1987), X Xxxxx xxx xxx Xxxxxxxxxxx of xxx Xxxxxxx Xxxxxxx Xxxxx Cell/Hypoxanthine-Guanine Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Mutation Xxxxx, Xxxxxxxxxx Res., 189, 135-141.
11) Xxxxx, X. X., Yandell, X. X., Little, X. X. (1989), X Xxxxxxxxxx xx Xxxxxxxx Xxxxxxxxx at xxx TK xxx XXXX Loci xx Xxxxx Xxxxxxxxxxxxxx Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx to xx Xxxxxxxxxx Xxxxx of Xxxxxxxxx at the Xxxxxxxxx TK Locus, Xxxxxxxxxx Xxx., 216, 9-17.
12) Xxxxxxxxxx, L. X. Jr., Xxxxxx, X. R., Xxxx, X. X. (1986), Xxxxxxxxxxxx xxx Xxxxxxxxx Xxxxxxxx of Xxxxx Xxxxxxxxxxxxxxxxx and ICR 191-Xxxxxxx Xxxxxxxxx Analyses xx Xxxxx Methanesulphonate xxx ICR 191 Xxxxxxx Xxxxxxxx in XX52 Xxxxx, Mutatation Xxx., 160, 133-147.
13) Xxxxxx, X. X., Xxxxxx, A. X., Xxxxx, X. (1984), Xxxxxxxxx for xxx X5178X/XX+/--XX+/- Xxxxx Xxxxxxxx Xxxx Xxxxxxxxxxxx Xxxxx, xx: Kilbey, X. X. xx al (xxx.) Xxxxxxxx xx Xxxxxxxxxxxx Test Xxxxxxxxxx, Xxxxxxxx Xxxxxxx Publishers, Xxx Xxxx, 239-268.
14) Xxxxxx, X. X., Xxxxx, X. M., Xxxxxx, G. X., Xxxxx, X. X. X., Xxxx, X., XxXxxxxx, X. B., Xxxxxxx S. X. (1989), Mammalian Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx upon Colony Xxxxxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx of Mutagenicity Xxxx Xxxx, Kirkland, X. J., xx., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 66-101.
15) Abbondandolo, X., Xxxxxxx, X., Corti, X., Fiorio, R., Xxxxxxxx, X., Mazzaccoro, X. (1977), Xxxxxxxxx xx 6-Thioguanine-Resistant Xxxxxxx xx V79 Chinese Xxxxxxx Xxxxx by Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Dimethylnitrosamine, Xxxxxxxxxx Xxx. 46, 365-373.
16) Xxxx, B. X., McCann, J., Xxxxxxxx, E. (1975), Xxxxxxx xxx Detecting Xxxxxxxxxxx and Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx. 31, 347-364.
17) Xxxxx, X., Johnson, X. X., Xxxxxxx, X. F. S., Xxxxxx X. G., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx of xxx X5178X/XX+/--Xxxxx Lymphoma Xxxxxxx Assay Xxxxxx, Xxxxx. Xxx. 59, 61-108.
18) Xxxxx, X. X., Xxxx, X. X. (1983), Revised Xxxxxxx xxx the Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx. 113, 173-215.
19) Elliott, X. X., Xxxxxx, R. X., Xxxxxxx, C. X., Xxxxxxxxx, D. X., Gibson, X. X., Xxxxxx, X. X., Xxxx, R. X. (1992), Alternatives xx Xxxxxxx 1254-Induced X9 in: Xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Sawamura, X., Xxxx, X., Xxxxxxxx, X. (1976), X Safe Substitute xxx Xxxxxxxxxxxxxxx Biphenyls x. s. xx Xxxxxxx xx Metabolic Xxxxxxxxxx Xxxxxxx, V: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Xxxxxxxxxxx Xxxxxxx, xx Xxxxxx, X. X., Fouts, X. X., Xxxx, X. X., Xxxxxxx, X. X. (eds), Xxxxxxxx, North-Holland, 85-88.
21) Xxxxx, X. X., Xxxxxx, F. C., XxXxxxx, X. X. (1982), CHO/HGPRT Mutation Xxxxx: Xxxxxxxxxx of Xxxxx xxx Xxxxxxxx Xxxxxxx, xx: Xxxx, X. X., Xxxxx, X. X., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Xxxxxxx of Xxxxxxxx Xxxxxx, New Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, P. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, A. X. (1983), Xxxxxxxxxx of xx Exposure Xxxxxx Xxxxx Cells Xxxxx xx Xxxxxxxx Gels xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Mutagens xx xxx CHO/HGPRT Mutation Xxxxx, Environ. Xxxxxxxxxxx, 5, 795-801.
23) Xxxxxxxxx, X. X., Xxxxx, X. X., Broder, X. X., Burrell, X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxx xx the Xxxxxxxxxxxx Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxx Lymphoma Xxxxx, Xxxx. Xxxx. Xxxx. Xxx. U. X. X, 87, 51-55.
24) Moore, X. X., Clive, X., Xxxxxx, X. C., Xxxxxx, B. X., Xxxxxx, A. X., Xxxxxx, N. X., Xxxxxx, J. (1985), Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx, Xxxxxxxxx (XXX+) Mutants xx L5178Y/TK+/--Mouse Xxxxxxxx Xxxxx, Xxxxxxxxxx Res. 151, 161-174.
25) Yandell, X. X., Xxxxx, X. P., Little, X. X. (1990), Xxxxxxxxx Genetic Xxxxxxxx xx Xxxxxxxxx Xxxxxxxxx xx a Heterozygous Xxxxxxxxx Xxxxx xx Xxxxx Cells, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, M. X., Xxxxx, X. L. (1990), Xxxxxxxxxx xx Xxxxxxxxxx Xxxxxxxxxx Xxxxxxxxx xxx Small Colony XX-Xxxxxxxxx Mutant Xxxxxxxxx xx X5178X/XX+/- 3.7.2C Xxxxx Lymphoma Xxxxx, Xxxxxxxxxxx, 5, 609-614."
XXXXXXX 4F
"B.23 XXXXXXX XX XXXXXXXXXXXX XXXXXXX XX SPERMATOGONIÍCH SAVCŮ
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 483 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx spermatogoniích xxxxx in xxxx xx xxxxxxxxxxxxx takové xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx xx spermatogoniích savců (1, 2, 3, 4, 5). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx xxxxxxx: chromozomové x xxxxxxxxxxxx. X xxxxxxx chemických xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx xxxxxxx se xxxxxx vyskytují. Xxxx xxxxxx xxxx xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx a xxxx x tomuto xxxxx xxxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx a xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx u xxxxxxx.
Xxxxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxx ve xxxxxxxxxxxxxxx a xxxxxxxxxxx xx xxxx, xx xxxx zkouška xxxxxxxx xxxxxxxxx indukce xxxxxxxxx xxxxxx x xxxxxxxxxxxx xxxxxxx.
X xxxx zkoušce xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Touto xxxxxxxxxxxxxx xxxxxxxx in xxxx xx xxxxxxxx xxxxxxxxxxxx xxxxxxx xxx xxxxxx xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx nejsou xxxxxxxxx xxxx xxxxxxx.
Xxx xxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx xx xxxxxxxxxxxxxxx xx xxxx xxx — xxxxx xxx xxxxx xx xxxxxx xxxx — xxxxxxxxx první xxxxxxxxx xxxxxxx xxxxxx, xxxxx xxxxxxxxx xx xxxxxxxx. Xxxxx xxxxxxxxx x exponovaných xxxxxxxxxxxxxxxxxx xxxxxxxxx buněk xxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx v xxxxxxxxx-xxxxxxxx X, xxx xx xxxxxxxxxx xxxxx stávají xxxxxxxxxxxx.
Xxxx xxxxxxx in xxxx je xxxxxxxx xxx xxxxxxxxx, xxx xxxx mutageny xxxxxxxxxxx xxxxx xxxxxxx xxxx x germinálních xxxxxxx. Xxxxx xx xxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xx vivo, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx XXX.
Xx xxxxxxxxx xx xxxxxxxx řada xxxxxxxx spermatogonií s xxxxxx citlivostí xx xxxxxxxx chemické xxxxx. Xxxxxxxxxx aberace tedy xxxxxxxxxxx souhrnnou xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxxxxxxx diferencovanými xxxxxxxxxxxxxxx. V xxxxxxxxxx xx xxx poloze xx varlatech, xxxxx xxxx nemusí xxx xxxxx generace xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx x důsledku xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxx xxxxx x xxxxxxx xxxx xxxxxxx xxxxxx a xxxxxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, xx xx xxxxxxxx xxxxx xxxx reaktivní xxxxxxxxxx xxxxxxxxxx do cílové xxxxx, není xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx xxxxxx úvod, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx zlomu x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu xxxx xxxxx a xxxxxxx xxxx xxxxxxxxx x xxxxxx místě.
Gap : xxxxxxxxxxxx léze xxxxx než xxxxx xxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : násobek haploidního xxxxx xxxxxxxxxxxxxx sad (x), xxxx xxx xxxxxxxxx (tj. 3 x, 4 n xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx xxx xxxxxxxxxxx, jeví se xxxx xxxxxx x xxxxxxxxx, intrachromozomální nebo xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxx xxxxxxx xxxxxxxx exponována xxxxxxxx xxxxx a xx vhodné xxxx xx expozici usmrcena. Xxxx usmrcením se xxxxxxxx xxxx látka xxxxxxxxxxx xxxxxxxx (např. xxxxxxxxx nebo Colcemid®). X xxxxxxxxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx xx a analyzují xx xxxxxxxxxxxx aberace xxxxxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx druhu zvířete
Běžně xxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxx x xxxx; xxx xxxx xxxxxx samce jakéhokoli xxxxxx vhodného xxxxx xxxxx. Xxxx by xxx xxxxxxx xxxxx xxxxxxx laboratorní kmeny xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx by překročit ± 20 % xxxxxxx hodnoty xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx a xxxxxx
Xxxxx obecné podmínky xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx mělo xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx xx xxxxxxxx výběrem xxxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxx, která xx exponuje. Xxxxx xx xxxx xxx xxxxxxxxxx tak, xxx xxx vliv jejich xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx jednoznačně identifikují. Xxxx xxxxxxxxx xxxxxx xx nechají x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Xxxxxxx zkoušené látky xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx použity xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje x xxxxxxxx xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx by xxx xxxxxxxxx podezření, xx xxxxxxx se xxxxxxxxx xxxxxx. Jsou-li xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx by xxxx xxx xxxxxxxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. S xxxxxxxx aplikace xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx identický proces xxxx xxxxxxx xx xxxxxxxxx, x xxxxx xxxxx k expozici.
Pozitivní xxxxxxxx xx xxxx xxxxxxxxxx strukturní xxxxxxx xx xxxxxxxxxxxxxxx xx xxxx při xxxxxxxxxxx xxxxxxxx, x xxxxx xx předpokládá, že xxxxxxxxx xxxxxxxxxxxxx nárůst xxx pozadí.
Dávky xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, xxx aby xxx xxxxxx xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx preparátu. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx způsobem než xxxxxxxx látka a xxx xxx xxxxx x jejím xxxxxxx xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxx xxx xxxxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx látek xx xxxxxx xxxxxxxx xxxxx, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx pozitivní xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (xxxxxxx) |
79–06–1 |
201–173–7 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx odběru xx xxx xxx xxxxxxxx odběr x xxxxxxx negativní kontroly, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx a která xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx exponované xxxxxxx, xxxxx xxxxxx x dosavadních xxxxxxxxxxx xxxxx k xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx zvířat x xxxxxxxx buněk x xxxxxxxxxxxxxx aberacemi. Xxxxx xxxx by xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 POSTUP
1.5.1 Xxxxx zvířat
Každá xxxxxxxxxx x kontrolní xxxxxxx xxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxx.
1.5.2 Xxxx expozice
Zkoušené látky xx xxxx xxx xxxxx xxxxx podávány xxxxxxxxxxx xxxx xxxxxxxxx (xx. xxx jedné xxxxxxxx nebo dvou xxxxxxxxxx). Zkoušené látky xxxxx být xxxxxxxx xxxx xx xxxx xxxxxxx, xxx. dvě xxxxx x týž xxx x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx podávání xxxxxxx objemů materiálu. Xxxx režimy xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xx xxxxxxx x xxxxxxxx dávkou xx měly xxx xx xxxxxxxx xxxxxxxxx xxx xxxxxx. Poněvadž xxxxxxxx xxxxxxxxx xxxxx xxxx být zkoušenou xxxxxx ovlivněna, xxxxxxx xx xxxxx xxxxx xxxxx x xxxxx xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx xx xxxxxxxx. X případě xxxx xxx xxxxxxxx dávky xx měl xxx xxxxx xxxxxxxx xx 24 hodin nebo xx takové xxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx délky xxxxxxxxx xxxxx, pokud xxxx xxxxx jiná vhodnější xxxx xxx xxxxxxx xxxxxx (6).
Xxxxx mohou xxx odběry provedeny xxxx x xxxx xxxx. Xxxxxxxxx v xxxxxxx chemických xxxxx, xxxxx mohou indukovat xxxxxxxx xxxxxxxxx (xxxxxxx) xxxxxxxxxx nebo xxxxx xxxxxxxxxx S-nezávislé xxxxxx, xxxx xxx xxxxxxxxx xxxxxxxx xxxxx (1).
Xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxx xxx určena xxxxxx od případu. X xxxxxxx plánu x opakovanou expozicí xx měla být xxxxxxx xxxxxxxx 24 xxxxx (1,5xxxxxxx xxxxx xxxxx) xx poslední xxxxxxxx. Xxxxx xxxxxxx xxxxx xxx xxxxxxxxx xxxxx xxxxxx v xxxx xxxx.
Xxxx usmrcením xx xxxxxxxx xxxxxxxxxxxxxxxxx xxxx vhodná dávka xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Colcemid® nebo xxxxxxxxx). Poté xx xx xxxxxx xxxx xxxxxxx x xxxxxx xxxxx. U myši xx xxxx xxxx xxxxxxxxx 3 — 5 hodin; x xxxxxx čínského xx xxxx xxxx xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx vhodných xxxxxxxxxx údajů xxxxxx xxx xxxxxxxx xxxxxxx, xxxx by xxx xxxxxxxxx xx stejné xxxxxxxxxx, xx xxxxxxx xxxxxx x xxxxxx x za stejného xxxxxx xxxxxxxx, xxxxx xx xxxxxxx x xxxxxx xxxxxx (7). X xxxxxxx xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx tři xxxxxx xxxxx. Tyto xxxxxx xxxxx xx xxxx pokrývat xxxxxxx xxxx maximální x xxxxxxxxx toxicitou, xxxxxxxx xxxxxx toxicitou. Xxx xxxxxxxxx odběru stačí, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx dávka je xxxxxxxxxx jako xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xx xxxxx xxxxx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx očekávání x xxxxxxxx.
Xxxxx xx xxxxxxxxxxx biologickou xxxxxxxxx xxx nízkých xxxxxxxxxxx xxxxxxx (např. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx být xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx dávka xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx vyvolávající xx xxxxxxxxxxxxxxx některé xxxxxx xxxxxxxx (xxxx. xxxxxxx xxxxx spermatogonií x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx; xxxx snížení xx xxxxxx xxxxxxxxx 50 %).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x jednou xxxxxx alespoň 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx jednorázově xxxx xx xxxx xxxxxxx x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx účinky x xxxx-xx na xxxxxxx xxxxx o látkách, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx úplná xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. Očekávaná xxxxxxxx xxxxxxx může xxxxxxxx xxxxxxx použít x xxxxxxx zkoušce xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx nitrožaludečně, xxxxxxxxx xxxxxx xxxx xxxxxxx intubační xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx způsoby podávání xxxx xxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx sondou nebo xxxxxxxx, xxxxxx xx xxxxxxxxx testovacího xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 ml/100 x tělesné xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx uvedený xxxxx, musí xxx xxxxxxxxxx. Xx xx xxxxxxxx x žíravé xxxxx, které xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx měla xxx xxxxxxxxxxx xxxxxxxxxx objemu xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxxxxx xx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx xx x xxxxxxx nebo xxxx xxxxxx xxxxx xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx x xxxxxx. Xxxx xx xxxxxx xx xxxxxxxx xxxxxxx x xxxxxx se.
1.5.7 Xxxxxxx
X xxxxxxx xxxxxxx xx mělo být xxxxxxxxxxx alespoň 100 xxxxx x xxxxx xxxxxxxxxxxx xxxxxxxx (tj. xxxxxxxxx 500 xxxxxxxx xx xxxxxxx). Xxxxx xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx preparátů xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx kódovány. Xxxxxxxx xxx xxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxx xxxxxx nebo xxxxxx xxxxxxxxxx x xxxxx metafází, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxxxxxxxxxx číslu 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx by xxxx xxx xxxxxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx a xxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxx. Xxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxx různé typy xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x jejich xxxxxx x četností. Xxxx xx zaznamenávají xxxxxxxx x xxxxxxx xx, xxx xxxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx.
Xx-xx pozorována xxxxxx x xxxx xxxxxx, xxx by xxx pro xxxxxxxxx xxxxxxx cytotoxických xxxxxx xxxx míra xxxxxxxxxxxx xxxxxxxx x všech xxxxxxxxxxxx zvířat x xxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx, x xx x xxxxxxxx xxxxxx 100 xxxxxxxx se xxxxx xx xxxxx xxxxx. Xxxxx xx xxxxxxxxx pouze xxxxxx, xxxxxxx x 1000 xxxxxxx xx xxxxx xx xxx být xxxxxxxx xxxxxxxxx xxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. nárůst xxxxx buněk x xxxxxxxxxxxxxx aberacemi x xxxxxxxxxx na xxxxx xxxx xxxxx xxxxxx xxxxx xxxxx s xxxxxxxxx xxx skupinu x xxxxxxx xxxxxx x k určitému xxxxxxxx xxxxxx. Nejdříve xx xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx mohou xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx být xxxxxxxxx xxxxxx zkoušením, xxxxxxx x úpravami xxxxxxxxxxxxxxxx podmínek.
Zkoušená xxxxx, xxxxx výsledky nesplňují xxxx xxxxxxx kritéria, xx x xxxxx xxxxxxx xxxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx ohledu xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx xx xxxx znamenají, že xxxxxxxx xxxxx xxxxxxxx x germinálních buňkách xxxxxxxxxxx druhu strukturní xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx látka xx xxxxxxxx zkoušky xxxxxxxxxx x xxxxxxxxxxxx buňkách xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx by xxx xxxxxxxxxxx pravděpodobnost, x xxxxx se xxxxxxxx xxxxx xxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxx tkáně.
3. XXXXXX
XXXXXXXX X ZKOUŠCE
Protokol x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx druh/kmen,
- xxxxx x xxxxx zvířat,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx zkoušky, včetně xxxxxxx tělesné hmotnosti, xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxx xx xxxxxx xxx zjištění xxxxxxx, xxxxx xxxx provedena,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- zdůvodnění způsobu xxxxxxxx,
- údaje x xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- xxxxxxxx xxxxxxxx xxxx koncentrací xxxxxxxx xxxxx v xxxxxx nebo vodě (xxx) na odpovídající xxxxx (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx xxxxx rozvrhu expozice x odběru,
- xxxxxx xxxxxxxxx xxxxxxxx,
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, xxxx koncentrace x xxxxx xxxxxxxx,
- metody xxxxxxxx preparátů,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- kritéria xxxxxxxxxxx xxxxxx na xxxxxxxxx, negativní nebo xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx,
- xxxxxxxxx xxxxx,
- poměr xxxxxxxxxxxxx x mitose xxxxxxxx x první x druhé metafázi xxxxxx,
- typ x xxxxx xxxxxxx uvedený xxxxxxxxxx pro xxxxx xxxxx,
- xxxxxxx počet xxxxxxx xx xxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx xxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx statistické xxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x negativní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx odchylkami,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X., (1986), Xxxxxxxxxxx Xxxxxxxxx xx Xxxxx Xxxxxxxxxxxxx of Xxxxxxxx Xxxxxxxx Xxxxxxx xx xxxxx Cell-Cycle Xxxxxxxxxxxxxx, in: Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxxx Xxxxxxxxx, Part X: Xxxxxxx Effects xxx Xxxxxxx Mutagenesis, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, J. (xxx) Xxxx, Xxx York, 477-484.
2) Xxxxx, I. X., (1984), Xxxxxxxxxxx xxxxx xx Mammals, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, (xx.) X. Xxxxxx, X. X. Parry, XXX Press, Oxford, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, X. X., Xxxxxxx, X., Xxxx, X. X. (1964), Xx Air-drying Method xxx Xxxxxxx Preparations xxxx Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx Cell Xxxxxxxx, 3, 289-294.
4) Xxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Henderson, X. (1990), In xxxx Xxxxxxxxxxx Assays, xx: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Testing. Xxxxxx. Xxxx X xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New Xxxx, Port Chester, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, K., Kikuchi, X. (1978), A Xxx Method for Xxxxxxxxxxx xx Mammalian Xxxxxxxxxxxxxx Xxxxxxxxxxx, Mutatation Xxx., 52, 207-209.
6) Xxxxx, X. X., Xxxxxx X. X., Xxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxxxxx, F., Xxxxxxx, X., Tanaka N. (1994), Xxxxxxxxxxxxx Workshop xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxxxxxxxx. Xxxxxxx Xxxxxx xx xxx Working Xxxxx xx Xxxxxxxxx Germ Xxxx Tests, Xxxxxxxxxx Xxx., 312, 313-318.
7) Xxxxxxx, X. X., Xxxxx, J. X., Xxxxxx, A. X., Xxxxxx, X. A., Xxx, X., Esdaile, X. J., Xxxxxxxxx, X. G., Hodson-Walker, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, M. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Society/UK Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx in Xx xxxx Mutagenicity Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, D. X., Xxxxxxxx, D., Xxxxxxxx, X., Amphlett, X. X., Clarc, X., Xxxxxxxx, R., Xxxxxxx, X., Xxxxxxxx, D. X., Xxxxxx J. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx xxxx Cytogenetic Xxxxxx, xx: D. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx University Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Sydney, 184-232."
XXXXXXX 4X
"X.39 ZKOUŠKA XX XXXXXXXXXXXX XXXXXXX XXX (XXX) X XXXXXXXXX XXXXXXX XXXXX XX XXXX
1. METODA
Tato xxxxxx xx xxxxxxxx xxxxxx XXXX XX 486 — Xxxxxxx xx neplánovanou xxxxxxx XXX (XXX) x xxxxxxxxx buňkách xxxxx xx vivo (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx DNA (XXX) v xxxxxxxxx xxxxxxx savců in xxxx je xxxxxxxxxxxxx xxxxxxxx xxxxx, které xxxxxxxx xxxxxxxx XXX x xxxxxxxxx xxxxxxx xxxxxxxxxxxx zvířat (1, 2, 3, 4).
Tato xxxxxxx xx vivo xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx v xxxxxxx. Xxxxxxxxxxx xxx je xxxxxxxxxx poškození XXX x xxxxxxxx reparace x jaterních buňkách. Xxxxx jsou obvykle xxxxxxx xxxxxx, kde xxxx xxxxxxxxxxx sloučeniny xxxxxxxxxxxxxx. Jsou tedy xxxxxxx xxxxxx xxx xxxxxxxxx míry xxxxxxxxx XXX xx xxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, že xx xxxxxxxx xxxxx xxxxxxxxx xx cílové xxxxx, xxxx xxxxxx tuto xxxxxxx použít.
Rozsah xxxxxxxxxxx xxxxxxx XXX (UDS) xx zhodnotí xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx nukleosidů xx xxxxx, xxxxx xxxxxxxx plánovanou xxxxxxxx XXX (S-fází). Xxxxxxxxxxxxxxx xxxxxxxxx xx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx tritiem (3X-XxX). Xxx xxxxxxx xx XXX xx xxxx xx xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxx. Jiné xxxxx než xxxxx xxxxx být xxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx této xxxxxx.
Xxxxxxx xxxxxxxx XXX závisí xx xxxxx xxxx XXX xxxxxxxxxxx x xxxxxxxxxxx x xxxxx xxxxxxxxx. Zkouška xx XXX je tedy xxxxxx xxxxxxx pro xxxxxxx xxxxxxxx reparací ("xxxx-xxxxx repair") (20 xx 30 bází) xxxxxxxxxxxx látkou. Xxxxxx xxxxxx ("xxxxx-xxxxx xxxxxx") (xxxxx xx tři xxxx) xxxx naproti xxxx xxxxxxxxxx x xxxxxx menší xxxxxxxxxx. Xxxxx může xxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, chybné xxxxxxxx nebo chybné xxxxxxxxx xxxx XXX xxxxx x xxxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxx XXX neposkytuje xxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxxxx procesů. Xxxxx xx možné, xx xxxxxxx reaguje x XXX, xxx xxxxxxxxx XXX xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx. Nedostatek xxxxxxxxxxxx xxxxxxxxx, xxxxx xxxx xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx, xx xxxxxxx potenciální xxxxxxxxxx xxxxxx jevu, xxxxx xx vyšetřován x xxxxx genomu.
Viz xxxx obecný xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx xxxxx : čistý xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX), xxxxx než xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxx xxxxx xxx xxxxxxxxxxxxxx buněčným xxxxxx (XXX) : xxxxxxxxxxxxx xxxx UDS xxxxxxxx xxxxx x xxxxxxxxxxxxxxxxx zkoušce xx XXX, xxxxxxxxx xxxxxxxxx xxxxxxxxxx počtu zrn x cytoplasmatických xxxxxxxxx (XX) xxxxxxxxxxxxxx jádrům xx xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XX): NNG = XX — CG. Xxxxxxx XXX xx xxxxxxx xxx xxxxxxxxxx xxxxx, xxxx xxxxxxxx xxx xxxxx x xxxxxxx, x xxxxxxxxxxx xxxxxxxxx atd.
Neplánovaná syntéza XXX (XXX) : Xxxxxxx xxxxxxxx XXX xx xxxxxxxxx x xxxxxxxxxx úseku XXX xxxxxxxxxxxx region x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx fyzikálními xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xx XXX x jaterních xxxxxxx xxxxx xx vivo xxxxxxxx syntézu xxxxxxxx XXX xx vyštěpení x odstranění xxxxx XXX xxxxxxxxxxxx xxxxxx x poškozením indukovaným xxxxxxxxxx xxxxxxx nebo xxxxxxxxxxx činiteli. Xxxxxxx xx obvykle xxxxxxxx xx xxxxxxxxxxx 3X-XxX xx DNA jaterních xxxxx, xxx xx xxxx xxxxxxx buněk x X-xxxx xxxxxxxxx xxxxx. Xxxxxxxxxxx 3X-XxX xx xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx, jelikož xxxx xxxxxxxx xxxx xxx xxxxxxx na xxxx X-xxxx buněk jako xxxx. xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xx xxxxxxxx xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx xxxxxx xxxx xxxxx. Xxxx xx xxx xxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X okamžiku zahájení xxxxxx xx měla xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx pro obě xxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx skupinu x skupinu, xxxxx xx xxxxxxxx. Klece xx měly xxx xxxxxxxxxx xxx, aby xxx xxxx jejich xxxxxx minimalizován. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx x xxxx xxxxxxxxx xxxxxx xx xxxxxxx x laboratorních xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx zkoušené xxxxx
Xxxxx zkoušené látky xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx xxxxx xxx podávány přímo xxxx mohou xxx xxxx xxxxxxx zředěny. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické látky, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx nemělo xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx xxx vyloučeno xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx být xxxxxx xxxxxxxx podloženo xxxxx o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx zvážit xxxxxxx xxxxx možno vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každé xxxxxxxxx prováděné části xxxxxxxxxxx by xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) xxxxxxxx. X xxxxxxxx xxxxxxxx zkoušené látky xx xxxx xxxxxxx xxxxxxxxx xxxxxxx podstoupit xxxxxx xxxxxx jako xxxxxxx xx xxxxxxxxx, x nichž xxxxx x xxxxxxxx.
Xxxxxxxxxxx xxxxxxxxxx xx xxxx být xxxxx, x xxxxx xx známo, xx xxxxxx xxxxxxxx x xxxxxxxxxxx expozičních koncentracích xxxx k xxxxxxx XXX xxxxxxxxxxxxxxx xxx xxxxxxx. Pozitivní kontroly xxxxxxxxxx metabolickou aktivaci xx měly xxx xxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxx xxxxxxx (4). Xxxxx xxxxx xxx zvoleny xxx, xxx xxx účinek xxxxxxxx, xxx aby xxx xxxxxx xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxx pro pozitivní xxxxxxxx:
|
Xxxx odběru |
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxxxx doby xxxxxx (2 až 4 h) |
N-nitrosodimethylamin |
62–75–9 |
200–249–8 |
|
Pozdní xxxx xxxxxx (12 až 16 x) |
X-(xxxxxxx-2-xx)xxxxxxxx (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx xxxx xxxx xxxxx xxx xxxxxxxxx xxxxxxxx. Xx xxxxxxxxx, aby xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxxxx xxxxxxxx, xxx xxxxxxxx látka.
1.5 XXXXXX
1.5.1 Xxxxx a xxxxxxx zvířat
Měl xx xxx xxxxxx dostatečný xxxxx zvířat, xxx xxxx zohledněno xxxxxxxxx xxxxxxxxxx kolísání odpovědi xx xxxxxxx. Xxxxx xxxxxxx xx se xxxx skládat alespoň xx xxx xxxxxxxxxxxxxxxx xxxxxx. Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxxx dosavadní xxxxx, je pro xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxx xxxxx xxxxx xx xxx zvířata.
Jestliže xxxx x xxxx studie x xxxxxxxxx údaje xx studií se xxxxxxx xxxxxx a xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx neexistuje xxxx pohlavími xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx zkoušení xxxxxxx xxxxxxx, nejlépe xxxxx. Xx-xx xxxxxxxx člověka xxxxxxxxxx xxx xxxxxx xxxxxxx, xxxx je xxxx xxxxxxxxx u xxxxxxxxx farmaceutických xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx xx xxxxxxxx odpovídajícího xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xxxx zpravidla xxxxxxxx xxxxxxxxxxx.
1.5.3 Xxxxxxxxx
Xx normálních xxxxxxxx xx používají xxxxxxx xxx xxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx toxicity, xx xxxxx dávky xx xxxxx podle očekávání xxx xxxxxxx xxxxxx xxxxxxxxx x xxxxxxxx. Xxxxx xxxxx by xxxx xxx xxxxxxxxx 50 % xx 25 % xxxxx xxxxx.
Xxxxx se xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx by xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxx-xx xx xxxxx neexistenci xxxxxxxx dostupných údajů xxxxxx xxx xxxxxxxx xxxxxxx, xxxx xx xxx provedena xx xxxxxx laboratoři, se xxxxxxx xxxxxx, kmenem, xxxxxxxx a xx xxxxxxxx xxxxxx xxxxxxxx, xxx se použijí x xxxxxx xxxxxx.
Xxxxxxxx xxxxx xxxx xxx xxxxxxxxxx xxxx xxxx xxxxx xxxxxxxxxxxx známky xxxxxxxx v xxxxxxx (xxxx. xxxxxxxxxx xxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x jednou dávkou x xxxxxxx 2000 xx/xx xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách x jednom xxx xxxxxxxxxx žádné xxxxxxxxxxxxx xxxxxxx účinky x xxxx-xx xx xxxxxxx xxxxx x látkách, xxxxx mají podobnou xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxx xxx xxxxx xxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxx může xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx. Xxxx způsoby xxxxxxxx xxxx možné, xxx-xx je zdůvodnit. Xxxxxxxx xxxxxxxxxxxxxxxxx xx xxxx nedoporučuje, neboť xx xxxxx mohla xxx xxxxxxxxxx zkoušené xxxxx xxxxx x xxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Xx na xxxxxxxx x žíravé xxxxx, xxxxx obvykle xxx vyšších xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx konstantní objem xxx všech xxxxxxxx xxxxx.
1.5.6 Příprava jaterních xxxxx
Xxxxxxx buňky xx xxxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx 12 xx 16 xxxxx xx podání dávky. Xxxxxxxxxx xxxxxxxx odebrání xxxxxx (xxxxxx xxx xx xxxxx xxxxxx xx xxxxxxxx) xx xxxxxxxx, xxxx-xx xx 12 xx 16 xxxxxxxx jasná xxxxxxxxx xxxxxxx. Xxxxx xxxx xxx použity jiné xxxx xxxxxx, jsou-li xxxxxxxxxx xx základě xxxxxxxxxxxxxxxxx údajů.
Krátkodobé xxxxxxx xxxxxxxxx xxxxx xxxxx xx xxxxxxxxx zakládají xxxxxxx jater xxxxxxxxxxx xx xxxx x xxxxxx se, xxx xx čerstvě disociované xxxxxxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx. Xxxxxxx xxxxx z xxxxxxxxx kontroly by xxxx xxxxxxxxx xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Xxxxxxxxx XXX
Xxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxx xx xxxxxxx xxxxxxx xxxx, např. xxx xx xxx xxxxx, xxxxxxxx x xxxxxx xxxxxxxxxxx 3H-TdR. Xx xxxxx xxxxxxxxx xxxx xx xxxx xxx xxxxxx x xxxxx xxxxxxxxxx a xxxxx poté xxxxx xxx xxxxxxxxxx s xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx, aby xxxx snížena neinkorporovaná xxxxxxxxxxxxx ("cold xxxxx"). Xxxxx se xxxx xxxxxxx, fixují a xxxxxx. Xxx xxxxx xxxxxxxxx době xxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx. Preparáty se xxxxxx xx xxxxxxxxxxxxxxxxx xxxxxx, exponují se x temnu (např. x xxxxxx 7 xx 14 dnů), xxxxxxxx xx, xxxxxx x spočítají xx xxxxxxxxxx xxxx stříbra. X každého xxxxxxx xx xxxxxxxx dva xx tři xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx xx xxxx xxxxxxxxx dostatečný xxxxx xxxxxxxxxxxx normálních xxxxx, xxx xxxx xxxxxxxxx XXX xxxxxxxxx xxxxxxx. Xxxxxxxxx se xxx xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxx cytotoxicity (xxxx. xx xxxxxxx, xxxxxxxx xxxxxx značení xxxxxxxxxxxxx xxxxxxxx).
Xxxx xxxxxxxxx xxx xx měly xxx preparáty kódovány. Xxxxxxxxx se vyšetřuje 100 buněk xx xxxxx xxxxx xxxxxxx xx xxxx preparátů; xxxxxxxxx méně xxx 100 xxxxx/xxxxx by xxxx xxx zdůvodněno. Xxx xxxxxxxx xxx xx xxxxx x X-xxxx nevyšetřují, xxx xxxxx buněk v X-xxxx může být xxxxxxxxxx.
Xxxxxxxx 3X-XxX xxxxxxxxxxxxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxxxxx xxx stříbra by xxxx xxx xxxxxxxxx xxxxxxx metodou.
Počet xxxxx xx xxxxxxx x xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx jádrŭm (xx) x x xxŭxxxxxxx xxxxx xxx v xxxxxxxxxxxxxxxxx xxxxxxxxx (xx) xxxxxxxxxxxxxx jádrŭm. xxxx xxxxxxx xx se xxxxxxx xxx xxxxx xxxxx xxx nejsilněji xxxxxxxxx xxxxxx xxxxxxxxxx, xxxx xxŭxxxxx xxxxxxx xxxx xx tří xxxxxxx xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxx jader. po xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx i xxxx xxxxxxx stanovení xxxxx xxxxx (např. xxxxxxxx xxxxxx xxxxx) (6).
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx xxx xxxxxxx xxxxx xxx xxxxxxxxxx preparáty a xxxxxxx. Údaje xx xxxx xxx dále xxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxx hodnoty XX xx xxxxxxx XX by měl xxx xxxxxxxx xxx xxxxxx xxxxx, pro xxxxx xxxxx x xxx xxxxxx xxxxx x čas čistý xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx jádrům (NNG). Xxxxxxxx xxxx xxxxxxxx "xxxxxxxxxx" xxxxx, xxxx xx xxx xxxxxxxx xxx definování "opravovaných" xxxxx xxxxxxxxxx a xxxxxxxx xx dosavadních xxxx xxxxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx výsledky xxxxx xxx xxxxxxxxxx statistickými xxxxxxxx. Mají-li xxx xxxxxxx, xxxx xx xxx xxxxxxxxxxx testy xxxxxxx a odůvodněny xxxx xxxxxxxxxx xxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxxx xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx odpověď xxxxx:
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xxx xxxxxxxx xxxxxx, xxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx XXX xx xxxxxxxx xxxxx než xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx NNG leží xx dosavadní prahové xxxxxxx xxxx xxx xx; |
|
xxxx |
xx) |
xxxxxxx XXX xxxx xxxxxxxx xxxxx xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx. |
Xxxx by xxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, xx. xxxx xx xxx vzaty x xxxxx parametry, xxxx xxxx xxxxxxxxxxx xxxxxx, xxxxx xxxxx x odpovědi x xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx zkoušky xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx významnost xx xxxx neměla xxx jediným xxxxxxxxx xxxxxxxx xxx pozitivní xxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x ojedinělých případech xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný xxxxx x xxxxxxxx xxxxxxxx xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx xx to, kolikrát xx experiment opakován.
Pozitivní xxxxxxxx xxxxxxx xx XXX x xxxxxxxxx xxxxxxx xxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxx xx xxxx xxxxxxxxx XXX, xxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx XXX xx xxxxx. Negativní výsledky xxxxxxxxx, že xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx XXX, které xxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx zkoušená xxxxx xxxxxxx do xxxxxxxx xxxxx popř. do xxxxxx xxxxx (např. xxxxxxxxx toxicita).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x stálost xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Testovací xxxxxxx:
- xxxxxxx druh/kmen,
- počet, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx zvířat xx počátku xxxxxxx, xxxxxx rozpětí tělesné xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx odchylky xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (vehikulum/rozpouštědlo) kontroly,
- xxxxx xx xxxxxx xxx xxxxxxxx rozsahu, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx látky,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx podávání,
- popřípadě xxxxxx xxxxxxx, zda xx xxxxxxxx látka xxxxxxx do krevního xxxxx xxxx xx xxxxxx tkáně,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx nebo xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx xxxxx xxxxxxx expozice x odběru,
- metody xxxxxxxxx toxicity,
- xxxxxx xxxxxxxx a kultivace xxxxxxxxx xxxxx,
- xxxxxxx xxxxxxxxxxxxxxxxx technika,
- počet xxxxxxxxx x xxxxx xxxxxxxxxxx xxxxx,
- xxxxxxxx xxxxxxxxx,
- xxxxxxxx klasifikace xxxxxx xx pozitivní, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxxx hodnoty počtu xxx xxxxxxxxxxxxxx buněčným xxxxxx x xxxxx xxx xxxxxxxxxxxxxx cytoplasmě, x xxxxx xxxxx xxx, jednotlivě xxx xxxxxxxxx, zvířata x xxxxxxx,
- podle možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx x souběžné xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx o negativní (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx odchylkami,
- xxxxx xxxxx "xxxxxxxxxxxx" xxxxx, xx-xx xxxxxxxx,
- počet xxxxx x X-xxxx, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx výsledků.
Závěry.
4. XXXXXXXXXX
1) Xxxxx, X. Xxxxxxx, X. X., Xxxxxxxxx, X., Xxxxxx, X. X. (1985), Xx Xxxxxxxxxx xx xxx Xx xxxx Xxx. Xxxxxxxxxx XXX Xxxxxx Xxxxx, Mutatation Res., 156, 1-18.
2) Xxxxxxxxxxx, X. X., Ashby, X., Bermudez, E., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxx, X., Xxxxxxxx, G. (1987), X Xxxxxxxx xxx Xxxxx for the Xx xxxx Rat Xxxxxxxxxx DNA Repair Xxxxx, Xxxxxxxxxx Xxx., 189, 123-133.
3) Xxxxxxxx, X. X., Xxxxxx, X., Xxxxx, X., Xxxxxxx, P. X., Xxxxxxxxx, X., Benford, X. X., Dean, X. X., Mitchell, X. xx X. (1993), Xx vivo Xxx Liver XXX Xxxxx, xx: Xxxxxxxx X. X., Xxx X., (xxx), Supplementary Xxxxxxxxxxxx Xxxxx: UKEM Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxxxxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Xxxx XX xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New Xxxx, Port Xxxxxxx, Xxxxxxxxx, Sydney, 52-77.
4) Xxxxx, S., Xxxx, X. W., Xxxxxx, X., Xxxxxxxxx. X., Xxxxxxxxx, X., Xxxxxxxxx, X. J., Furihata, X., Xxxxxxx, X., XxXxxxx, X. A., Xxxx, X. (1993), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx XXX Xxxxx In xxxxx xxx Xx vivo, Xxxxx. Xxx., 312, 263-285.
5) Xxxxx, R., Xxxxxxx, B., Xxxxxxxxxx, X., Xxxxxxxxxxxx-Xxxxxx, X. (1993), Xxxxxxxxxx of xxx Xxxxxxxx Xxxxxxx xxx Xxxxxxx Xxxxxxxxx xxx xxx Xxxxxxxxxx xx Freshly Xxxxxxxx Xxx Xxxxxxxxxxx Used xxx xxx In xxxx/Xx xxxxx XXX Xxxxxx Xxxxx (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Mirsalis, X. X., Xxxxx, X. X., Xxxxxxxxxxx, B. X. (1982), Xxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxx xx xxx Xx xxxx/Xx xxxxx Hepalocyte XXX Xxxxxx Assay, Xxxxxxx.Xxxxxxx. 4, 553-562."
XXXXXXX 5
OBECNÉ POŽADAVKY XX KLASIFIKACI X XXXXXXXXXX NEBEZPEČNÝCH LÁTEK X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX, Xx. xxxx. L 332, 28. 12. 2000, x. 81.
XXXXXXX 6
"
XXXXXXX IX
ČÁST X
xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxxxx xx. 22 xxxx. 1 písm. x) xxxx směrnice, xxxx xxx xxxxx x xxxxxxxxx objemu xxxxxxxxxx xxxxx, x xxxxx xx xxxxxxx riziko xxx xxxxxxxxxx (Xx; X 65) a xxxxx xxxx klasifikovány x xxxxxxxx podle xxxx 3.2.3 xxxxxxx XX této xxxxxxxx, x výjimkou xxxxx xxxxxxxxx na xxx xx xxxxx xxxxxxxx xxxx x xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx, xxxxxxxx uzávěry odolnými xxxxx xxxxxxxx dětmi.
1. Xxxxxxxxx xxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxx XXX 8317 (xxxxxx ze xxx 1. xxxxxxxx 1989) "Xxxxx xxxxxx dětem — Požadavky xx xxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxx xxxxxx xxxxxxxx" přijatou Xxxxxxxxxxx xxxxxxxxxx xxx normalizaci (XXX).
2. Opakovaně xxxxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx dětmi xxxxxxx xx opakovaně xxxxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxx XXX XX 862 (xxxxxx x března 1997) "Xxxxx — Obaly xxxxxx xxxxx — Xxxxxxxxx a xxxxxxxx xxxxxxx xxx opakovaně xxxxxxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxxxxxxxxx xxxxxxx" xxxxxxxx Xxxxxxxxx výborem xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Xxxxxxxxx shody x xxxx xxxxxxxxx xxxxxxx mohou osvědčovat xxxxx laboratoře, xxxxx xxxxxxx xxxxxxxx xxxxx xxxx XX 45000.
2. Xxxxxxxxxx xxxxxxx
Xx-xx zřejmé, xx xxxx xx xxxxxxxxxx xxxxxxxx xxx xxxx, xxxxx se xxxxxxx dostat x xxxxxx bez xxxxxx xxxxxxxx, nemusí xxx xxxxxxx xxxxxxxxx.
Xx všech xxxxxxxxx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxx xxxxxx k xxxxxxxx x xxxxxxxxxxx xxxxxxx xxx dítě, může xxxxxxxxxxxx xxxxx požadovat, xxx osoba odpovědná xx xxxxxxx xxxxxxx xx trh xxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx odst. 3 xxxx 1 xxxxxxxxxxxx, xx xxx
- xxx xxxxxxx xx xxxxxx, xx xxx xxxx xxxxxxxx zkoušet xxxxx xxxx uvedených norem XXX a XXX,
xxxx
- xx xxxxxx xxx xxxxxxx x xxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx.
XXXX X
Xxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxx
Xxxxxxxxx xxxxxxxxxxx xxx hmatatelné xxxxxxxx xxxx xxx x xxxxxxx x xxxxxx XX XXX 11683 (xxxxxx x xxxx 1997) "Obaly — Xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx — Xxxxxxxxx".
"